UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 ____________________________________________________________
FORM 10-Q
 ____________________________________________________________
ý
QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended December 29, 2017
or
¨
TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                      to                     
Commission File Number 1-7598
 ____________________________________________________________ 
VARIAN MEDICAL SYSTEMS, INC.
(Exact name of registrant as specified in its charter)
 ____________________________________________________________ 
Delaware
 
94-2359345
(State or other jurisdiction of
incorporation or organization)
 
(I.R.S. Employer
Identification Number)
 
 
 
3100 Hansen Way,
Palo Alto, California
 
94304-1038
(Address of principal executive offices)
 
(Zip Code)
(650) 493-4000
(Registrant’s telephone number, including area code)
 ____________________________________________________________ 
I ndicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes   ý     No   ¨
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).     Yes   ý     No   ¨
Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.  
Large Accelerated filer
 
x
  
Accelerated filer
 
o
Non-Accelerated filer
 
o   (Do not check if a smaller reporting company)
  
Smaller reporting company
 
o
Emerging growth company
 
o
 
 
 
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes   ¨     No   ý
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 91,300,252 shares of common stock, par value $1 per share, outstanding as of January 26, 2018 .
 




VARIAN MEDICAL SYSTEMS, INC.
FORM 10-Q for the Quarter Ended December 29, 2017
INDEX
 
Part I.
 
 
 
 
 
Item 1.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Item 2.
 
 
 
 
 
Item 3.
 
 
 
 
 
Item 4.
 
 
 
 
 
Part II.
 
 
 
 
 
Item 1.
 
 
 
 
 
Item 1A.
 
 
 
 
 
Item 2.
 
 
 
 
 
Item 3.
 
 
 
 
 
Item 4.
 
 
 
 
 
Item 5.
 
 
 
 
 
Item 6.
 
 
 
 
 

2



PART I
FINANCIAL INFORMATION

Item 1. Unaudited Financial Statements

VARIAN MEDICAL SYSTEMS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS (LOSS)
(Unaudited)

 
Three Months Ended
 
December 29,
 
December 30,
(In millions, except per share amounts)
2017
 
2016
Revenues:
 
 
 
Product
$
365.6

 
$
309.2

Service
312.9

 
292.3

Total revenues
678.5

 
601.5

Cost of revenues:
 
 
 
Product
223.9

 
206.2

Service
151.8

 
128.3

Total cost of revenues
375.7

 
334.5

Gross margin
302.8

 
267.0

Operating expenses:
 
 
 
Research and development
55.9

 
49.9

Selling, general and administrative
125.5

 
161.4

Impairment charges

 
38.3

Total operating expenses
181.4

 
249.6

Operating earnings
121.4

 
17.4

Interest income
3.2

 
4.8

Interest expense
(2.1
)
 
(2.9
)
Earnings from continuing operations before taxes
122.5

 
19.3

Taxes on earnings
234.7

 
11.3

Net earnings (loss) from continuing operations
(112.2
)
 
8.0

Net earnings from discontinued operations

 
6.5

Net earnings (loss)
(112.2
)
 
14.5

Less: Net earnings attributable to noncontrolling interests
0.1

 
0.6

Net earnings (loss) attributable to Varian
$
(112.3
)
 
$
13.9

 
 
 
 
Net earnings (loss) per share - basic
 
 
 
Continuing operations
$
(1.22
)
 
$
0.08

Discontinued operations

 
0.07

Net earnings (loss) per share - basic
$
(1.22
)
 
$
0.15

 
 
 
 
Net earnings (loss) per share - diluted
 
 
 
Continuing operations
$
(1.22
)
 
$
0.08

Discontinued operations

 
0.07

Net earnings (loss) per share - diluted
$
(1.22
)
 
$
0.15

 
 
 
 
Shares used in the calculation of net earnings per share:
 
 
 
Weighted average shares outstanding - basic
91.6

 
93.5

Weighted average shares outstanding - diluted
91.6

 
94.2

See accompanying notes to the condensed consolidated financial statements.

3



VARIAN MEDICAL SYSTEMS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE EARNINGS (LOSS)
(Unaudited)
 
 
Three Months Ended
 
December 29,
 
December 30,
(In millions)
2017
 
2016
Net earnings (loss)
$
(112.2
)
 
$
14.5

Other comprehensive earnings (loss), net of tax:
 
 
 
Defined benefit pension and post-retirement benefit plans:
 
 
 
Amortization of prior service cost included in net periodic benefit cost, net of tax benefit of $0.1 and $0.1
(0.2
)
 
(0.1
)
Amortization of net actuarial loss included in net periodic benefit cost, net of tax expense of ($0.2) and ($0.2)
0.5

 
0.9

 
0.3

 
0.8

Derivative instruments:
 
 
 
Change in unrealized loss, net of tax benefit of $0.1 and $0.0
(0.2
)
 

Reclassification adjustments, net of tax expense of $0.0 and $0.0
(0.1
)
 

 
(0.3
)
 

Currency translation adjustment
3.1

 
(13.1
)
Other comprehensive earnings (loss)
3.1

 
(12.3
)
Comprehensive earnings (loss)
(109.1
)
 
2.2

Less: Comprehensive earnings attributable to noncontrolling interests
0.1

 
0.6

Comprehensive earnings (loss) attributable to Varian
$
(109.2
)
 
$
1.6

 
See accompanying notes to the condensed consolidated financial statements.

4



VARIAN MEDICAL SYSTEMS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
 
December 29,
 
September 29,
(In millions, except par values)
2017
 
2017
Assets
 
 
 
Current assets:
 
 
 
Cash and cash equivalents
$
822.6

 
$
716.2

Trade and unbilled receivables, net of allowance for doubtful accounts of $42.6 at December 29, 2017 and $45.9 at September 29, 2017
880.1

 
961.5

Inventories
431.4

 
417.7

Prepaid expenses and other current assets
206.2

 
190.3

Current assets of discontinued operations
11.3

 
11.1

Total current assets
2,351.6

 
2,296.8

Property, plant and equipment, net
250.4

 
255.3

Goodwill
223.4

 
222.6

Intangible assets
65.6

 
71.6

Deferred tax assets
112.8

 
147.3

Other assets
296.0

 
300.8

Total assets
$
3,299.8

 
$
3,294.4

Liabilities and Equity
 
 
 
Current liabilities:
 
 
 
Accounts payable
$
152.0

 
$
162.3

Accrued liabilities
350.0

 
374.9

Deferred revenues
772.3

 
755.4

Short-term borrowings
340.0

 
350.0

Current liabilities of discontinued operations
2.1

 
2.5

Total current liabilities
1,616.4

 
1,645.1

Other long-term liabilities
292.4

 
127.4

Total liabilities
1,908.8

 
1,772.5

Commitments and contingencies (Note 9)

 

Equity:
 
 
 
Varian stockholders' equity:
 
 
 
Preferred stock of $1 par value: 1.0 shares authorized; none issued and outstanding

 

Common stock of $1 par value: 189.0 shares authorized; 91.6 and 91.7 shares issued and outstanding at December 29, 2017, and at September 29, 2017, respectively
91.6

 
91.7

Capital in excess of par value
740.5

 
716.1

Retained earnings
620.2

 
778.6

Accumulated other comprehensive loss
(65.7
)
 
(68.8
)
Total Varian stockholders' equity
1,386.6

 
1,517.6

Noncontrolling interests
4.4

 
4.3

Total equity
1,391.0

 
1,521.9

Total liabilities and equity
$
3,299.8

 
$
3,294.4

  
See accompanying notes to the condensed consolidated financial statements.

5



VARIAN MEDICAL SYSTEMS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
 
Three Months Ended
 
December 29,
 
December 30,
(In millions)
2017
 
2016
Cash flows from operating activities:
 
 
 
Net earnings (loss)
$
(112.2
)
 
$
14.5

Adjustments to reconcile net earnings to net cash provided by operating activities:
 

 
 

Share-based compensation expense
10.7

 
11.5

Depreciation
12.8

 
17.2

Amortization of intangible assets
6.3

 
5.1

Deferred taxes
44.9

 
(20.9
)
Provision for doubtful accounts receivable
1.5

 
38.1

Impairment charges

 
38.3

Other, net
(0.8
)
 
(0.6
)
Changes in assets and liabilities:
 

 
 
Trade and unbilled receivables
65.9

 
32.4

Inventories
(11.7
)
 
(30.1
)
Prepaid expenses and other assets
28.2

 
(10.1
)
Accounts payable
(10.3
)
 
(20.7
)
Accrued liabilities and other long-term liabilities
125.1

 
(20.3
)
Deferred revenues
18.6

 
27.8

Net cash provided by operating activities
179.0

 
82.2

Cash flows from investing activities:
 

 
 

Purchases of property, plant and equipment
(9.3
)
 
(17.2
)
Issuance of notes receivable

 
(11.4
)
Investment in available-for-sale securities
(6.0
)
 
(0.6
)
Loans to CPTC
(4.6
)
 

Escrow deposit
(2.6
)
 

Investment in privately-held company
(2.5
)
 

Amounts paid to deferred compensation plan trust account
(1.3
)
 
(3.4
)
Principal payments on notes receivable
0.5

 

Other, net

 
0.8

Net cash used in investing activities
(25.8
)
 
(31.8
)
Cash flows from financing activities:
 

 
 

Repurchases of common stock
(56.7
)
 
(49.5
)
Proceeds from issuance of common stock to employees
24.2

 
16.1

Employees' taxes withheld and paid for restricted stock and restricted stock units
(0.3
)
 
(1.2
)
Borrowings under credit facility agreement
166.4

 
10.0

Repayments under credit facility agreement
(166.4
)
 
(10.0
)
Net (repayments) borrowings under the credit facility agreements with maturities less than 90 days
(10.0
)
 
(55.0
)
Net cash used in financing activities
(42.8
)
 
(89.6
)
Effects of exchange rate changes on cash and cash equivalents
(4.0
)
 
10.4

Net increase (decrease) in cash and cash equivalents
106.4

 
(28.8
)
Cash and cash equivalents at beginning of period *
716.2

 
843.5

Cash and cash equivalents at end of period *
$
822.6

 
$
814.7

* Cash and cash equivalents includes $32.7 million at December 30, 2016 classified as discontinued operations. See Note 2, "Discontinued Operations" for more information.
See accompanying notes to the condensed consolidated financial statements.

6



VARIAN MEDICAL SYSTEMS, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
 
1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Description of Business
Varian Medical Systems, Inc. (“VMS”) and subsidiaries (collectively, the “Company”) designs, manufactures, sells and services hardware and software products for treating cancer with radiotherapy, stereotactic radiosurgery, stereotactic body radiotherapy, and brachytherapy. Software solutions also include informatics software for information management, clinical knowledge exchange, patient care management, practice management and decision-making support for comprehensive cancer clinics, radiotherapy centers and medical oncology practices. The Company also develops, designs, manufactures, sells and services proton therapy products and systems for cancer treatment.
Distribution
On January 28, 2017 (the "Distribution Date"), the Company completed the separation and distribution (the "Distribution") of Varex Imaging Corporation ("Varex"), the Company's former Imaging Components business segment. On the Distribution Date, each of Varian's stockholder of record as of the close of business on January 20, 2017 (the "Record Date") received 0.4 of a share of Varex common stock for every one share of Varian common stock as of the Record Date. Varex is now an independent publicly traded company and is listed on The NASDAQ Global Select Market under the ticker “VREX.” Varian continues to trade on the New York Stock Exchange under the ticker “VAR.” See Note 2, "Discontinued Operations" for additional information.
Basis of Presentation
The condensed consolidated financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC"). Certain information and note disclosures normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) have been condensed or omitted pursuant to such rules and regulations. These condensed consolidated financial statements and the accompanying notes are unaudited and should be read in conjunction with the consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the year ended September 29, 2017 (the “ 2017 Annual Report”). In the opinion of management, the condensed consolidated financial statements herein include adjustments (consisting only of normal recurring adjustments) necessary for a fair statement of the Company’s financial position as of December 29, 2017 and September 29, 2017 , results of operations and statements of comprehensive earnings (loss) for the three months ended December 29, 2017 and December 30, 2016 , and cash flows for the three months ended December 29, 2017 and December 30, 2016 . The results of operations for the three months ended December 29, 2017 are not necessarily indicative of the operating results to be expected for the full fiscal year or any future period.
At the beginning of the Company's fiscal year 2018, the Company early adopted the new revenue recognition Accounting Standard Codification 606 "Revenues from Contracts with Customers" ("ASC 606") by using the full retrospective method. All financial statements and disclosures have been recast to comply with ASC 606. See "Recently Adopted Accounting Pronouncements" below for further information.

The historical financial position and results of operations of the Imaging Components business and costs relating to the Distribution are reported in the condensed consolidated financial statements as discontinued operations for all the periods presented. Information in the accompanying notes to the condensed consolidated financial statements have been recast to reflect the effect of the Distribution. The Condensed Consolidated Statements of Comprehensive Earnings and Cash Flows have not been recast to reflect the effect of the Distribution.




7

VARIAN MEDICAL SYSTEMS, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (CONTINUED)
(Unaudited)


Fiscal Year
The fiscal years of the Company as reported are the 52- or 53-week periods ending on the Friday nearest September 30. Fiscal year 2018 is the 52-week period ending September 28, 2018 . Fiscal year  2017 was the 52-week period that ended on September 29, 2017 . The fiscal quarters ended December 29, 2017 and December 30, 2016 were both 13-week periods.
Principles of Consolidation
The condensed consolidated financial statements include those of VMS and its wholly-owned and majority-owned or controlled subsidiaries. Intercompany balances, transactions and stock holdings have been eliminated in consolidation.
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.
Significant Accounting Policies
The Company's significant accounting policies are detailed in "Note 1: Summary of Significant Accounting Policies" within Item 8 of the Company's Annual Report on Form 10-K for the year ended September 29, 2017. Significant changes to these accounting policies as a result of adoption of ASC 606 are discussed below:
Revenue Recognition

The Company's revenues are derived primarily from the sale of radiotherapy and proton therapy hardware and software products, support, training and maintenance of all those products, installation services and the sale of parts.

The Company accounts for a contract with a customer when there's approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable.

The Company's revenues are measured based on consideration specified in the contract with each customer, net of any sales incentives and amounts collected on behalf of third parties such as sales taxes. The Company recognizes revenues as the performance obligations are satisfied by transferring control of the product or service to a customer.

The majority of the Company's revenue arrangements consist of multiple performance obligations including hardware, software, and services. Determining the stand-alone selling price ("SSP") and allocation of consideration from an arrangement to the individual performance obligations, and the appropriate timing of revenue recognition are significant judgments with respect to these arrangements.

The Company's products are generally not sold with a right of return and the Company does not provide credits or incentives, which may be required to be accounted for as variable consideration when estimating the amount of revenue to be recognized.

The Company recognizes an asset for the incremental costs of obtaining a contract with a customer if the Company expects the benefit of those costs to be longer than one year. The Company applies a practical expedient to expense costs as incurred for costs to obtain a contract when the amortization period would have been one year or less. These costs mainly include the Company's internal sales force compensation program; under the terms of these programs these are generally earned and the costs are recognized at the time the revenue is recognized.

The majority of the Company’s products and services are sold in bundled arrangements (e.g., hardware, software, and services). For bundled arrangements, the Company accounts for individual products and services separately if they are distinct, that is, if a product or service is separately identifiable from other items in the bundled package and if a customer can benefit from it on its own or with other resources that are readily available to the customer. The consideration (including any discounts) is allocated between separate products and services in a bundle based on their individual SSP. The SSP is determined based on observable prices at which the Company separately sells the products and services. If an SSP is not directly observable, then the Company

8

VARIAN MEDICAL SYSTEMS, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (CONTINUED)
(Unaudited)


will estimate the SSP considering marketing conditions, entity-specific factors, and information about the customer or class of customer that is reasonably available.

The following is a description of the principal activities, separated by reportable segment, from which the Company generates its revenues.

Oncology Systems
The Company's Oncology Systems linear accelerators are generally sold in a bundled arrangement with hardware and software accessory products that enhance efficiency and enable delivery of advanced radiotherapy and radiosurgery treatments, however, certain products are occasionally sold on a stand-alone basis. The majority of machine and software sales include installation services and training. Delivery of different elements in a revenue arrangement often span more than one reporting period. For example, a linear accelerator and software may be delivered in one reporting period, but the related installation of those products may be completed in a later period. Hardware and software extended maintenance and service contracts are occasionally sold during the initial product sale, but the majority are sold separately near or at the end of the initial warranty period. Revenues related to extended warranty and service contracts are earned after the expiration of the initial warranty period.

Payment terms and conditions vary by contract type, although, terms are generally commensurate with a significant milestone, such as contract signing, shipment, delivery, acceptance or service commencement. In instances where the timing of revenue recognition differs from the timing of invoicing, the Company has determined its contracts generally do not include a significant financing component. The primary purpose of the Company's invoicing terms is to provide customers with simplified and predictable ways of purchasing the Company's products and services, not to receive financing from the Company's customers, such as invoicing at the beginning of a contract term with revenue recognized ratably over the contract period for a service contract. Payment terms can also vary based on the type of customer, such as government purchases. There are occasions where the Company provides extended payment terms in which case a portion of the transaction price is allocated to imputed interest income.

From time to time, the Company's contracts are modified to account for additional, or change existing, performance obligations. The Company's contract modifications are generally accounted for prospectively.

Hardware Products and Installation
Hardware products may include software that the hardware is dependent on and highly interrelated with and cannot operate without. The Company typically has a standard base configuration for its hardware products, but there are typically multiple options and configuration choices. Revenues from the sale of hardware are recognized when the Company transfers control to the customer.

Product installation includes uncrating, moving the machine to the treatment room, connection and validating configuration. In addition, a number of testing protocols are completed to confirm the equipment is performing to the contracted specifications. The Company recognizes revenues for hardware installation over time as the customer receives and consumes benefits provided as the Company performs the installation services.

Software Products and Installation
Software products include information management, treatment planning, image processing, clinical knowledge exchange, patient care management, decision-making support, and practice management software. Software installation includes transferring software to the customer’s computers, configuration of the software and potentially data migration. The Company recognizes revenues for software and software installation upon the customer's acceptance of the software and installation services.

Service
Service revenues include revenues from initial and extended software support agreements, extended hardware warranty agreements, training, paid service arrangements when a customer does not have an extended warranty and parts that are sold by the service department.

Revenues from hardware and software support agreements are accounted for ratably over the term of the agreement. Services and training revenues are recognized in the period the services and training are performed. Revenues for sales of parts are recognized when the parts are delivered to the customer and control is transferred.

9

VARIAN MEDICAL SYSTEMS, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (CONTINUED)
(Unaudited)



Warranties
The Company's sale of hardware includes a one-year warranty. The Company uses the cost accrual method to account for assurance-type warranties. The standard warranty provision further includes services in addition to an assurance-type warranty (preventative maintenance inspections, help desk support, when and if available operating system upgrades). These service-type warranty features are recorded as a separate performance obligation and recognized ratably over the one-year warranty period.

Varian Particle Therapy ("VPT")
The manufacturing of the major components of a proton therapy system, installation, and commissioning typically lasts 18 to 24 months. The Company's proton therapy system is highly customized. A proton therapy system typically includes hardware, software that the hardware is dependent upon and highly interrelated with, and without which the hardware cannot operate, and installation. The Company also sells software products that include information management, treatment planning, image processing, clinical knowledge exchange, patient care management, decision-making support, and practice management software, and software installation.

The Company provides operations and maintenance services related to the proton therapy system under a separate arrangement. These contracts are typically executed at or about the same time as the proton therapy system contracts, however, the pricing and performance of the proton therapy system contracts are not typically related to the pricing or performance of the operations and maintenance contracts. Therefore, the Company recognizes operations and maintenance services as a separate performance obligation.

Under the typical payment terms of the Company's fixed-price contracts, the customer pays the Company an up-front advance payment and then performance-based payments based on quantifiable measures of performance or on the achievement of specified events or milestones. As the revenue is recognized over time relative to the costs incurred and the customer billing milestones are typically event driven this may result in revenue recognized in excess of billings at some point during the contract which the Company presents as unbilled receivables on the Condensed Consolidated Balance Sheets. Amounts billed and due from the Company's customers are classified as trade accounts receivable on the Condensed Consolidated Balance Sheets. In most contracts, the Company is entitled to receive an advance payment at the beginning of the contract. The Company recognizes a liability for these advance payments in excess of revenue recognized and presents it as deferred revenues on the Condensed Consolidated Balance Sheets. The advance payment typically is not considered a significant financing component because it is used to ensure the customer's commitment to the project.

The Company recognizes revenue for its proton therapy systems over time because the customer controls the work in process, the Company's performance does not create an asset with an alternative use to the Company, and the Company has an enforceable right to payment for performance completed to date.

Due to the nature of the work required to be performed on many of the Company's performance obligations, the estimation of total revenues and costs at completion is complex, subject to many variables and requires significant judgment. The Company's contracts generally do not include award fees, incentive fees or other provisions that may be considered as a variable consideration.

The Company has a standard quarterly progress review process in which management reviews the progress and execution of the Company's performance obligations. As part of this process, management reviews information including, but not limited to, any outstanding key contract matters, progress towards completion and the related program schedule, identified risks and the related changes in estimates of revenues and costs. The risks and opportunities include management's judgment about the ability and costs to achieve the schedule (e.g., the number and type of milestone events), technical and other contract requirements. Management must make assumptions and estimates regarding the complexity of the work to be performed, the availability of materials and outside services, the length of time to complete the performance obligation and labor and overhead cost rates, among other significant judgments. Based on this analysis, any quarterly adjustments to revenues, cost of revenues, and the related impact to operating earnings are recognized as necessary in the period they become known on a cumulative catch-up basis. When estimates of total costs to be incurred on a performance obligation exceed total estimates of revenues to be earned, a provision for the entire loss on the performance obligation is recognized in the period the loss is determined.

Similar to the Oncology Systems segment, the Company recognizes VPT revenues for software and installation upon completion and acceptance of the software and installation services.

10

VARIAN MEDICAL SYSTEMS, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (CONTINUED)
(Unaudited)


Unfulfilled Performance Obligations for Oncology Systems and VPT
The following table represents the Company's unfulfilled performance obligations as of December 29, 2017 and the estimated revenue expected to be recognized in the future related to these performance obligations:
 
Fiscal years of revenue recognition
(In millions)
2018
 
2019
 
2020
 
Thereafter
Unfulfilled Performance Obligations
$
1,588.2

 
$
1,857.4

 
$
697.4

 
$
1,384.6


The table above includes both product and service unfulfilled performance obligations, which includes a component of service performance obligations which have not been invoiced. The time bands reflect management’s best estimate of when the Company will transfer control to the customer and may change based on timing of shipment, readiness of customers’ facilities for installation, installation requirements, and availability of products or customer acceptance terms.

As part of the Company's adoption of ASC 606, the Company elected to use the following practical expedients (i) to exclude disclosures of transaction prices allocated to remaining performance obligations when the Company expects to recognize such revenue for all periods prior to the date of initial application of ASC 606 (ii) not to adjust the promised amount of consideration for the effects of a significant financing component when the Company expects, at contract inception, that the period between the Company's transfer of a promised product or service to a customer and when the customer pays for that product or service will be one year or less (iii) to expense costs as incurred for costs to obtain a contract when the amortization period would have been one year or less, which mainly includes the Company's internal sales force compensation program and certain partner sales incentive programs (iv) not to recast revenue for contracts that begin and end in the same fiscal period, and (v) not to assess whether promised goods or services are performance obligations if they are immaterial in the context of the contract with the customer.

Contract Balances

The timing of revenue recognition, billings and cash collections results in trade and unbilled receivables, and deferred revenues on the Condensed Consolidated Balance Sheet. In Oncology Systems, the Company often collects an advance payment and the balance is typically billed on a combination of delivery and/or acceptance. In VPT, the Company usually collects an advance payment and additional amounts are billed as work progresses in accordance with agreed-upon contractual terms upon achievement of contractual milestones. Service contracts are usually billed at the beginning of the contract period or at periodic intervals (e.g. monthly or quarterly) during the contract which could result in a contract asset and contract liability. At times, billing occurs subsequent to revenue recognition, resulting in an unbilled receivable which represents a contract asset. However, when the Company receives advances or deposits from customers, which can be higher in the initial stages of the contract, particularly international contracts in the case of Oncology Systems, before revenue is recognized, this results in deferred revenues which represents a contract liability. These contract assets and liabilities are reported as unbilled receivables and deferred revenues, respectively, on the Condensed Consolidated Balance Sheet on a contract-by-contract basis at the end of each reporting period.
Recently Adopted Accounting Pronouncements
In May 2014, the Financial Accounting Standards Board ("FASB") issued ASC 606. Under the standard, revenue is recognized when a customer obtains control of promised goods or services in an amount that reflects the consideration the entity expects to receive in exchange for those goods or services. Effective September 30, 2017, the Company elected to early adopt the requirements of ASC 606 using the full retrospective method, which required the Company to recast the prior reporting periods presented.
The most significant impacts on adoption were in the Oncology Systems segment and are primarily due to the removal of the contingent revenue cap which limited revenue recognition to the amount of cash received from the customer, the elimination of the mandatory revenue deferral for software sold with extended payment terms and the removal of the vendor-specific objective evidence requirement for the separation of bundled software products. The Company also identified additional performance obligations for training and certain elements of warranty that are recognized as separate performance obligations, and identified that certain new performance obligations were previously accounted for as part of hardware products and will result in a change in classification of revenues from product to service. In preparation for adoption of the standard, the Company has implemented internal controls and key system functionalities to enable the preparation of financial information.

11

VARIAN MEDICAL SYSTEMS, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (CONTINUED)
(Unaudited)


The Company has recast its condensed consolidated financial statements from amounts previously reported due to the adoption of ASC 606. Select Condensed Consolidated Statements of Earnings line items, which reflect the adoption of ASC 606 are as follows:
 
Three Months Ended
 
December 30, 2016
(In millions, except per share amounts)
As Previously Reported
 
Adjustments
 
As Adjusted
Revenues:
 
 
 
 
 
Product
$
343.6

 
$
(34.4
)
 
$
309.2

Service
268.2

 
24.1

 
292.3

Total revenues
611.8

 
(10.3
)
 
601.5

Cost of revenues:
 
 
 
 
 
Product
224.4

 
(18.2
)
 
206.2

Service
111.7

 
16.6

 
128.3

Total cost of revenues
336.1

 
(1.6
)
 
334.5

Gross margin
275.7

 
(8.7
)
 
267.0

Earnings from continuing operations before taxes
28.0

 
(8.7
)
 
19.3

Taxes on earnings
13.5

 
(2.2
)
 
11.3

Net earnings from continuing operations
14.5

 
(6.5
)
 
8.0

Net earnings from discontinued operations
6.5

 

 
6.5

Net earnings
$
21.0

 
$
(6.5
)
 
$
14.5

Net earnings attributable to Varian
$
20.4

 
$
(6.5
)
 
$
13.9

 
 
 
 
 
 
Diluted net earnings per share from continuing operations attributable to Varian
$
0.15

 
$
(0.07
)
 
$
0.08

Select Condensed Consolidated Statements of Balance Sheet line items, which reflect the adoption of ASC 606 are as follows:
 
September 29, 2017
(In millions)
As Previously Reported
 
Adjustments
 
As Adjusted
Assets:
 
 
 
 
 
Trade and unbilled receivables, net
$
823.5

 
$
138.0

 
$
961.5

Inventories
439.7

 
(22.0
)
 
417.7

Prepaid expenses and other current assets
199.8

 
(9.5
)
 
190.3

Deferred tax assets
138.8

 
8.5

 
147.3

 
 
 
 
 
 
Liabilities and Equity:
 
 
 
 
 
Accrued liabilities
394.7

 
(19.8
)
 
374.9

Deferred revenues
640.6

 
114.8

 
755.4

Other long-term liabilities
130.0

 
(2.6
)
 
127.4

Retained earnings
756.0

 
22.6

 
778.6

In addition, the cumulative effect of ASC 606 to the Company's retained earnings at October 2, 2015 was $56.7 million . Adoption of ASC 606 had no impact to net cash from or used in operating, investing or financing activities in the Company's Condensed Consolidated Statements of Cash Flows.
In the first quarter of fiscal year 2018, the Company elected to early adopt the FASB guidance which targeted improvements to the accounting for hedging activities. The guidance allows companies to more accurately present the economic effects of risk management activities in the financial statements. This amendment is required to be applied prospectively. The primary impact

12

VARIAN MEDICAL SYSTEMS, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (CONTINUED)
(Unaudited)


of the adoption is the required disclosure changes. The adoption of the new guidance did not have material impact on the Company's condensed consolidated financial statements.
In the first quarter of fiscal year 2018, the Company adopted the FASB guidance related to employee share-based payments. The amendment simplifies several aspects of the accounting for employee share-based payments including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. The Company has elected to use the prospective transition method for the presentation of excess tax benefits on the statement of cash flows. Under the new standard, excess tax benefits are now included in taxes on earnings in the Consolidated Statement of Earnings. The Company elected to recognize forfeitures as they occur and the impact of this change in accounting policy was recorded as a $0.4 million reduction, net, to its beginning retained earnings balance as of September 30, 2017. See Note 11, "Income Taxes" for more information on the impact of this accounting guidance. The remaining provisions of this amendment did not have a material impact on the Company's condensed consolidated financial statements.
In the first quarter of fiscal year 2018, the Company adopted the FASB accounting guidance related to inventory measurement. The amendment requires inventory measured using first-in, first-out (FIFO) or average cost to be subsequently measured at the lower of cost and net realizable value, thereby simplifying the current guidance that requires an entity to measure inventory at the lower of cost or market. This amendment is required to be applied prospectively. The adoption of this new guidance did not have a material impact to the Company’s condensed consolidated financial statements.
In the first quarter of fiscal year 2018, the Company elected to early adopt the FASB guidance on the definition of a business in accounting for transactions when determining whether they represent acquisitions or disposals of assets or of a business. The Company adopted this amendment prospectively. The adoption of this new guidance did not have an impact to the Company’s condensed consolidated financial statements.
In the first quarter of fiscal year 2018, the Company elected to early adopt the FASB guidance simplifying the measurement of goodwill by eliminating the Step 2 impairment test. The new guidance requires companies to perform the goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. The Company adopted this amendment prospectively. The adoption of this new guidance did not have an impact to the Company’s condensed consolidated financial statements.
Recent Accounting Standards or Updates Not Yet Effective
In May 2017, the FASB provided guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting. The guidance is effective for the Company beginning in the first quarter of fiscal 2019. Early adoption is permitted. The Company does not expect that the adoption of this guidance will have a material impact on its condensed consolidated financial statements.
In March 2017, the FASB amended its guidance on the accounting related to defined benefit plans and other post-retirement benefits. This amendment requires the service cost component of net periodic pension and post-retirement benefit cost be presented in the same line item as other employee compensation costs, while the other components be presented separately as non-operating income (expense). The amendment will be effective for the Company beginning in its first quarter of fiscal year 2019. Early adoption is permitted. The Company is evaluating the impact of adopting this amendment to its condensed consolidated financial statements.
In November 2016, the FASB amended its guidance on the classification and presentation of restricted cash in the statement of cash flow. The amendment requires entities to include restricted cash and restricted cash equivalents in its cash and cash equivalents in the statement of cash flows. The amendment will be effective for the Company beginning in its first quarter of fiscal year 2019 with early adoption permitted. The amendment is required to be adopted retrospectively. The amendment is not expected to have a material impact to the Company’s condensed consolidated financial statements.
In October 2016, the FASB amended its guidance for tax accounting for intra-entity asset transfers. The amendment removes the prohibition against the immediate recognition of the current and deferred income tax effects of intra-entity transfers of assets other than inventory. The amendment will be effective for the Company beginning in its first quarter of fiscal year 2019. Early adoption is permitted. The amendment is required to be adopted on a modified retrospective basis. The Company is evaluating the impact of adopting this amendment to its condensed consolidated financial statements.

13

VARIAN MEDICAL SYSTEMS, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (CONTINUED)
(Unaudited)


In August 2016, the FASB issued an amendment to its accounting guidance related to the classification of certain cash receipts and cash payments. The amendment was issued to reduce the diversity in practice in how certain transactions are classified in the statement of cash flows. The amendment will be effective for the Company beginning in its first quarter of fiscal year 2019 with early adoption permitted. The amendment is required to be adopted retrospectively unless it is impracticable. The Company is evaluating the impact of adopting this amendment to its condensed consolidated financial statements.
In June 2016, the FASB issued an amendment to its accounting guidance related to impairment of financial instruments. The amendment adds a new impairment model that is based on expected losses rather than incurred losses. The amendment will be effective for the Company beginning in its first quarter of fiscal year 2021 with early adoption permitted beginning in the first quarter of fiscal year 2020. The Company is evaluating the impact of adopting this amendment to its condensed consolidated financial statements.
In February 2016, the FASB issued a new standard on accounting for leases. The new standard is intended to provide enhanced transparency and comparability by requiring lessees to record right-of-use assets and corresponding lease liabilities on the balance sheet. The new standard will continue to classify leases as either finance or operating, with classification affecting the pattern of expense recognition in the statement of earnings. The new standard is required to be adopted using a modified retrospective method to each prior reporting period presented with various optional practical expedients. The new standard will be effective for the Company beginning in its first quarter of fiscal year 2020 with early adoption permitted. The Company is evaluating the impact of adopting this new standard to its condensed consolidated financial statements.
In January 2016, the FASB issued an amendment to its accounting guidance related to recognition and measurement of financial assets and financial liabilities. The amendment addresses certain aspects of recognition, measurement, presentation and disclosure of financial instruments. The amendment will be effective for the Company beginning in its first quarter of fiscal year 2019. The Company is evaluating the impact of adopting this amendment to its condensed consolidated financial statements.
2. DISCONTINUED OPERATIONS

On January 28, 2017, the Company completed the Distribution of Varex. In connection with the Distribution, the Company and Varex entered into a separation and distribution agreement as well as various other agreements that governs the relationships between the parties, including a transition services agreement, a tax matters agreement, an employee matters agreement, an intellectual property matters agreement, a trademark license agreement and supply/distribution agreements. The separation and distribution agreement and other agreements related to the separation were entered into on January 27, 2017. Services under the transition services agreement were for 60 days to 24 months following the Distribution Date, depending on the service provided.
On January 25, 2017, the Company entered into a term facility ("Varex Term Facility"), and on the same day drew down $203.0 million under the facility. In conjunction with the Distribution, the Company used $200.0 million of those proceeds to repay a portion of its outstanding 2013 Revolving Credit Facility. At the Distribution Date, the Company contributed $81.3 million in cash and cash equivalents to Varex as part of the distribution and transfer of certain legal entities. In fiscal year 2017, the Company received $38.7 million from Varex for excess cash and cash equivalents contributed at the Distribution Date. In fiscal year 2017, the Company recorded a $334.1 million reduction to retained earnings as a result of the Distribution of Varex, which included assets and liabilities transferred to Varex on the distribution date, including $203.0 million debt outstanding under the Varex Term Facility.
Following the Distribution, Varex retained a specified amount of cash that would enable Varex to pay the Company consideration for certain net assets outside of the United States that were required to be transferred to Varex but which did not occur on the Distribution Date due to not having received regulatory approvals for such transfers. Once those regulatory approvals are received, the Company will receive a cash payment from Varex in consideration for such net asset transfers. At December 29, 2017 , the Company had $9.2 million in assets (net of liabilities) on its Condensed Consolidated Balance Sheet related to Varex net assets to be transferred. The Company expects the remainder of Varex's net assets will be transferred in fiscal year 2018. If the Company does not receive the necessary regulatory approvals during a specified time period, Varex will be required to transfer such cash amounts to Varian.
The financial results of Varex are presented as net earnings from discontinued operations on the Condensed Consolidated Statements of Earnings, and primarily include the financial results of the Company's former Imaging Components operating segment and costs relating to the Distribution. Corporate costs previously allocated to the Company's Imaging Components

14

VARIAN MEDICAL SYSTEMS, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (CONTINUED)
(Unaudited)


operating segment are not included in discontinued operations. See Note 16, "Segment Information" for more information related to corporate allocated costs.
The following table summarizes the key components of net earnings from discontinued operations:
 
Three Months Ended (1)
(In millions)
December 30,
2016
Revenues
$
151.5

Cost of revenues
92.7

Gross margin
58.8

Operating expenses (2)
46.4

Operating earnings
12.4

Taxes on earnings
5.9

Net earnings from discontinued operations
6.5

Less: Net earnings from discontinued operations attributable to noncontrolling interests
0.1

Net earnings from discontinued operations attributable to Varian
$
6.4

(1)  
There was no activity in net earnings from discontinued operations during the three months ended December 29, 2017 .
(2)  
Operating expenses included separation costs of $14.9 million during the three months ended December 30, 2016 . Separation costs include expenses for transaction advisory services, consulting services, restructuring and other expenses.
The following table summarizes the major classes of assets and liabilities of discontinued operations that were included in the Company's balance sheet:
(In millions)
December 29,
2017
 
September 29,
2017
Assets:
 
 
 
Trade accounts receivable, net
$
9.0

 
$
8.1

Inventories
2.2

 
2.9

Prepaid expenses and other current assets
0.1

 
0.1

Current assets of discontinued operations
11.3

 
11.1

Total assets of discontinued operations
$
11.3

 
$
11.1

Liabilities:
 
 
 
Accounts payable
$
1.2

 
$
2.0

Accrued liabilities
0.9

 
0.5

Current liabilities of discontinued operations
2.1

 
2.5

Total liabilities of discontinued operations
$
2.1

 
$
2.5


15

VARIAN MEDICAL SYSTEMS, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (CONTINUED)
(Unaudited)


The following table presents supplemental cash flow information of discontinued operations:
 
Three Months Ended (1)
(In millions)
December 30,
2016
Operating activities:
 
Share-based compensation expense
$
1.3

Depreciation expense
3.3

Amortization expense
1.3

Investing activities:
 
Purchases of property, plant and equipment
(5.0
)
(1)  
There was no cash flow activity from discontinued operations during the three months ended December 29, 2017 .
3. BALANCE SHEET COMPONENTS  

The following table provides the Company's unbilled receivables and deferred revenues from contracts with customers as of December 29, 2017 and September 29, 2017 :

(In millions)
December 29,
2017
 
September 29,
2017
Unbilled receivables - current
$
269.5

 
$
259.1

Unbilled receivables - long-term (1)
29.0

 
10.9

Deferred revenues - current
(772.3
)
 
(755.4
)
Deferred revenues - long-term (2)
(8.8
)
 
(7.2
)
Total net unbilled receivables (deferred revenues)
$
(482.6
)
 
$
(492.6
)
(1)  
Included in other assets on the Company's Condensed Consolidated Balance Sheets.
(2)  
Included in other long-term liabilities on the Company's Condensed Consolidated Balance Sheets.

During the three months ended December 29, 2017 , unbilled receivables net of deferred revenues increased by $10.0 million primarily due to timing of billings occurring after the revenue was recognized and also milestone payments.

During the three months ended December 29, 2017 and December 30, 2016 , the Company recognized revenue of $196.4 million and $218.8 million , respectively, which was included in the deferred revenues balance at September 29, 2017 and September 30, 2016 , respectively.

The Company did not have any impairment losses on its unbilled receivables during the three months ended December 29, 2017 . The Company recognized an impairment loss of $17.2 million from long-term unbilled receivables during the three months ended December 30, 2016 . See Note 15, "VPT Loans and Securities" for further information.

The following table summarizes the Company's inventories:
(In millions)
December 29,
2017
 
September 29,
2017
Raw materials and parts
$
319.8

 
$
296.5

Work-in-process
47.6

 
47.7

Finished goods
64.0

 
73.5

Total inventories
$
431.4

 
$
417.7



16

VARIAN MEDICAL SYSTEMS, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (CONTINUED)
(Unaudited)


The following tables summarize the Company's available-for-sale securities:
 
December 29, 2017
(In millions)
Amortized Cost
 
Gross Unrealized Gains
 
Gross Unrealized Losses
 
Fair Value
DRTC securities (1)
$
8.0

 
$

 
$

 
$
8.0

APTC securities (1)
6.0

 

 

 
6.0

GPTC securities (2)
4.5

 

 

 
4.5

   Total available-for-sale securities
$
18.5

 
$

 
$

 
$
18.5


 
September 29, 2017
(In millions)
Amortized Cost
 
Gross Unrealized Gains
 
Gross Unrealized Losses
 
Fair Value
Original CPTC loans (2)
$
47.4

 
$

 
$

 
$
47.4

DRTC securities  (2)
8.0

 

 

 
8.0

GPTC securities (2)
4.4

 

 

 
4.4

   Total available-for-sale securities
$
59.8

 
$

 
$

 
$
59.8


(1)  
Included in prepaid and other current assets on the Company's Condensed Consolidated Balance Sheets because the Company has the ability and intent to sell these securities in the next twelve months. Subsequent to December 29, 2017, the Company sold its DRTC securities.
(2)  
Included in other assets on the Company's Condensed Consolidated Balance Sheets because the maturity dates are greater than one year and the Company does not have the intent and ability to collect or sell all or a portion of its loans or securities in the next twelve months.

See Note 4, "Fair Value" and Note 15, "VPT Loans and Securities" for more information on the Original California Proton Treatment Center, LLC (“Original CPTC”) Loans, Alabama Proton Therapy Center ("APTC"), Delray Radiation Therapy Center (“DRTC”) and Georgia Proton Treatment Center ("GPTC") Securities.

The following table summarizes the Company's other long-term liabilities:
(In millions)
December 29,
2017
 
September 29,
2017
Long-term income taxes payable
$
203.0

 
$
48.6

Deferred income taxes
27.3

 
17.1

Other
62.1

 
61.7

Total other long-term liabilities
$
292.4

 
$
127.4


17

VARIAN MEDICAL SYSTEMS, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (CONTINUED)
(Unaudited)


4. FAIR VALUE

Assets/Liabilities Measured at Fair Value on a Recurring Basis
In the tables below, the Company has segregated all assets and liabilities that are measured at fair value on a recurring basis into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date.
 
 
Fair Value Measurement Using
 
 
Quoted Prices in
Active Markets
for Identical
Instruments
 
Significant
Other
Observable
Inputs
 
Significant
Unobservable
Inputs
 
Total
Type of Instruments
 
(Level 1)
 
(Level 2)
 
(Level 3)
 
Balance
(In millions)
 
 
 
 
 
 
 
 
Assets at December 29, 2017:
 
 
 
 
 
 
 
 
Available-for-sale securities:
 
 
 
 
 
 
 
 
DRTC securities
 
$

 
$
8.0

 
$

 
$
8.0

APTC securities
 

 
6.0

 

 
6.0

GPTC securities
 

 
4.5

 

 
4.5

Total assets measured at fair value
 
$

 
$
18.5

 
$

 
$
18.5

 
 
 
 
 
 
 
 
 
Liabilities at December 29, 2017:
 
 
 
 
 
 
 
 
Derivative liabilities:
 
$

 
$
(0.4
)
 
$

 
$
(0.4
)
Total liabilities measured at fair value
 
$

 
$
(0.4
)
 
$

 
$
(0.4
)
 
 
 
 
 
 
 
 
 
Assets at September 29, 2017:
 
 
 
 
 
 
 
 
Available-for-sale securities:
 
 
 
 
 
 
 
 
Original CPTC loans
 
$

 
$

 
$
47.4

 
$
47.4

DRTC securities
 

 
8.0

 

 
8.0

GPTC securities
 

 
4.4

 

 
4.4

Total assets measured at fair value
 
$

 
$
12.4

 
$
47.4

 
$
59.8

 
The Company's Level 2 available-for-sale securities consist of bonds for DRTC, APTC and GPTC. The observable inputs for these securities are comparable bond issues, broker/dealer quotations for the same or similar investments in active markets and other observable inputs such as yields, credit risks, default rates, and volatility. As of December 29, 2017 and September 29, 2017, the carrying amount of the Level 2 available-for-sale securities approximated their fair value. See Note 15, "VPT Loans and Securities" for further information about these bonds.

The Company has elected to use the income approach to value its derivative instruments using standard valuation techniques and Level 2 inputs, such as currency spot rates, forward points and credit default swap spreads. The Company’s derivative instruments are generally short-term in nature, typically one month to thirteen months in duration. See Note 8, "Derivative Instruments and Hedging Activities" for more information about the Company's derivative instruments.
In December 2017, the Original CPTC loans were modified and partially satisfied resulting in a Term Loan of $53.5 million , as defined in Note 15, "VPT Loans and Securities" for further information. One of the modifications was that the loan agent no longer has the option to purchase these loans from the Company, therefore, the Original CPTC loans are no longer classified as an available-for-sale security. The Company had no unrealized gains or unrealized losses associated with the Original CPTC loans recorded in its other comprehensive income. The modification to the Original CPTC Loans had no impact on the Company's Condensed Consolidated Statements of Earnings for the three months ended December 29, 2017. As of September 29, 2017, the Company classified the Original CPTC loans as available-for-sale securities, the fair value of which was based on the income approach by using the discounted cash flow model with key assumptions that include discount rates corresponding to the terms and risks associated with the loans as well as underlying cash flow assumptions. However, the Company did not increase the fair value of the Original CPTC loans above their par values as ORIX Capital Markets, LLC (“ORIX”), the loan agent, had the option to purchase these loans from the Company under the original terms and conditions at par value.

18

VARIAN MEDICAL SYSTEMS, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (CONTINUED)
(Unaudited)


The following table presents the reconciliation for all assets and liabilities measured and recorded at fair value on a recurring basis using significant unobservable inputs (Level 3):
(In millions)
Available-for-sale Securities
Balance at September 29, 2017
$
47.4

Reclassification of Original CPTC Loans to Term Loan
(47.4
)
Balance at December 29, 2017
$


There were no transfers of assets or liabilities between fair value measurement levels during either the three months ended December 29, 2017 , or the three months ended December 30, 2016 . Transfers between fair value measurement levels are recognized at the end of the reporting period.
Fair Value of Other Financial Instruments
The fair values of certain of the Company’s financial instruments, including bank deposits included in cash and cash equivalents, trade and unbilled receivables, net of allowance for doubtful accounts, short-term notes receivable, revolving loan to CPTC, senior secured debt, accounts payable, and short-term borrowings approximate their carrying amounts due to their short maturities.
As of December 29, 2017 , the fair value of the Term Loan with CPTC approximated its carrying value of $44.0 million . See Note 15, "VPT Loans and Securities" for further information. The carrying value is based on the present value of expected future cash payments discounted at a rate reflecting the nature and duration of the loans, risks involved with CPTC, and its industry. As a result, the Term Loan is categorized as Level 3 in the fair value hierarchy.
The fair value of the outstanding long-term notes receivable approximated their carrying value of $56.0 million and $86.7 million at December 29, 2017 and September 29, 2017 , respectively, because they are based on terms of recent comparable transactions and are categorized as Level 3 in the fair value hierarchy. The fair value is based on the income approach by using the discounted cash flow model with key assumptions that include discount rates corresponding to the terms and risks as well as underlying cash flow assumptions. See, Note 5, "Receivables" for information on the long-term notes receivable.
5. RECEIVABLES
The following table summarizes the Company's trade and unbilled receivables, net and notes receivable as of December 29, 2017 and September 29, 2017 :
(In millions)
December 29,
2017
 
September 29,
2017
Trade and unbilled receivables, gross
$
955.5

 
$
1,039.2

Allowance for doubtful accounts
(42.6
)
 
(63.1
)
Trade and unbilled receivables, net
$
912.9

 
$
976.1

Short-term
$
880.1

 
$
961.5

Long-term (1)  
$
32.8

 
$
14.6

 
 
 
 
Notes receivable
$
86.0

 
$
91.7

Short-term (2)  
$
30.0

 
$
5.0

Long-term (1)
$
56.0

 
$
86.7

(1)  
Included in other assets on the Company's Condensed Consolidated Balance Sheets.
(2)  
Included in prepaid expenses and other current assets on the Company's Condensed Consolidated Balance Sheets.
A financing receivable represents a financing arrangement with a contractual right to receive money, on demand or on fixed or determinable dates, and that is recognized as an asset on the Company’s Condensed Consolidated Balance Sheets. The Company’s financing receivables consist of trade receivables with contractual maturities of more than one year and notes receivable. A small portion of the Company's financing trade receivables are included in short-term trade accounts receivable.

19

VARIAN MEDICAL SYSTEMS, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (CONTINUED)
(Unaudited)


As of December 29, 2017 , the allowance for doubtful accounts is entirely related to short-term trade and unbilled receivables. As of September 29, 2017 , the allowance for doubtful accounts included $45.9 million related to short-term trade and unbilled receivables and $17.2 million related to long-term unbilled receivables, which was written off in the first quarter of fiscal year 2018.
See Note 15, "VPT Loans and Securities" for more information on the Company's short-term and long-term notes receivable balances.
6. GOODWILL AND INTANGIBLE ASSETS
The following table reflects the activity of goodwill by reportable operating segment: 
(In millions)
Oncology
Systems
 
Varian Particle Therapy
 
Total
Balance at September 29, 2017
$
170.2

 
$
52.4

 
$
222.6

Foreign currency translation adjustments

 
0.8

 
0.8

Balance at December 29, 2017
$
170.2

 
$
53.2

 
$
223.4

The following table reflects the gross carrying amount and accumulated amortization of the Company's intangible assets: 
 
December 29, 2017
 
September 29, 2017
(In millions)
Gross Carrying Amount
 
Accumulated Amortization
 
Net Carrying Amount
 
Gross Carrying Amount
 
Accumulated Amortization
 
Net Carrying Amount
Technologies and patents
$
102.0

 
$
(65.3
)
 
$
36.7

 
$
102.0

 
$
(60.9
)
 
$
41.1

Customer contracts and supplier relationship
33.9

 
(15.3
)
 
18.6

 
33.9

 
(14.3
)
 
19.6

Other
5.5

 
(4.0
)
 
1.5

 
5.5

 
(3.4
)
 
2.1

Total intangible with finite lives
141.4

 
(84.6
)
 
56.8

 
141.4

 
(78.6
)
 
62.8

In-process research and development with indefinite lives
8.8

 

 
8.8

 
8.8

 

 
8.8

Total intangible assets
$
150.2

 
$
(84.6
)
 
$
65.6

 
$
150.2

 
$
(78.6
)
 
$
71.6

Amortization expense for intangible assets was $6.3 million and $3.8 million in the three months ended December 29, 2017 and December 30, 2016 , respectively.
As of December 29, 2017 , the Company estimates its remaining amortization expense for intangible assets with finite lives will be as follows (in millions):
Fiscal Years:
Remaining Amortization Expense
Remainder of 2018
$
12.6

2019
11.7

2020
9.3

2021
7.2

2022
6.0

Thereafter
10.0

Total remaining amortization for intangible assets
$
56.8



20

VARIAN MEDICAL SYSTEMS, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (CONTINUED)
(Unaudited)


7. BORROWINGS
The following table summarizes the Company's short-term borrowings:
 
December 29, 2017
 
September 29, 2017
(In millions, except for percentages)
Amount
 
Weighted-Average Interest Rate
 
Amount
 
Weighted-Average Interest Rate
Short-term borrowings:
 
 
 
 
 
 
 
2017 Revolving Credit Facility
$
340.0

 
2.49
%
 
$
350.0

 
2.36
%
Total short-term borrowings
$
340.0

 
 
 
$
350.0

 
 
The Company entered into an agreement, dated September 1, 2017, ("Credit Agreement") with certain lenders and Bank of America, N.A. (“BofA”) as administrative agent ("Debt Lenders"). The Credit Agreement provides for a five -year revolving credit facility (the "2017 Revolving Credit Facility") in an aggregate principal amount of up to $600.0 million . The 2017 Revolving Credit Facility also includes a $50 million sub-facility for the issuance of letters of credit and permits swing line loans of up to $25 million . The Company may increase the aggregate commitments under the 2017 Revolving Credit Facility by up to $100 million , plus an amount based on the Company's consolidated leverage ratio on a pro forma basis, subject to certain conditions being met, including lender approval. The Credit Agreement will expire in September 2022. The 2017 Revolving Credit Facility can be prepaid without any premium or penalty. The proceeds of the 2017 Credit Facility may be used for working capital, capital expenditures, Company share repurchases, acquisitions and other corporate purposes, as well as to satisfy the outstanding obligation under the prior credit facility. The Company incurred $1.8 million in debt issuance costs for its 2017 Revolving Credit Facility, which will be amortized over the five -year term. Debt issuance costs are recorded in prepaid expenses and other current assets and other assets on the Condensed Consolidated Balance Sheets.
 
Borrowings under the 2017 Revolving Credit Facility accrue interest at either (i) based on the Eurodollar Rate plus a margin of 1.125% to 1.875% based on a leverage ratio involving funded indebtedness and EBITDA, or (ii) based upon a base rate of (a) the federal funds rate plus 0.50% , (b) BofA’s announced prime rate, or (c) the Eurodollar Rate plus 1.00% , whichever is highest, plus a margin of 0.125% to 0.875% based on the same leverage ratio, depending upon instructions from the Company. Borrowings under the 2017 Revolving Credit Facility have a contract repayment date of twelve months , or less, and a final maturity of five years if based on the Eurodollar Rate and all overnight borrowings on the base rate would also have a final maturity of five years.
The Company must pay a commitment fee on the unused portion of the 2017 Revolving Credit Facility at a rate from 0.125% to 0.25% based on a leverage ratio. The Company may prepay, reduce or terminate the commitments without penalty. Swing line loans under the 2017 Credit Facility will bear interest at the base rate plus the then applicable margin for base rate loans.
The Credit Agreement provides that certain material domestic subsidiaries must guarantee the 2017 Revolving Credit Facility, subject to certain limitations on the amount secured. As of December 29, 2017 , no subsidiary guaranties were required to be executed under the Credit Agreement.
The Credit Agreement contains provisions that limit the Company's ability to, among other things, incur future indebtedness, contingent obligations or liens, guarantee indebtedness, make certain investments and capital expenditures, sell stock or assets and pay dividends, and consummate certain mergers or acquisitions.
The Credit Agreement contains affirmative and negative covenants applicable to the Company and its subsidiaries that are typical for credit facilities of this type, and that are subject to materiality and other qualifications, carve-outs, baskets and exceptions. The Company has also agreed to maintain certain financial covenants including (i) a maximum consolidated leverage ratio, involving funded indebtedness and EBITDA, and (ii) a minimum consolidated interest coverage ratio. The Company was in compliance with all financial covenants under the Credit Agreement for all periods within these condensed consolidated financial statements.

VMS’s Japanese subsidiary (“VMS KK”) has an unsecured uncommitted credit agreement with Sumitomo that enables VMS KK to borrow and have outstanding at any given time a maximum of 3.0 billion Japanese Yen (the “Sumitomo Credit Facility”). In February 2017, the Sumitomo Credit Facility was extended and will expire in February 2018 . Borrowings under the Sumitomo Credit Facility accrue interest based on the basic loan rate announced by the Bank of Japan plus a margin of 0.5% .

21

VARIAN MEDICAL SYSTEMS, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (CONTINUED)
(Unaudited)



8. DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES
The Company measures all derivatives at fair value on the Condensed Consolidated Balance Sheets. The accounting for gains or losses resulting from changes in the fair value of those derivatives depends upon the use of the derivative and whether it qualifies for hedge accounting.
The fair value of derivative instruments reported on the Condensed Consolidated Balance Sheets was as follows:
 
Liability Derivatives
 
Balance Sheet
 
December 29, 2017
(In millions)
Location
 
Fair Value
Derivatives designated as hedging instruments:
 
 
 
Foreign exchange forward contracts
Accrued liabilities
 
$
(0.4
)
Total derivatives
 
 
$
(0.4
)
At September 29, 2017 , the Company did not have any outstanding derivatives designated as hedging instruments. As of December 29, 2017 and September 29, 2017 , the fair value of the Company's derivatives not designated as hedging instruments were not material. See Note 4, "Fair Value" for the valuation of the Company’s derivative instruments. Also, see Note 1, "Summary of Significant Accounting Policies" in the Consolidated Financial Statements in the Company’s 2017 Annual Report for the credit risk associated with the Company’s derivative instruments.
Offsetting of Derivatives
The Company presents its derivative assets and derivative liabilities on a gross basis on the Condensed Consolidated Balance Sheets. However, under agreements containing provisions on netting with certain counterparties of foreign exchange contracts, subject to applicable requirements, the Company is allowed to net-settle transactions in the same currency, with a single net amount payable by one party to the other. As of  December 29, 2017  and  September 29, 2017 , there were no potential effects of rights of setoff associated with derivative instruments. The Company is neither required to pledge nor entitled to receive cash collateral related to these derivative transactions.
Cash Flow Hedging Activities
The Company has many transactions denominated in foreign currencies and addresses certain of those financial exposures through a risk management program that includes the use of derivative financial instruments. The Company sells products throughout the world, often in the currency of the customer’s country, and may hedge certain of the larger foreign currency transactions when they are either not denominated in the relevant subsidiary’s functional currency or the U.S. Dollar. These foreign currency sales transactions are hedged using foreign currency forward contracts. The Company may use other derivative instruments in the future. The Company does not enter into foreign currency forward contracts for speculative or trading purposes. Foreign currency forward contracts are entered into up to several times a quarter and range from one to thirteen months in maturity.

The hedges of foreign currency denominated forecasted revenues are designated and accounted for as cash flow hedges. The designated cash flow hedges de-designate when the anticipated revenues associated with the transactions are recognized and the change in fair value of the derivatives in accumulated other comprehensive loss on the Condensed Consolidated Balance Sheets is reclassified to revenues in the Condensed Consolidated Statements of Earnings. Subsequent changes in fair value of the derivative instrument are recorded in selling, general and administrative expenses in the Condensed Consolidated Statements of Earnings to offset changes in fair value of the resulting non-functional currency receivables. For derivative instruments that are designated and qualified as cash flow hedges, the Company formally documents for each derivative instrument at the hedge’s inception, the relationship between the hedging instrument (foreign currency forward contract) and hedged item (forecasted foreign currency revenues), the nature of the risk being hedged and its risk management objective and strategy for undertaking the hedge. The Company records the gain or loss on the derivative instruments that are designated and qualified as cash flow hedges in accumulated other comprehensive loss on the Condensed Consolidated Balance Sheets and reclassifies these amounts into revenues in the Condensed Consolidated Statements of Earnings (Loss) in the period in which the hedged transaction is

22

VARIAN MEDICAL SYSTEMS, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (CONTINUED)
(Unaudited)


recognized in earnings. The Company assesses hedge effectiveness both at the onset of the hedge and on an ongoing basis using regression analysis. The time value of the derivative and hedged item is included in the assessment of hedge effectiveness.

At the inception of the hedge relationship and quarterly thereafter, the Company assesses whether the likelihood of meeting the forecasted cash flow is highly probable. As of December 29, 2017 , all forecasted cash flows were still probable to occur. As of December 29, 2017 , the net unrealized loss, before tax, on derivative instruments of $0.4 million was included in accumulated other comprehensive loss and is expected to be reclassified to earnings over the next twelve months.

The Company had the following outstanding foreign currency forward contracts that were entered into to hedge forecasted revenues and designated as cash flow hedges:
 
December 29, 2017
(In millions)
Notional
Value Sold
Euro
$
24.9

Total
$
24.9


During the three months ended December 29, 2017 , the Company recognized an unrealized loss of $0.3 million , in other comprehensive earnings on foreign currency forward contracts designated as cash flow hedges. The Company did not have any foreign currency forward contracts designated as cash flow hedges during the three months ended December 30, 2016 .

The effect of cash flow hedge accounting on the Condensed Consolidated Statements of Earnings (Loss) was as follows:
 
Location and Amount Recognized in Earnings (Loss) on Cash Flow Hedging Relationships
 
December 29,
 
December 30,
 
2017
 
2016
(In millions)
Revenues
 
Revenues
Total amounts of income and expense line items presented in the Condensed Consolidated Statements of Earnings (Loss) in which the effects of fair value and cash flow hedges are recorded
$
678.5

 
$
601.5

 
 
 
 
Loss on cash flow hedge relationships:
 
 
 
Foreign exchange contracts:
 
 
 
Amount of gain reclassified from accumulated other comprehensive loss into earnings (loss)
$
0.1

 
$

Balance Sheet Hedging Activities
The Company also hedges balance sheet exposures from its various subsidiaries and business units where the U.S. Dollar is the functional currency. The Company enters into foreign currency forward contracts to minimize the short-term impact of foreign currency fluctuations on monetary assets and liabilities denominated in currencies other than the U.S. Dollar functional currency. The foreign currency forward contracts are short term in nature, typically with a maturity of approximately one month , and are based on the net forecasted balance sheet exposure. For derivative instruments not designated as hedging instruments, changes in their fair values are recognized in selling, general and administrative expenses in the Condensed Consolidated Statements of Earnings (Loss). Changes in the values of these hedging instruments are offset by changes in the values of foreign-currency-denominated assets and liabilities. Variations from the forecasted foreign currency assets or liabilities, coupled with a significant currency rate movement, may result in a material gain or loss if the hedges are not effectively offsetting the change in value of the foreign currency asset or liability. Other than foreign exchange hedging activities, the Company has no other free-standing or embedded derivative instruments.

23

VARIAN MEDICAL SYSTEMS, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (CONTINUED)
(Unaudited)


The Company had the following outstanding foreign currency forward contracts:
 
December 29, 2017
(In millions)
Notional
Value Sold
 
Notional
Value Purchased
Australian Dollar
$
34.7

 
$

Brazilian Real
10.9

 

British Pound
31.7

 

Canadian Dollar
3.4

 

Euro
252.1

 
6.0

Hungarian Forint
3.2

 

Indian Rupee
11.2

 

Japanese Yen
62.9

 

Norwegian Krone
2.2

 

Polish Zloty
33.2

 

Swiss Franc

 
40.9

Thai Baht
4.6

 

Totals
$
450.1

 
$
46.9

 
The following table presents the gains (losses) recognized in the Condensed Consolidated Statements of Earnings (Loss) related to the foreign currency forward contracts that are not designated as hedging instruments.
Location of Gain (Loss) Recognized in Income on Derivative Instruments
 
Amount of Gain (Loss) Recognized in Net Earnings (Loss) on Derivative Instruments
 
 
Three Months Ended
(In millions)
 
December 29,
2017
 
December 30,
2016
Selling, general and administrative expenses
 
$
(4.7
)
 
$
14.9

 
The gains (losses) on these derivative instruments were significantly offset by the gains (losses) resulting from the re-measurement of monetary assets and liabilities denominated in currencies other than the U.S. Dollar functional currency.
Contingent Features
Certain of the Company’s derivative instruments are subject to master agreements which contain provisions that require the Company, in the event of a default, to settle the outstanding contracts in net liability positions by making settlement payments in cash or by setting off amounts owed to the counterparty against any credit support or collateral held by the counterparty. As of December 29, 2017 and September 29, 2017 , the Company did not have any outstanding derivative instruments with credit-risk-related contingent features that were in a net liability position.
9. COMMITMENTS AND CONTINGENCIES
Product Warranty
The following table reflects the changes in the Company’s accrued product warranty:
 
Three Months Ended
(In millions)
December 29,
2017
 
December 30,
2016
Accrued product warranty, at beginning of period
$
41.3

 
$
41.9

Charged to cost of revenues
14.4

 
9.2

Actual product warranty expenditures
(8.6
)
 
(12.1
)
Accrued product warranty, at end of period
$
47.1

 
$
39.0


24

VARIAN MEDICAL SYSTEMS, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (CONTINUED)
(Unaudited)


 
Accrued product warranty was included in accrued liabilities and other long-term liabilities on the Condensed Consolidated Balance Sheets as of December 29, 2017 and September 29, 2017 .
Contingencies
Environmental Remediation Liabilities
The Company’s operations and facilities, past and present, are subject to environmental laws, including laws that regulate the handling, storage, transport and disposal of hazardous substances. Certain of those laws impose cleanup liabilities on the Company in connection with its past and present operations. Those include facilities sold as part of the Company’s electron devices business in 1995 and thin film systems business in 1997. As a result, the Company oversees various environmental cleanup projects and receives reimbursements from third parties for a portion of the costs of its cleanup activities.
The Company also reimburses certain third parties for cleanup activities. The Company spent $0.2 million and $0.1 million (net of amounts borne by third-parties) in the three months ended December 29, 2017 and December 30, 2016 , respectively, on environmental cleanup costs, third-party claim costs, project management costs and legal costs.
With respect to some of these facilities, inherent uncertainties make it difficult to estimate the likelihood of the cost of future cleanup, third-party claims, project management and legal services for the cleanup sites (“Group A Sites”). Nonetheless, as of December 29, 2017 , the Company estimated that, net of third parties’ indemnification obligations, future costs associated with the environmental remediation liabilities for the Group A Sites would range in total from $1.0 million to $7.9 million . The time frames over which these cleanup project costs are estimated vary, ranging from one year to thirty years as of December 29, 2017 . Management believes that no amount in that range is more probable of being incurred than any other amount and therefore accrued $1.0 million for these cleanup projects as of December 29, 2017 . The accrued amount has not been discounted to present value due to the uncertainties that make it difficult to develop a single best estimate.

In addition to the Group A Sites, there are other past and present facilities (“Group B Sites”) where the Company believes it has gained sufficient knowledge to better estimate the scope and cost of monitoring, cleanup and management activities. This, in part, is based on agreements with other parties and also cleanup plans approved by or completed in accordance with the requirements of, the governmental agencies having jurisdiction. As of December 29, 2017 , the Company estimated that the Company’s future exposure on the Group B Sites, net of third parties’ indemnification obligations, for the costs at these facilities, and reimbursements of third-party’s claims for these facilities, ranged in total from $3.5 million to $19.5 million . The time frames over which these costs are estimated to be incurred vary, ranging from one year to thirty years as of December 29, 2017 . As to each of these facilities, management determined that a particular amount within the range of estimated costs was a better estimate than any other amount within the range, and that the amount and timing of these future costs were reliably determinable. The best estimate within that range was $5.6 million at December 29, 2017 . Accordingly, the Company had accrued $4.8 million as of December 29, 2017 for these costs, which represented the best estimate discounted at 4% , net of inflation. This accrual is in addition to the $1.0 million accrued for the Group A Sites.
These amounts are only estimates of anticipated future costs. The amounts the Company will actually spend may be greater than the estimates. The Company believes its reserve is adequate, however, as the scope of the Company’s obligations becomes more clearly defined, the Company may modify the reserve, and charge or credit future earnings accordingly. Based on information currently known to management, management believes the costs of these environmental-related matters are not reasonably likely to have a material adverse effect on the consolidated financial statements of the Company in any one fiscal year.

The Company evaluates its liability for investigation and cleanup costs in light of the obligations and financial strength of potential third parties and insurance companies the Company believes it has rights to indemnity or reimbursement. The Company has an agreement with an insurance company under which that insurer has agreed to pay a portion of the Company’s past and future environmental-related expenditures. Receivables, net of the portion due to third parties who reimburse the Company, from that insurer amounted to $1.6 million at both December 29, 2017 and September 29, 2017 , with the respective current portion included in prepaid expenses and other current assets and the respective noncurrent portion included in other assets. The payable portion to that insurer is included in other long-term liabilities on the Condensed Consolidated Balance Sheets. The Company believes that this receivable is recoverable because it is based on a binding, written settlement agreement with an insurance company who appears to be financially viable and who has paid the Company’s claims in the past.

25

VARIAN MEDICAL SYSTEMS, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (CONTINUED)
(Unaudited)


Other Matters
From time to time, the Company is a party to or otherwise involved in legal proceedings, claims and government inspections or investigations and other legal matters, both inside and outside the United States, arising in the ordinary course of its business or otherwise. The Company accrues amounts, to the extent they can be reasonably estimated, that it believes are adequate to address any liabilities related to legal proceedings and other loss contingencies that the Company believes will result in a probable loss (including, among other things, probable settlement value). A loss or a range of loss is disclosed when it is reasonably possible that a material loss will be incurred and can be estimated or when it is reasonably possible that the amount of a loss, when material, will exceed the recorded provision. 
In addition to the above, the Company is involved in other legal matters. However, such matters are subject to many uncertainties and outcomes are not predictable with assurance. The Company is unable to estimate a loss or a range of reasonably possible losses with respect to such matters. There can be no assurances as to whether the Company will become subject to significant additional claims and liabilities with respect to ongoing or future proceedings. If actual liabilities significantly exceed the estimates made, the Company’s consolidated financial position, results of operations or cash flows could be materially adversely affected. Legal expenses relating to legal matters are expensed as incurred.
Restructuring Charges
2017 Restructuring Plan
In the first quarter of fiscal year 2017, the Company offered an enhanced retirement program to its qualifying employees and implemented a workforce reduction (collectively "the 2017 Restructuring Plan"), primarily in its Oncology Systems and VPT segments, to improve operational performance. The Company did not incur any restructuring charges during the three months ended December 29, 2017 and incurred $3.8 million in restructuring charges during the three months ended December 30, 2016 . As of December 29, 2017 , the Company plans to complete this plan in fiscal year 2018 and does not expect any additional restructuring charges under this plan.
The following table provides a summary of changes in the restructuring liability related to the Company's restructuring plans:
(In millions)
September 29,
2017
 
Restructuring Charges
 
Cash Payments
 
December 29,
2017
2017 Restructuring Plan
$
3.9

 
$

 
$
(2.2
)
 
$
1.7

Total
$
3.9

 
$

 
$
(2.2
)
 
$
1.7

The restructuring charges are included in selling, general and administrative expenses in the Condensed Consolidated Statements of Earnings (Loss).
10. RETIREMENT PLANS
The Company sponsors five defined benefit pension plans for regular full-time employees in Germany, Japan, Switzerland and the United Kingdom. The Company also sponsors a post-retirement benefit plan that provides healthcare benefits to certain eligible retirees in the United States.
The components of net defined benefit costs were as follows:
 
Three Months Ended
(In millions)
December 29,
2017
 
December 30,
2016
Defined Benefit Plans
 
 
 
Service cost
$
1.6

 
$
1.7

Interest cost
0.8

 
0.6

Expected return on plan assets
(2.0
)
 
(1.7
)
Amortization of prior service cost
(0.1
)
 
(0.1
)
Recognized actuarial loss
0.7

 
1.1

Net periodic benefit cost
$
1.0

 
$
1.6


26

VARIAN MEDICAL SYSTEMS, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (CONTINUED)
(Unaudited)


11. INCOME TAXES
The Company’s effective tax rate was 191.5% and 58.6% for the three months ended December 29, 2017 and December 30, 2016 , respectively. The increase in the Company’s effective tax rate during the three months ended December 29, 2017 , compared to the year-ago period, was primarily due to the tax effect of the Tax Cuts and Jobs Act (the "Act") which was signed into law on December 22, 2017. The Company’s effective tax rate in the year-ago period was also high due to the impairment of the CPTC loans in December 2016, which were made by one of the Company's Swiss subsidiaries, which has a low tax rate, and a significant portion of the expense associated with the allowance for doubtful accounts recorded in the period being attributable to one of the Company's German subsidiaries which has a full valuation allowance.

The Act was signed into law on December 22, 2017. Among other changes, the Act reduces the U.S. corporate tax rate from 35% to 21% , and imposes a one-time transition tax on the unremitted earnings of the Company's foreign subsidiaries. U.S. GAAP generally requires that the tax effect of a change in tax laws or rates be accounted for in the period of enactment.

The reduction in the U.S. corporate tax rate is effective January 1, 2018. As the Company has a September fiscal year end, the lower corporate tax rate will be phased in, resulting in a U.S. corporate rate of approximately 24.6% for the Company's fiscal year ending September 28, 2018, and 21% for subsequent fiscal years. The reduction in the rate requires the Company to re-measure its net deferred tax assets that were originally recorded assuming a future tax benefit at the 35% rate. During the three months ended December 29, 2017 , the Company recorded a provisional discrete tax expense of $37.8 million related to re-measuring its net deferred tax assets as a result of the rate reduction.

As part of the transition to a modified territorial system, the Act imposes a one-time transition tax on the unremitted earnings of the Company's foreign subsidiaries. During the three months ended December 29, 2017 , the Company recorded a provisional discrete tax expense of $169.3 million related to the one-time transition tax. The Company intends to elect to pay this tax over the eight -year period allowed for in the Act. The transition to a modified territorial regime and the one-time transition tax on unremitted earnings has also caused the Company to re-evaluate its intentions with respect to the unremitted earnings of foreign subsidiaries. In the past, the Company did not accrue U.S. taxes on certain undistributed profits of certain foreign subsidiaries because the earnings were considered to be indefinitely reinvested. In light of the changes to the taxation of foreign earnings in the Act, the Company no longer considers the earnings of its foreign subsidiaries to be indefinitely reinvested.
Other provisions of the Act include a new minimum tax on certain foreign earnings (the Global Intangibles Low-taxed Income, or "GILTI"), a new tax on certain payments to foreign related parties (the Base Erosion Anti-avoidance Tax, or "BEAT"), a new incentive for Foreign-derived Intangibles Income ("FDII"), changes to the limitation on the deductibility of certain executive compensation, and new limitations on the deductibility of interest expense. Generally, these other provisions take effect for the Company in the fiscal year ending September 28, 2018 .

On December 22, 2017, the SEC issued Staff Accounting Bulletin No. 118 (“SAB 118”). This guidance allows registrants a “measurement period,” not to exceed one year from the date of enactment, to complete their accounting for the tax effects of the Act. SAB 118 further directs that during the measurement period, registrants who are able to make reasonable estimates of the tax effects of the Act should include those amounts in their financial statements as “provisional” amounts. Registrants should reflect adjustments over subsequent periods as they are able to refine their estimates and complete their accounting for the tax effects of the Act. The amounts of the tax effects related to the Act described in the paragraphs above represent the Company’s reasonable estimates and are provisional amounts within the meaning of SAB 118. Also, it is expected that the U.S. Treasury will issue regulations and other guidance on the application of certain provisions of the Act. In subsequent periods, but within the measurement period, the Company will analyze that guidance and other necessary information, including the amount of foreign earnings and profits, pools of foreign tax, and the Company's foreign cash position, to refine its estimates and complete its accounting for the tax effects of the Act.
The Company adopted the FASB guidance related to employee share-based payments during the period ended December 29, 2017. Among other changes, this standard changes the treatment of the tax effect of the excess stock deduction. For a share-based compensation instrument, the excess stock deduction is the difference between the amount of the deduction for taxable income and the amount of expense in the financial statements related to that instrument. Under the prior standard, the tax effect of the excess stock deduction related to share-based compensation was recorded to additional paid-in capital in the equity section on the Condensed Consolidated Balance Sheets. Under the new standard, the tax effect of the excess stock deduction related to share-based compensation is recorded as a discrete item to income taxes in the Condensed Consolidated Statements of Earnings (Loss). During the three months ended December 29, 2017, the Company recorded a discrete tax benefit of $1.5 million related to excess stock deduction activity in the quarter. The Company expects that the new standard may cause its effective tax rate to be less predictable and more volatile going forward.

27

VARIAN MEDICAL SYSTEMS, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (CONTINUED)
(Unaudited)


The Company’s effective income tax rate differs from the U.S. federal statutory rate primarily because the Company’s foreign earnings are taxed at rates that are, on average, lower than the U.S. federal rate, and because the Company’s domestic earnings are subject to state income taxes. The total amount of unrecognized tax benefits increased by $10.5 million during the three months ended December 29, 2017 , primarily due to the impact of the Act on the Company's unrecognized tax benefits. The impact of this increase in tax expense is included in the amount of the provisional discrete expense related to the one-time transition tax above. In addition, the amount of unrecognized tax benefits has increased as a result of positions taken during the current and prior years, and has decreased as the result of the expiration of the statute of limitations in various jurisdictions.
12. STOCKHOLDERS’ EQUITY AND NONCONTROLLING INTERESTS
Share Repurchase Program
In November 2016, the VMS Board of Directors authorized the repurchase of an additional 8.0 million shares of VMS common stock commencing on January 1, 2017. Share repurchases under the Company's authorizations may be made in open market purchases, in privately negotiated transactions (including accelerated share repurchase (“ASR”) programs), or under Rule 10b5-1 share repurchase plans, and may be made from time to time in one or more blocks. All shares that were repurchased under the Company's share repurchase programs have been retired. As of December 29, 2017 , approximately 4.7 million shares of VMS common stock remained available for repurchase under the November 2016 authorization.
The Company repurchased shares of VMS common stock under various authorizations during the periods presented as follows:
 
Three Months Ended
(In millions, except per share amounts)
December 29,
2017
 
December 30,
2016
Number of shares
0.5

 
0.5

Average repurchase price per share
$
108.16

 
$
98.98

Total cost
$
56.7

 
$
49.5


Other Comprehensive Earnings
The changes in accumulated other comprehensive loss by component and related tax effects are summarized as follows:
(In millions)
Net Unrealized Gains
(Losses) Defined
Benefit Pension and
Post-Retirement
Benefit Plans
 
Net
Unrealized
Gains
(Losses)
Cash Flow
Hedging
Instruments
 
Cumulative
Translation
Adjustment
 
Accumulated
Other
Comprehensive
Loss
Balance at September 29, 2017
$
(44.1
)
 
$

 
$
(24.7
)
 
$
(68.8
)
Other comprehensive earnings (loss) before reclassifications

 
(0.3
)
 
3.1

 
2.8

Amounts reclassified out of other comprehensive earnings (loss)
0.4

 
(0.1
)
 

 
0.3

Tax (expense) benefit
(0.1
)
 
0.1

 

 

Balance at December 29, 2017
$
(43.8
)
 
$
(0.3
)
 
$
(21.6
)
 
$
(65.7
)


28

VARIAN MEDICAL SYSTEMS, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (CONTINUED)
(Unaudited)


(In millions)
Net Unrealized Gains
(Losses) Defined
Benefit Pension and
Post-Retirement
Benefit Plans
 
Cumulative
Translation
Adjustment
 
Accumulated
Other
Comprehensive Earnings
(Loss)
Balance at September 30, 2016
$
(63.3
)
 
$
(37.5
)
 
$
(100.8
)
Other comprehensive loss before reclassifications

 
(13.1
)
 
(13.1
)
Amounts reclassified out of other comprehensive earnings
0.9

 

 
0.9

Tax expense
(0.1
)
 

 
(0.1
)
Balance at December 30, 2016
$
(62.5
)
 
$
(50.6
)
 
$
(113.1
)
 
The amounts reclassified out of other comprehensive loss into the Condensed Consolidated Statements of Earnings (Loss), with line item location, during each period were as follows: 
 
Three Months Ended
 
  (In millions)
December 29,
2017
 
December 30,
2016
 
Comprehensive Earnings Components
Income (Loss) Before Taxes
Line Item in Statements of Earnings (Loss)
Unrealized loss on defined benefit pension and post-retirement benefit plans
$
(0.4
)
 
$
(0.9
)
Cost of revenues & Operating expenses
Unrealized gain on cash flow hedging instruments
0.1

 

Revenues
Total amounts reclassified out of other comprehensive earnings
$
(0.3
)
 
$
(0.9
)
 
 
Noncontrolling Interests
In connection with the Distribution of Varex in January 2017, the Company's redeemable noncontrolling interests relating to MeVis Medical Solutions AG ("MeVis") were transferred to Varex.

Changes in noncontrolling interests and redeemable noncontrolling interests relating to MeVis and other subsidiaries of the Company were as follows:
 
Three Months Ended
 
December 29, 2017
 
December 30, 2016
  (In millions)
Noncontrolling Interests
 
Noncontrolling Interests
 
Redeemable Noncontrolling Interests
Beginning of Period
$
4.3

 
$
3.7

 
$
10.3

Net earnings attributable to noncontrolling interests
0.1

 
0.5

 
0.1

Other

 

 
(0.1
)
End of Period
$
4.4

 
$
4.2

 
$
10.3


29

VARIAN MEDICAL SYSTEMS, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (CONTINUED)
(Unaudited)


13. EMPLOYEE STOCK PLANS
The table below summarizes the share-based compensation expense recognized for employee stock awards and employee stock purchase plan shares:
 
Three Months Ended
(In millions)
December 29,
2017
 
December 30,
2016
Cost of revenues - Product
$
0.7

 
$
0.8

Cost of revenues - Service
1.0

 
1.0

Research and development
1.2

 
1.2

Selling, general and administrative
7.8

 
7.2

Total share-based compensation expense
$
10.7

 
$
10.2

Income tax benefit for share-based compensation
$
(2.1
)
 
$
(3.0
)
 
The Company adopted new accounting guidance in the three months ended December 29, 2017 where it elected to change its accounting policy to account for forfeitures as they occur rather than estimating expected forfeitures. Share based compensation expense for the three months ended December 30, 2016 was recorded net of estimated forfeitures. See Note 1, "Summary of Significant Accounting Policies" for further information.

The fair value of options granted was estimated at the date of grant using the Black-Scholes model with the following weighted average assumptions: 
 
Three Months Ended
 
December 29,
2017
 
December 30,
2016
Employee Stock Option Plans
 
 
 
Expected term (in years)
3.82

 
4.13

Risk-free interest rate
1.9
%
 
1.4
%
Expected volatility
18.7
%
 
20.5
%
Expected dividend
%
 
%
Weighted average fair value at grant date
$
19.45

 
$
15.44


The option component of employee stock purchase plan shares was estimated at the date of grant using the Black-Scholes model with the following weighted average assumptions: 
 
Three Months Ended
 
December 29,
2017
 
December 30,
2016
Employee Stock Purchase Plan
 
 
 
Expected term (in years)
0.50

 
0.50

Risk-free interest rate
1.2
%
 
0.5
%
Expected volatility
17.9
%
 
22.3
%
Expected dividend
%
 
%
Weighted average fair value at grant date
$
20.97

 
$
19.37



30

VARIAN MEDICAL SYSTEMS, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (CONTINUED)
(Unaudited)


A summary of share-based awards available for grant is as follows:
(In millions)
Shares Available for Grant
Balance at September 29, 2017
2.5

Granted
(0.8
)
Cancelled or expired
0.3

Balance at December 29, 2017
2.0

 
For purposes of the total number of shares available for grant under the Fourth Amended 2005 Plan, any shares subject to awards of stock options and performance stock options are counted against the available-for-grant limit as one share for every one share subject to the award. Awards other than stock options and performance stock options are counted against the available-for-grant limit as 2.6 shares for every one share awarded on or after February 9, 2012. The shares available for grant limit is further adjusted to reflect a maximum payout that could be issued for each performance grant. The maximum payouts that could be issued for each performance grant are 2.0 shares beginning in fiscal year 2018, 1.75 shares in fiscal years 2017 and 2016, and 2.0 shares in fiscal year 2015. All awards may be subject to restrictions on transferability and continued employment as determined by the Compensation and Management Development Committee.
Activity under the Company’s employee stock plans related to stock options is presented below: 
 
Options Outstanding
(In millions, except per share amounts)
Number of
Shares
 
Weighted
Average
Exercise
Price
 
Weighted
Average
Remaining
Term (in years)
 
Aggregate
Intrinsic
Value
 (1)
Balance at September 29, 2017
2.3

 
$
74.08

 
 
 
 
Granted
0.2

 
109.05

 
 
 
 
Cancelled or expired (2)

 
75.38

 
 
 
 
Exercised
(0.2
)
 
67.62

 
 
 
 
Balance at December 29, 2017
2.3

 
$
78.45

 
4.8
 
$
74.3

 
 
 
 
 
 
 
 
Exercisable at December 29, 2017
1.1

 
$
72.45

 
3.7
 
$
41.2


(1)  
The aggregate intrinsic value represents the total pre-tax intrinsic value, which is computed based on the difference between the exercise price and the closing price of VMS common stock of $111.15 as of December 29, 2017 , the last trading date of the first quarter of fiscal year 2018 , and which represents the amount that would have been received by the option holders had all option holders exercised their options and sold the shares received upon exercise as of that date.
(2)  
The cancelled and expired shares were not material for disclosure.
As of December 29, 2017 , there was $12.0 million of total unrecognized compensation expense related to stock options granted under the Company's employee stock plans. This unrecognized compensation expense is expected to be recognized over a weighted average period of 2.2 years.

31

VARIAN MEDICAL SYSTEMS, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (CONTINUED)
(Unaudited)


The activity for restricted stock, restricted stock units, deferred stock units and performance units is summarized as follows:
(In millions, except per share amounts)
Number of
Shares
 
Weighted Average
Grant-Date Fair
Value
Balance at September 29, 2017
0.9

 
$
75.37

Granted
0.1

 
109.16

Vested  (1)

 
74.62

Cancelled or expired
(0.1
)
 
84.96

Balance at December 29, 2017
0.9

 
$
79.38

(1)  
The vested shares were not material for disclosure.
As of December 29, 2017 , unrecognized compensation expense totaling $32.7 million was related to awards of restricted stock, restricted stock units, deferred stock units and performance units granted under the Company's employee stock plans. This unrecognized share-based compensation expense is expected to be recognized over a weighted average period of 2.0 years.
14. EARNINGS PER SHARE
Basic net earnings per share is computed by dividing net earnings attributable to Varian by the weighted average number of shares of VMS common stock outstanding for the period. Diluted net earnings per share is computed by dividing net earnings attributable to Varian by the sum of the weighted average number of common shares outstanding and dilutive common shares under the treasury stock method.
The following table sets forth the computation of basic and diluted net earnings per share:
 
Three Months Ended
(In millions, except per share amounts)
December 29,
2017
 
December 30,
2016
Net earnings (loss) from continuing operations
$
(112.2
)
 
$
8.0

Less: Net earnings from continuing operations attributable to noncontrolling interests
0.1

 
0.5

Net earnings (loss) from continuing operations attributable to Varian
$
(112.3
)
 
$
7.5

 
 
 
 
Net earnings from discontinued operations
$

 
$
6.5

Less: Net earnings from discontinued operations attributable to noncontrolling interests

 
0.1

Net earnings from discontinued operations attributable to Varian

 
6.4

Net earnings (loss) attributable to Varian
$
(112.3
)
 
$
13.9

 
 
 
 
Weighted average shares outstanding - basic
91.6

 
93.5

Dilutive effect of potential common shares

 
0.7

Weighted average shares outstanding - diluted
91.6

 
94.2

 
 
 
 
Net earnings (loss) per share attributable to Varian - basic
 
 
 
Continuing operations
$
(1.22
)
 
$
0.08

Discontinued operations

 
0.07

Net earnings per share - basic
$
(1.22
)
 
$
0.15

 
 
 
 
Net earnings (loss) per share attributable to Varian - diluted
 
 
 
Continuing operations
$
(1.22
)
 
$
0.08

Discontinued operations

 
0.07

Net earnings per share - diluted
$
(1.22
)
 
$
0.15

Anti-dilutive employee share-based awards, excluded
3.2

 
0.6

 

32

VARIAN MEDICAL SYSTEMS, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (CONTINUED)
(Unaudited)


The Company excludes potentially dilutive common shares (consisting of shares underlying stock options and the employee stock purchase plan) from the computation of diluted weighted average shares outstanding if the per share value, either the exercise price of the awards or the sum of (a) the exercise price of the awards and (b) the amount of the compensation cost attributed to future services and not yet recognized and (c) the amount of tax benefit or shortfall that would be recorded in additional paid-in capital when the award becomes deductible, is greater than the average market price of the shares, because the inclusion of the shares underlying these stock awards would be anti-dilutive to earnings per share. For the three months ended December 29, 2017 , the diluted net loss per share is the same as the basic net loss per share as the effects of all potential common stock equivalents are anti-dilutive.
15. VPT LOANS AND INVESTMENT

In limited cases, the Company participates, along with other investors and at market terms, in the financing of proton therapy centers. Over time the Company has divested some of its investments, including investments in CPTC, NYPC and DRTC.
The following table lists the Company's outstanding loans, investment and commitments for funding development, construction and operations of various proton therapy centers:
 
 
December 29, 2017
 
September 29, 2017
(In millions)
 
Balance
 
Commitment
 
 Balance
 
Commitment
Notes receivable and secured debt:
 
 
 
 
 
 
 
 
MPTC loans   (1)
 
$
60.1

 
$

 
$
60.1

 
$

RPTC senior secured debt   (2)
 
25.8

 

 
25.4

 

NYPC loan   (3)
 
18.5

 

 
18.5

 

PI loan   (3)
 
2.5

 

 
3.0

 

CPTC DIP loan   (3)
 

 

 
5.1

 
2.2

 
 
$
106.9

 
$

 
$
112.1

 
$
2.2

Available-for-sale Securities:
 
 
 
 
 
 
 
 
Original CPTC loans   (3)
 
$

 
$

 
$
47.4

 
$

DRTC securities   (4)
 
8.0

 

 
8.0

 

APTC securities (2)
 
6.0

 

 

 

GPTC securities   (3)
 
4.5

 
11.8

 
4.4

 
11.8

 
 
$
18.5

 
$
11.8

 
$
59.8

 
$
11.8

 
 
 
 
 
 
 
 
 
CPTC Loans and Investment:
 
 
 
 
 
 
 
 
Short-term revolving loan (2)
 
$
2.4

 
$
4.8

 
$

 
$

Term loan (3)

 
44.0

 

 

 

Equity investment in CPTC  (3)
 
9.5

 

 

 

 
 
$
55.9

 
$
4.8

 
$

 
$

(1)  
Includes $35.0 million in other assets at both December 29, 2017 and September 29, 2017 , respectively, and $25.1 million in prepaid and other current assets at December 29, 2017 and other assets at September 29, 2017 on the Company's Condensed Consolidated Balance Sheets.
(2)  
Included in prepaid and other current assets on the Company's Condensed Consolidated Balance Sheets.
(3)  
Included in other assets on the Company's Condensed Consolidated Balance Sheets.
(4)  
Included in prepaid and other current assets at December 29, 2017 and in other assets at September 29, 2017 on the Company's Condensed Consolidated Balance Sheets.
Alabama Proton Therapy Center ("APTC") Securities
In December 2017, the Company purchased $6.0 million in Subordinate Revenue Bonds from the Public Finance Authority which is financing the APTC. The Subordinate Revenue Bonds carry an interest rate of 8.5% and pay interest semi-annually.

33

VARIAN MEDICAL SYSTEMS, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (CONTINUED)
(Unaudited)


The Company is scheduled, based upon the terms, to start receiving annual principal payments on the Subordinate Bonds beginning on November 1, 2022. The Subordinate Bonds will mature on October 1, 2047.
Rinecker Proton Therapy Center ("RPTC") Senior Secured Debt
In July 2017, the Company purchased the outstanding senior secured debt related to the RPTC in Munich, Germany for 21.5 million Euros or $24.5 million . By purchasing the senior secured debt, the Company has a right to 89 million Euros in claims against all of RPTC's assets. In September 2017, the management of RPTC filed for bankruptcy in Germany. In January 2018, the final insolvency proceedings commenced, and the Company expects the insolvency proceedings to be finalized within the next twelve months. Upon finalization of bankruptcy proceedings, the Company believes it is probable it will recover its outstanding senior secured debt balance and trade accounts receivable, net.
At both December 29, 2017 and September 29, 2017 , the Company had $4.5 million in trade receivables, net for RPTC, which does not include any unbilled receivables.
Georgia Proton Treatment Center ("GPTC") Security
In July 2017, the Company committed to purchase up to $16.1 million in Senior Capital Appreciation Bonds ("Senior Bonds") from the Atlanta Development Authority, which is financing the GPTC. In July 2017, the Company purchased $4.3 million of the Senior Bonds that carry an interest rate of 8.0% per annum with interest accruing up to the principal amount of $6.6 million until January 1, 2023 and then will pay cash interest semi-annually. The Company will purchase the remaining commitment in July 2018. The Company is scheduled, based upon the original terms, to start receiving annual principal payments on the Senior Bonds beginning on January 1, 2024. The Senior Bonds will mature on January 1, 2028.
Delray Radiation Therapy Center ("DRTC") Securities and Loan
In April 2017, the Company purchased $8.0 million in Subordinate Bonds from the Public Finance Authority, which is financing the DRTC. The Subordinate Bonds carry an interest rate of 8.5% and pay interest semi-annually. The Company was scheduled, based upon the original terms, to start receiving annual principal payments on the Subordinate Bonds beginning on November 1, 2021. The Subordinate Bonds will mature on November 1, 2046. In January 2018, the Company sold all of its Subordinate Bonds for $8.5 million , which included accrued interest.
In addition to the purchase of the Subordinate Bonds, the Company also loaned $3.0 million to Proton International LLC ("PI") to allow PI to purchase $3.0 million in Subordinate Bonds from the Public Finance Authority. The loan to PI carries an interest rate of 8.5% per annum, paid semi-annually and matures on April 30, 2022, subject to early repayment as proceeds are received by PI from the bonds purchased, and is secured by the related bonds. During the three months ended December 29, 2017 , the Company received a principal payment of $0.5 million .
New York Proton Center ("NYPC") Loan
In July 2015, the Company committed to loan up to $91.5 million to MM Proton I, LLC `in connection with a purchase agreement to supply a proton system to equip the NYPC. In June 2016, the Company assigned $73.0 million of this loan to Deutsche Bank AG. The remaining balance is comprised of an $18.5 million “Subordinate Loan” with a six-and-a-half-year term at up to 13.5% interest. The principal balance and accrued interest on the Subordinate Loan are due in full at maturity in January 2022.
In addition to the outstanding loan, the Company had $7.9 million and $13.3 million , as of December 29, 2017 and September 29, 2017 , respectively, in trade and unbilled receivables, which included $7.9 million and $1.3 million in unbilled receivables as of December 29, 2017 and September 29, 2017 , respectively, from NYPC.
Maryland Proton Treatment Center ("MPTC") Loans
In May 2015, the Company committed to loan up to $35.0 million to MPTC. The Company completed its funding requirements per the loan agreement in the first quarter of fiscal year 2017. Varian's lending is in the form of a subordinated loan that is due, with accrued interest, in three annual payments from 2020 to 2022. The interest on the loan accrues at 12.0% .
In addition, the Company had previously entered into an agreement with MPTC to supply it with a proton system, which included a deferral of up to $25.1 million of equipment payments when triggered by achievement of delivery milestones under the contract. As of December 29, 2017 , the Company has recorded $25.1 million as a notes receivable related to this deferred payment arrangement. The notes receivable carries an interest rate of 15.0% and is due September 30, 2018.

34

VARIAN MEDICAL SYSTEMS, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (CONTINUED)
(Unaudited)


As of December 29, 2017 and September 29, 2017 , the Company had zero net trade and unbilled receivables from MPTC.
Variable Interest Entities
The Company has determined that MM Proton I, LLC, MPTC, and RPTC are variable interest entities and that the Company holds a significant variable interest of each of the entities through its participation in the loan facilities and its agreements to supply and service the proton therapy equipment. The Company has concluded that it is not the primary beneficiary of any of these entities. The Company has no voting rights, has no approval authority or veto rights for these centers' budget, and does not have the power to direct patient recruitment, clinical operations and management of these Centers, which the Company believes are the matters that most significantly affect their economic performance. The Company’s exposure to loss as a result of its involvement with MM Proton I, LLC, MPTC, and RPTC is limited to the carrying amounts of the above mentioned assets on its Condensed Consolidated Balance Sheets.
California Proton Therapy Center ("CPTC") Loans and Investment
Between September 2011 and November 2015, the Company, ORIX and J.P. Morgan (“the Lenders”) committed to loan up to $185.0 million (the “Original CPTC Loans”), of which the Company's commitment was $84.7 million , to fund the development, construction, initial operations, and working capital needs of the Scripps Proton Therapy Center in San Diego, California. ORIX is the loan agent. In November 2015, the Lenders and California Proton Treatment Center ("Original CPTC") entered into a forbearance agreement whereby the Lenders agreed not to enforce their rights to principal and interest payments until April 2017, subject to Original CPTC maintaining certain covenants and achieving certain targets, with additional extensions through September 2017 based on hitting additional targets largely around patient volume and cash flow.
As of December 30, 2016, even though patient volumes continued to increase, Original CPTC was not in compliance with one of the patient volume covenants in the forbearance agreement, which would allow the Lenders to cease funding and terminate the forbearance agreement. In January 2017, the Company was informed of actions taken by Original CPTC and the loan agent, including Original CPTC obtaining shareholder consents for voluntary bankruptcy filing and the loan agent deciding that no additional funding would be available outside of a bankruptcy process. As a result of this information and the Company’s analysis that these actions would likely lead to insolvency or bankruptcy proceedings of Original CPTC, the Company determined that it was appropriate to record a $38.3 million impairment, as determined by the discounted cash flow model using a single best estimate methodology, of its Original CPTC Loans on the Condensed Consolidated Statements of Earnings in the first quarter of fiscal year 2017. As a result of this impairment, the Original CPTC Loans were written down to their estimated fair value of $60.0 million and reclassified from short-term investments to other assets on the Company's Condensed Consolidated Balance Sheet because the Company did not expect to collect or sell all or a portion of these loans in the next twelve months.
In March 2017, Original CPTC filed for bankruptcy and concurrently entered into a Debtor-in-Possession facility (the "DIP Facility") with the Lenders for up to $16.0 million of additional financing during the bankruptcy process. The Company's pro-rata share of the DIP Facility was $7.3 million . As of December 29, 2017 , the Company had funded its entire commitment under the DIP Facility. The DIP Facility carried an interest rate at the London Interbank Offer Rate (“LIBOR”) plus 9.0% per annum and had a senior secured position ahead of the Original CPTC Loans.
Between April 2017 and August 2017, the Company did not become aware of any new information that warranted an impairment assessment. In September 2017, the Lenders and Scripps signed a Transition Agreement to transition the operations of the center from Scripps to Proton Doctors Professional Corporation (“Practice”). Based on the terms of the Transition Agreement, a slower projected growth in patient volume, an increase in additional projected capital needs and the Company's analysis, the Company determined that an additional $13.1 million impairment charge was deemed appropriate on its Original CPTC Loans which was recorded on the Consolidated Statements of Earnings in the fourth quarter of fiscal year 2017.
Pursuant to an order of the Bankruptcy Court, Original CPTC conducted an auction of the Scripps Proton Therapy Center. On December 6, 2017 (“Closing Date”), the Bankruptcy Court approved the sale of Scripps Proton Therapy Center to California Proton Therapy Center, LLC (“CPTC”), an entity owned by the Lenders. The Lenders purchased all assets and assumed $112.0 million of Original CPTC’s outstanding liabilities. On December 13, 2017, the Bankruptcy Court dismissed the bankruptcy filing of Original CPTC.

35

VARIAN MEDICAL SYSTEMS, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (CONTINUED)
(Unaudited)


On the Closing Date, the Lenders entered into a Credit Agreement with Original CPTC of which the terms of the Original CPTC Loans, DIP Facility and accrued interest (collectively “Former Loans”) have been modified. In addition to the partially satisfied Original CPTC Loans reinstated by the Bankruptcy Court, the Company received a 47.08% equity ownership in CPTC. Original CPTC has assigned all its Former Loans to CPTC at an amount of $112.0 million , the partially satisfied loan balance. Per the terms of the Credit Agreement, the Company's portion of the $112.0 million is $53.5 million ; the remainder is allocated between ORIX and J.P. Morgan. The $53.5 million is composed of four Tranches: Tranche A of $2.0 million , Tranche B of $7.2 million , Tranche C of $15.6 million , and Tranche D of $28.7 million (collectively the "Term Loan"). The maturity date of the Term Loan is three years from the Closing Date. The Term Loan is secured by the assets of CPTC.
In addition, the Lenders have committed to lend up to $15.0 million in a Revolving Loan with a maturity date of one year from the Closing Date. The Company's share of the funding commitment from the Revolving Loan is $7.2 million , and as of December 29, 2017, the Company has funded $2.4 million .

All of the Tranches accrue paid-in-kind interest at 7.5% per annum, except the Tranche B and Revolving Loan which accrue paid-in-kind interest at 10% per annum. The seniority of these loans is as follows: Revolving Loan, Tranche A, Tranche B, Tranche C and Tranche D. If CPTC is in default the interest rate of the Tranche A, C and D will increase to 9.5% and the Tranche B and the Revolving Loan will increase to 12.0% .

Considering Original CPTC’s financial difficulties, the modification of the original terms of the Former Loans, and the Lenders agreement to grant a concession on the Original CPTC Loans, the Company classified the transaction above as a troubled debt restructuring (“TDR”). The Company does not have any unamortized fees from the Former Loans and any prepayment penalties. As a result, the cost basis and fair value of the Company's outstanding Term Loan as of December 29, 2017 is $53.5 million , which approximates the carrying value of the Former Loans prior to TDR.

The Company, using a discounted cash flow approach, determined that the fair value of CPTC's equity as of Closing Date is $20.1 million . The Company's 47.08% ownership percentage amounts to a $9.5 million equity interest in CPTC. Since the common stock received were in addition to a loan receivable partially satisfied through the bankruptcy proceedings, in accordance with the TDR accounting guidance, the Company recorded the equity interest at fair value and as an offset to the reinstated loan balance. The equity investment in CPTC is accounted for under the equity method of accounting as of December 29, 2017. The Company will account for its equity method share of the income or loss of CPTC on a quarter lag basis as provided by the equity method accounting guidance.

Per the terms of the Former Loans, as of September 29, 2017, ORIX had the option to purchase the Company's share of the Original CPTC Loans at par and therefore they were accounted for as available-for-sale securities. Per the terms of the new agreement, ORIX no longer has the option to purchase the Company’s share of the Term Loan at par. As a result, the Term Loan no longer qualifies for available-for-sale classification as of December 29, 2017.
Further, the Company has determined that CPTC is a variable interest entity (“VIE”) because of the Company's participation in the loan facilities, equity ownership and its operations and maintenance agreement. The Company has one board seat out of five, has no special approval authority or veto rights for CPTC’s budget, and does not have the power to direct patient recruitment, clinical operations and management of CPTC, which the Company believes are the matters that most significantly affect their economic performance. Therefore, the Company does not have majority voting rights and no power to direct activities at CPTC as a result it is not the primary beneficiary of CPTC.
16. SEGMENT INFORMATION
The Company has two reportable operating segments: Oncology Systems and VPT. The operating segments were determined based on how the Company’s Chief Executive Officer, its Chief Operating Decision Maker (“CODM”), views and evaluates the Company’s operations. The CODM allocates resources to and evaluates the financial performance of each operating segment primarily based on operating earnings.
Description of Segments
The Oncology Systems segment designs, manufactures, sells and services hardware and software products for treating cancer with conventional radiation therapy, and advanced treatments such as fixed field intensity-modulated radiation therapy (“IMRT”), image-guided radiation therapy (“IGRT”), VMAT, stereotactic radiosurgery (“SRS”), stereotactic body radiotherapy (“SBRT”) and brachytherapy. Products include linear accelerators, brachytherapy afterloaders, treatment simulation and verification equipment and accessories; as well as information management, treatment planning and image processing, clinical

36

VARIAN MEDICAL SYSTEMS, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (CONTINUED)
(Unaudited)


knowledge exchange, patient care management, decision-making support and practice management software. Oncology Systems’ products enable radiation oncology departments in hospitals and clinics to perform conventional radiotherapy treatments and offer advanced treatments such as IMRT, IGRT, VMAT, SRS and SBRT, as well as to treat patients using brachytherapy techniques, which involve temporarily implanting radioactive sources. The Company’s Oncology Systems products are also used by neurosurgeons to perform stereotactic radiosurgery. Oncology Systems’ customers worldwide include university research and community hospitals, private and governmental institutions, healthcare agencies, physicians’ offices and cancer care clinics.
The VPT segment develops, designs, manufactures, sells and services products and systems for delivering proton therapy, a form of external beam radiotherapy using proton beams for the treatment of cancer.
Accordingly, the following information is provided for purposes of achieving an understanding of operations, but may not be indicative of the financial results of the reported segments were they independent organizations. In addition, comparisons of the Company’s operations to similar operations of other companies may not be meaningful.
The Company allocates corporate costs to its operating segments based on the relative revenues of Oncology Systems and VPT. The Company allocates these costs excluding certain corporate related costs, transactions or adjustments that the Company's CODM considers to be non-operational, such as restructuring and impairment charges, significant litigation charges or benefits and legal costs, acquisition-related expenses and benefits. Although the Company excludes these amounts from segment operating earnings and loss, they are included in the consolidated operating earnings and included in the reconciliation below.
The following table summarizes select operating results information for each reportable segment:
 
Three Months Ended
(In millions)
December 29,
2017
 
December 30,
2016
Revenues
 
 
 
Oncology Systems
$
649.4

 
$
571.2

Varian Particle Therapy
29.1

 
30.3

Total Company
$
678.5

 
$
601.5

Operating Earnings
 
 
 
Oncology Systems
$
138.2

 
$
116.1

Varian Particle Therapy
(15.2
)
 
(50.3
)
Total reportable segments
123.0

 
65.8

Unallocated corporate
(1.6
)
 
(48.4
)
Total Company
$
121.4

 
$
17.4


Disaggregation of Revenues
The Company disaggregates its revenues from contracts by major product categories and by geographic region for each of its reportable operating segments, as the Company believes this best depicts how the nature, amount, and timing an uncertainty of revenues and cash flows are affected by economic factors. See details in the tables below.
Total Revenues by product type
Three Months Ended December 29, 2017
(In millions)
Oncology
 
VPT
 
Total
Hardware
$
293.1

 
$
27.3

 
$
320.4

Software (1)
115.1

 

 
115.1

Service
241.2

 
1.8

 
243.0

Total Revenues
$
649.4

 
$
29.1

 
$
678.5

(1)
Includes software support agreements that are recorded in revenues from service in the Condensed Consolidated Statements of Earnings (Loss).

37

VARIAN MEDICAL SYSTEMS, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (CONTINUED)
(Unaudited)


Total Revenues by product type
Three Months Ended December 30, 2016
(In millions)
Oncology
 
VPT
 
Total
Hardware
$
238.6

 
$
26.8

 
$
265.4

Software (1)
112.2

 

 
112.2

Service
220.4

 
3.5

 
223.9

Total Revenues
$
571.2

 
$
30.3

 
$
601.5

(1)  
Includes software support agreements that are recorded in revenues from service in the Condensed Consolidated Statements of Earnings (Loss).
Total Revenues by geographical region
Three Months Ended December 29, 2017
(In millions)
Oncology
 
VPT
 
Total
Americas
$
337.4

 
$
19.3

 
$
356.7

EMEA
183.5

 
9.5

 
193.0

APAC
128.5

 
0.3

 
128.8

Total Revenues
$
649.4

 
$
29.1

 
$
678.5

 
 
 
 
 
 
North America
$
326.3

 
$
19.3

 
$
345.6

International
323.1

 
9.8

 
332.9

Total Revenues
$
649.4

 
$
29.1

 
$
678.5

Total Revenues by geographical region
Three Months Ended December 30, 2016
(In millions)
Oncology
 
VPT
 
Total
Americas
$
290.8

 
$
7.4

 
$
298.2

EMEA
169.0

 
15.0

 
184.0

APAC
111.4

 
7.9

 
119.3

Total Revenues
$
571.2

 
$
30.3

 
$
601.5

 
 
 
 
 
 
North America
$
275.0

 
$
7.4

 
$
282.4

International
296.2

 
22.9

 
319.1

Total Revenues
$
571.2

 
$
30.3

 
$
601.5


Timing of revenue recognition
Three Months Ended December 29, 2017
(In millions)
Products transferred at a point in time
 
Products and Services transferred over time

 
Total
Oncology Systems
$
338.3

 
$
311.1

 
$
649.4

VPT

 
29.1

 
29.1

Total Revenues
$
338.3

 
$
340.2

 
$
678.5


38

VARIAN MEDICAL SYSTEMS, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (CONTINUED)
(Unaudited)


Timing of revenue recognition
Three Months Ended December 30, 2016
(In millions)
Products Transferred at a Point in Time
 
Products and Services Transferred Over Time

 
Total
Oncology Systems
$
282.4

 
$
288.8

 
$
571.2

VPT

 
30.3

 
30.3

Total Revenues
$
282.4

 
$
319.1

 
$
601.5

17. SUBSEQUENT EVENTS

On January 30, 2018, the Company signed an agreement to acquire Sirtex Medical Limited ("Sirtex"), an Australian company that is listed on the Australian Securities Exchange, for A$28 per share or approximately A$1.6 billion ( $1.3 billion ). Sirtex is an Australian-based global life sciences company focused on interventional oncology therapies. The Company plans to finance the acquisition using cash on hand as well as proceeds from borrowings. The transaction, which is expected to close in late May 2018, is subject to the approval of the Sirtex shareholders, the Federal Court of Australia and other customary closing conditions, including applicable regulatory approvals. 

On February 1, 2018, the Company acquired Mobius Medical Systems L.P. ("Mobius") for approximately $24.0 million . Mobius makes quality assurance software for the radiation oncology field. In December 2017, the Company deposited $2.6 million in an escrow account related to the acquisition of Mobius. Per the acquisition agreement, the entire amount in escrow was released to a third party on the acquisition date. The initial purchase accounting for this transaction was not yet complete at the filing of this Report.

39



REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Board of Directors and
Stockholders of Varian Medical Systems, Inc.:

We have reviewed the accompanying condensed consolidated balance sheet of Varian Medical Systems, Inc. and its subsidiaries as of December 29, 2017, and the related condensed consolidated statements of earnings (loss), of comprehensive earnings (loss) and of cash flows for the three-month periods ended December 29, 2017 and December 30, 2016. These interim financial statements are the responsibility of the Company’s management.

We conducted our review in accordance with the standards of the Public Company Accounting Oversight Board (United States). A review of interim financial information consists principally of applying analytical procedures and making inquiries of persons responsible for financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with the standards of the Public Company Accounting Oversight Board (United States), the objective of which is the expression of an opinion regarding the financial statements taken as a whole. Accordingly, we do not express such an opinion.

Based on our review, we are not aware of any material modifications that should be made to the accompanying condensed consolidated interim financial statements for them to be in conformity with accounting principles generally accepted in the United States of America.

We previously audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated balance sheet as of September 29, 2017, and the related consolidated statements of earnings and of comprehensive earnings, of equity, and of cash flows for the year then ended (not presented herein), and in our report dated November 27, 2017, we expressed an unqualified opinion on those consolidated financial statements. As discussed in Note 1 to the accompanying condensed consolidated interim financial statements, the Company adopted Accounting Standard Codification 606, Revenue from contracts with customers . The accompanying September 29, 2017 condensed consolidated balance sheet reflects this change.

/s/ P RICEWATERHOUSE C OOPERS LLP
PricewaterhouseCoopers LLP
San Jose, California
February 7, 2018

40



Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Forward-Looking Statements
This Quarterly Report on Form 10-Q contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, which provides a “safe harbor” for statements about future events, products and future financial performance that are based on the beliefs of, estimates made by, and information currently available to the management of Varian Medical Systems, Inc. (“VMS”) and its subsidiaries (collectively “we,” “our” or the “Company”). The outcome of the events described in these forward-looking statements is subject to risks and uncertainties. Actual results and the outcome or timing of certain events may differ significantly from those projected in these forward-looking statements or management’s current expectations due to the factors cited in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” (“MD&A”), the Risk Factors listed under Part II, Item 1A of this Quarterly Report on Form 10-Q, and other factors described from time to time in our other filings with the Securities and Exchange Commission (“SEC”), or other reasons. For this purpose, statements concerning: Varian's planned acquisition of Sirtex, expected synergies, accretive expectations, estimated closing date of the Sirtex acquisition, Varian's financing plans; growth strategies; industry or market segment outlook; market acceptance of or transition to new products or technology such as fixed field intensity-modulated radiation therapy, image-guided radiation therapy, stereotactic radiosurgery, volumetric modulated arc therapy, brachytherapy, software, treatment techniques, and proton therapy; growth drivers; future orders, revenues, backlog, earnings or other financial results; and any statements using the terms “believe,” “expect,” “anticipate,” “can,” “should,” “would,” “could,” “estimate,” “may,” “intended,” “potential,” and “possible” or similar statements are forward-looking statements that involve risks and uncertainties that could cause our actual results and the outcome and timing of certain events to differ materially from those projected or management’s current expectations. By making forward-looking statements, we have not assumed any obligation to, and you should not expect us to, update or revise those statements because of new information, future events or otherwise.
Overview
We, Varian Medical Systems, Inc., are a Delaware corporation originally incorporated in 1948 as Varian Associates, Inc. We are the world’s leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, stereotactic radiosurgery, stereotactic body radiotherapy, brachytherapy and proton therapy. Our mission is to combine the ingenuity of people with the power of data and technology to achieve new victories against cancer. To meet this challenge, we offer comprehensive solutions for fighting cancer.

We have two reportable operating segments: Oncology Systems and Varian Particle Therapy ("VPT"). The operating segments were determined based on how our Chief Executive Officer, who is our Chief Operating Decision Maker (“CODM”), views and evaluates our operations. The CODM allocates resources to and evaluates the financial performance of each operating segment primarily based on operating earnings.
Long-term growth and value creation strategy. We are focused on cancer care solutions and well-positioned to positively influence more and more patients globally every day by bringing smarter and simpler solutions to healthcare providers. Our long-term growth and value creation strategy is to transform our company from the global leader in radiation therapy to become the global leader in multidisciplinary, integrated cancer care solutions. We intend to leverage our deep customer relationships, human-centered design, scale and financial strength to selectively broaden our capabilities to capitalize on industry trends. To achieve these long-term objectives, we are focused on driving growth through strengthening our leadership in radiation therapy, extending our global footprint and expanding into other addressable markets.
Adoption of ASC 606. At the beginning of our fiscal year 2018, we early adopted the new revenue recognition Accounting Standard Codification 606 "Revenues from Contracts with Customers" ("ASC 606") and used the full retrospective method. All financial statements and disclosures have been recast to comply with ASC 606. See Note 1, "Summary of Significant Accounting Policies" of the Notes to the condensed consolidated financial statements, for additional information.
As we completed our adoption of ASC 606 in the first quarter of fiscal year 2018, certain balance sheet adjustments were necessary from the Preliminary Condensed Consolidated Balance Sheets as of December 29, 2017 and September 29, 2017 that were filed in the Company’s 8-K on January 24, 2018 announcing its fiscal year 2018 first quarter results. The impact of these adjustments was to increase both unbilled receivables and deferred revenue by $25.8 million and $78.5 million as of December 29, 2017 and September 29, 2017, respectively which results in Oncology Systems accounts receivable days sales outstanding, or DSO, of 107 days at December 29, 2017 and 125 days at December 30, 2016. There has been no change to our Condensed Consolidated Statements of Earnings.


41



Change in Gross Orders Policy. In the first quarter of fiscal year 2018, we decided to retroactively change our policy on how we record services gross orders. Under the new policy, services gross orders do not include changes in deferred services revenue. We made the change to more accurately reflect the operational performance of the services business and to eliminate variations in orders reporting due to the timing of services billings. This policy change also impacts backlog, which no longer reflects the deferred revenue related to purchasable services. These changes only impact the Oncology Systems gross orders. All prior periods gross orders and backlog have been recast to reflect this policy change.
Distribution. On January 28, 2017 (the "Distribution Date"), we completed the separation and distribution (the "Distribution") of Varex Imaging Corporation ("Varex"), our former Imaging Components business segment. The historical financial position and results of operations of the Imaging Components business and costs relating to the Distribution are reported in the condensed consolidated financial statements as discontinued operations for all the periods presented. Unless otherwise noted, the financial information herein has been recast to reflect the effect of the Distribution. The Condensed Consolidated Statements of Comprehensive Earnings (Loss) and the Statements of Cash Flows have not been recast to reflect the effect of the Distribution. See Note 2, "Discontinued Operations" of the Notes to the condensed consolidated financial statements, for additional information.
Acquisition of Sirtex Medical Limited. On January 30, 2018, we signed an agreement to acquire Sirtex Medical Limited ("Sirtex"), an Australian company that is listed on the Australian Securities Exchange, for A$28 per share or approximately A$1.6 billion ($1.3 billion). Sirtex is an Australian-based global life sciences company focused on interventional oncology therapies. We plan to finance the acquisition using cash on hand as well as proceeds from borrowings. The transaction, which is expected to close in late May 2018, is subject to the approval of the Sirtex shareholders, the Federal Court of Australia and other customary closing conditions, including applicable regulatory approvals. We plan to finance the acquisition using cash on hand as well as proceeds from borrowings.

Acquisition of Mobius Medical Systems L.P. On February 1, 2018, we acquired Mobius Medical Systems L.P. ("Mobius") for approximately $24.0 million . Mobius makes quality assurance software for the radiation oncology field.
Financial Information. Total revenues increased 13% , gross margin percentage increased 0.2% , and the effective tax rate increased by 132.9 percentage points, compared to the year-ago period. Net loss from continuing operations was $112.2 million , and a net loss of $1.22 from continuing operations per diluted share, in the first quarter of fiscal year 2018 , compared to $8.0 million net earnings from continuing operations and $0.08 net earnings per diluted share from continuing operations in the year-ago period.
Gross orders increased 7% in Oncology Systems in the first quarter of fiscal year 2018 , compared to the year-ago period. Our total backlog at December 29, 2017 was 10% higher than at the end of the first quarter of fiscal year 2017 .
In order to assist with the assessment of how our underlying businesses performed, we compare the percentage change in revenues and Oncology Systems gross orders from one period to another, excluding the effect of foreign currency fluctuations ( i.e., using constant currency exchange rates). To present this information on a constant currency basis, we convert current period revenues and gross orders in currencies other than U.S. Dollars into U.S. Dollars using the comparable prior period’s average exchange rate. Percentage changes in revenue and gross orders are not adjusted for constant currency unless indicated.
Currency fluctuations did not have a significant impact on total revenues and Oncology Systems gross orders in the first quarter of fiscal year 2018 , compared to the year-ago period. We expect that fluctuations of non-U.S. Dollar currencies against the U.S. Dollar may cause variability in our financial performance.

The Americas region includes North America (primarily United States and Canada) and Latin America. The EMEA region includes Europe, Russia, the Middle East, India and Africa. The APAC region primarily includes East and Southeast Asia and Australia.

The first quarter of 2018 reflects the enactment of the Tax Cuts and Jobs Act, which was signed into U.S. law on December 22, 2017. Two provisions of the new law had an immediate impact.

First, the U.S. corporate tax rate was reduced from 35% to 21%. This rate reduction required us to re-measure our net deferred tax assets which were originally recorded assuming a future tax benefit at the 35% rate. We estimate that the total impact of this re-measurement of our net deferred tax assets will be about $47.0 million. The impact to our first quarter of fiscal year 2018 is a charge to income tax expense of $37.8 million. As the Company has a September fiscal year end, the change to the lower corporate tax rate will be phased in. As a result of this phase in, the remainder, or about $9.2 million, will be charged to income tax expense over the balance of fiscal year 2018.

42



Second, as part of the transition to a modified territorial system, the new law imposes a one-time transition tax on the unremitted earnings of our foreign subsidiaries. We estimate the tax effect of this deemed repatriation to be $169.3 million. We intend to elect to pay this tax over an eight-year period.
The Securities and Exchange Commission has issued guidance allowing companies a measurement period, not to exceed one-year from the date of enactment, to refine their estimates of the tax impact of the new law. We fully expect that we will true up our estimates of these tax impacts of the new tax legislation over the measurement period.
On January 22, 2018, a continuing budget resolution was signed into law that included a provision to extend the moratorium on the 2.3% medical device excise tax for two more years, or until January 1, 2020. This tax has had, and may continue to have, a negative impact on our gross margin when the moratorium expires.
Oncology Systems. Our Oncology Systems business designs, manufactures, sells and services hardware and software products for treating cancer with conventional radiotherapy, and advanced treatments, such as fixed field intensity-modulated radiation therapy ("IMRT"), image-guided radiation therapy ("IGRT"), volumetric modulated arc therapy ("VMAT"), stereotactic radiotherapy, stereotactic body radiotherapy and brachytherapy. Our software solutions also include informatics software for information management, clinical knowledge exchange, patient care management, practice management and decision-making support for comprehensive cancer clinics, radiotherapy centers and medical oncology practices.
Our primary goal in the Oncology Systems business is to promote the adoption of more advanced and effective cancer treatments. In our view, the fundamental market forces that drive long-term growth in our Oncology Systems business are the rise in cancer cases; technology advances and product developments that are leading to improvements in patient care; customer demand for the more advanced and effective cancer treatments that we enable; competitive conditions among hospitals and clinics to offer such advanced treatments; continued improvement in safety and cost efficiency in delivering radiation therapy; and underserved medical needs outside of the United States. Over the last few years, we have seen a greater percentage of Oncology Systems gross orders and revenues coming from emerging markets within our international region, which typically have lower gross margins and longer installation cycles compared to mature markets. We have also seen an increased portion of gross orders and revenues coming from services and software licenses, both of which have higher gross margin percentages than our hardware products. We have also been investing a higher portion of our Oncology Systems research and development budget in software and software-related products.
The radiation oncology market in North America is largely characterized by replacements of older machines, with periodic increases in demand driven by the introduction of new technologies. Reimbursement rates in the United States have generally supported a favorable return on investment for the purchase of new radiotherapy equipment and technologies. While we believe that improved product functionality, greater cost-effectiveness and prospects for better clinical outcomes with new capabilities such as IMRT, IGRT and VMAT tend to drive demand for radiotherapy products, large changes in reimbursement rates or reimbursement structure can affect customer demand and cause market shifts. We do not know the full impact of the Affordable Care Act or its potential repeal, or the possible impact of changes in policy resulting from President Trump's administration, will have on long-term growth or demand for our products and services. We believe, however, that growth of the radiation oncology market in the United States could be impacted as customers’ decision-making processes are complicated by the uncertainties surrounding the Affordable Care Act, or its replacement, and reimbursement rates for radiotherapy and radiosurgery, and that this uncertainty will likely continue in future fiscal years. We believe this uncertainty could impact transaction size, timing and purchasing processes, and also contribute to increased quarterly business variability. Given all the dynamic elements affecting this market, as outlined above, we believe the North America market will continue to grow in the low to mid-single digit range.
In the radiation oncology markets outside of North America, we expect the EMEA market to grow over the long-term with mixed performance across the region. In APAC, we expect China to lead longer-term regional growth, off-setting a slower Japanese market. Latin America is currently experiencing volatility; however, our long-term outlook is cautiously optimistic. Overall, we believe the global radiation oncology market can grow over the long-term, in constant currencies, in the low to mid-single-digit range.
In the first quarter of fiscal year 2018 , Oncology Systems revenues increased 14% and gross margin percentage increased by 0.4 percentage points compared to the year-ago period.
In the first quarter of fiscal year 2018 , Oncology Systems gross orders increased 7% , compared to the year-ago period, primarily due to an increase in gross orders of 12% and 2% from our international and North America regions, respectively. On a constant currency basis, Oncology Systems gross orders and international gross orders increased 6% and 9% , respectively, in the first quarter of fiscal year 2018 , compared to the year-ago period.

43



Varian Particle Therapy .  Our VPT business develops, designs, manufactures, sells and services products and systems for delivering proton therapy, another form of external beam radiotherapy using proton beams, for the treatment of cancer.
In the first quarter of fiscal year 2018 , VPT revenues decreased $1.2 million and gross orders increased $41.9 million compared to the year-ago period.
In January 2017, we were informed of actions taken by California Proton Treatment Center, LLC (“Original CPTC”) and the loan agent, including Original CPTC obtaining shareholder consents for voluntary bankruptcy filing and the loan agent deciding that no additional funding would be available outside of a bankruptcy process. In March 2017, Original CPTC filed for bankruptcy and concurrently entered into a Debtor-in-Possession facility (the "DIP Facility") with ORIX Capital Markets, LLC, J.P. Morgan and Varian for up to $16.0 million of additional financing during the bankruptcy process. Our pro-rata share of the DIP Facility was $7.3 million . In September 2017, ORIX, J.P. Morgan and Varian (collectively the "Lenders") and the Scripps Proton Therapy Center ("Scripps") signed a Transition Agreement to transition the operations of the center from Scripps to a new operator.
Pursuant to an order from the Bankruptcy Court, Original CPTC conducted an auction of the sale of Scripps Proton Therapy Center. On December 6, 2017 (“Closing Date”), the Bankruptcy Court approved the sale of Original CPTC to the California Proton Therapy Center, LLC (“CPTC”), an entity owned by the Lenders. The Lenders purchased all assets and assumed $112.0 million (“Term Loan”) of Original CPTC’s outstanding liabilities. On December 13, 2017, the Bankruptcy Court dismissed the bankruptcy filing of Original CPTC.
On the Closing Date, the Lenders entered into a Credit Agreement with Original CPTC of which the terms of the Original CPTC Loans, DIP Facility and accrued interest (collectively “Former Loans”) have been modified. In addition to the partially satisfied Original CPTC Loans reinstated by the Bankruptcy Court, the Company received a 47.08% equity ownership in CPTC. Original CPTC has assigned all its Former Loans to CPTC at an amount of $112.0 million , the partially satisfied loan balance. Per the terms of the Credit Agreement, our portion of the $112.0 million is $53.5 million ; the remainder is allocated between ORIX and J.P. Morgan. The $53.5 million is composed of four Tranches: Tranche A of $2.0 million , Tranche B of $7.2 million , Tranche C of $15.6 million , and Tranche D of $28.7 million (collectively the "Term Loan"). The maturity date of the Term Loan is three years from the Closing Date. The Term Loan is secured by the assets of CPTC.
In addition, the Lenders have committed to lend up to $15.0 million in Revolving Loans. Our share of the funding commitment from the Revolving Loan is $7.2 million and as of December 29, 2017, we have funded $2.4 million. The Revolving Loan accrues paid-in-kind interest at 10% per annum and has a maturity date one year from the Closing Date.

All of the Tranches accrue paid-in-kind interest at 7.5% per annum, except the Tranche B, loan which accrues paid-in-kind interest at 10% per annum. The seniority of these loans is as follows: Revolving Loan, Tranche A, Tranche B, Tranche C and Tranche D. If CPTC is in default the interest of the Tranche A, C and D will increase to 9.5% and the Tranche B and the Revolving Loan will increase to 12.0%.

Considering Original CPTC’s financial difficulties, the modification of the original terms of the Former Loans, and the Lenders agreement to grant a concession on the Original CPTC Loans, we classified this transaction as a troubled debt restructuring (“TDR”). We did not have any unamortized fees from the Former Loans and any prepayment penalties. As a result, the cost basis and fair value of our outstanding term loan as of December 29, 2017 to CPTC is $53.5 million , which approximates the carrying value of the Former Loans prior to TDR.

We used a discounted cash flow approach and determined the fair value of CPTC's equity as of Closing Date is $20.1 million . Our 47.08% ownership percentage amounts to a $9.5 million equity interest in CPTC. Since the common stock received were in addition to a loan receivable partially satisfied through the bankruptcy proceedings, in accordance with the TDR accounting guidance, we recorded the equity interest at fair value and as an offset to the reinstated loan balance. The equity investment in CPTC is accounted for under the equity method of accounting as of December 29, 2017. We will account for our equity method share of the income or loss of CPTC on a quarter lag basis as provided by the equity method accounting guidance.
Per the terms of the Former Loans, as of September 29, 2017, ORIX had the option to purchase our share of the Original CPTC Loans at par and therefore they were accounted as available-for-sale securities. Per the terms of the new agreement, ORIX no longer has the option to purchase our share of the Term Loan at par. As a result, the Term Loan no longer qualifies for available-for-sale classification as of December 29, 2017. As of December 29, 2017 , we had a total of $125.4 million carrying value of loans outstanding to VPT customers, available-for-sale securities, notes receivable and short-term senior secured debt. See Note 15, "VPT Loans and Securities" of the Notes to the Condensed Consolidated Financial Statements for further information.

44



This discussion and analysis of our financial condition and results of operations is based upon and should be read in conjunction with the Condensed Consolidated Financial Statements and the Notes included elsewhere in this Quarterly Report on Form 10-Q and the Consolidated Financial Statements and the Notes to the Consolidated Financial Statements and the related Management’s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the fiscal year ended September 29, 2017 (the “ 2017 Annual Report”), as well as the information contained under Part II, Item 1A "Risk Factors" of this Quarterly Report on Form 10-Q, and other information provided from time to time in our other filings with the SEC.
Critical Accounting Estimates
The preparation of our financial statements and related disclosures in conformity with accounting principles generally accepted in the United States (“GAAP”) requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. These estimates and assumptions are based on historical experience and on various other factors that we believe are reasonable under the circumstances. We periodically review our accounting policies, estimates and assumptions and make adjustments when facts and circumstances dictate. In addition to the accounting policies that are more fully described in the Notes to the Consolidated Financial Statements included in our 2017 Annual Report on Form 10-K, we consider the critical accounting policies described below to be affected by critical accounting estimates. Our critical accounting policies that are affected by accounting estimates include revenue recognition, share-based compensation expense, valuation of allowance for doubtful accounts, impairment of investments and notes receivable, valuation of inventories, assessment of recoverability of goodwill and intangible assets, valuation of warranty obligations, assessment of loss contingencies, valuation of defined benefit pension and post-retirement benefit plans, valuation of derivative instruments, and taxes on earnings. Such accounting policies require us to use judgments, often as a result of the need to make estimates and assumptions regarding matters that are inherently uncertain, and actual results could differ materially from these estimates. For a discussion of how these estimates and other factors may affect our business, see Part II, Item 1A, “Risk Factors.”
Revenue Recognition
Our revenues are derived primarily from the sale of hardware and software products, and services from our Oncology Systems and VPT businesses. We recognize revenues net of any value added or sales tax and net of sales discounts.
We frequently enter into revenue arrangements with customers that contain multiple performance obligations including hardware, software, and services. Judgments as to the stand alone selling price and allocation of consideration from an arrangement to the individual performance obligations, and the appropriate timing of revenue recognition are critical with respect to these arrangements.
Changes to the elements in an arrangement and the amounts allocated to each element could affect the timing and amount of revenue recognition. Revenue recognition also depends on the timing of shipment, readiness of customers’ facilities for installation, installation requirements, and availability of products or customer acceptance terms. If shipments or installations are not made on scheduled timelines or if the products are not accepted by the customer in a timely manner, our reported revenues may differ materially from expectations.
Service revenues include revenues from hardware service contracts, software service agreements, bundled support arrangements, paid services and trainings, and parts that are sold by our service department. Revenues allocated to service contracts are generally recognized ratably over the period of the related contracts.
We recognize revenues on proton therapy contracts over the life of the project as costs are incurred. We recognize revenue related to our proton therapy systems over time because the customer controls the work in process, the Company's performance does not create an asset with alternative use to the Company, and the Company has an enforceable right to payment for performance completed to date. Changes in estimates of total contract revenue, total contract cost or the extent of progress towards completion are recognized in the period in which the changes in estimates are identified. Estimated losses on contracts are recognized in the period in which the loss is identified. In circumstances in which the final outcome of a contract cannot be reliably estimated but a loss on the contract is not expected, we recognize revenues to the extent of costs incurred until reliable estimates can be made. If and when we can make reliable estimates, revenues and costs of revenues are adjusted in the same period. Recognizing revenue over time based on costs incurred requires the use of estimates in determining revenues, costs and profits and in assigning the dollar amounts to relevant accounting periods. Because the estimates must be periodically reviewed and appropriately adjusted, if our estimates prove to be inaccurate or circumstances change over time, we may be forced to adjust revenues or even record a contract loss in later periods.

45



For a discussion of the impact of ASC 606 on our revenue recognition, please see Note 1, "Summary of Significant Accounting Policies" of the Notes to the condensed consolidated financial statements.
Share-based Compensation Expense
We grant restricted stock units, deferred stock units, performance units, and stock options to employees and permit employees to purchase shares under the VMS employee stock purchase plan. We value our stock options granted and the option component of the shares of VMS common stock purchased under the employee stock purchase plan using the Black-Scholes option-pricing model. We value our performance units, which contain a market condition, using the Monte Carlo simulation model. The determination of fair value of share-based payment awards on the date of grant under both the Black-Scholes option-pricing model and the Monte Carlo simulation model is affected by VMS’s stock price, as well as the input of other subjective assumptions, including the expected terms of share-based awards and the expected price volatilities of shares of VMS common stock and peer companies that are used to assess certain performance targets over the expected term of the awards, and the expected dividend yield of shares of VMS common stock.
The expected term of our stock options is based on the observed and expected time to post-vesting exercise and post-vesting cancellations of stock options by our employees. We use a blended volatility in deriving the expected volatility assumption for our stock options. Blended volatility represents the weighted average of implied volatility and historical volatility. Implied volatility is derived based on traded options on VMS common stock. In determining the grant date fair value of our performance units, historical volatilities of shares of VMS common stock, as well as the shares of common stock of peer companies, were used to assess certain performance targets. The risk-free interest rate assumption is based upon observed interest rates appropriate for the term of our stock awards. The dividend yield assumption is based on our history and expectation of no dividend payouts. If factors change and we employ different assumptions in future periods, the compensation expense that we record may differ significantly from what we have recorded in the current period.
Beginning in the first quarter of fiscal year 2018, we now record forfeitures as they occur. We estimate the probability that certain performance conditions that affect the vesting of performance units will be achieved, and recognize expense only for those awards expected to vest. If the actual number of performance units that vest based on achievement of performance conditions are materially different from our estimates, the share-based compensation expense could be significantly different from what we have recorded in the current period.
Allowance for Doubtful Accounts
We evaluate the creditworthiness of our customers prior to authorizing shipment for all major sale transactions. Except for government tenders, group purchases and orders with letters of credit in Oncology Systems our payment terms often require payment of a small portion of the total amount due when the customer signs the purchase order, a significant amount upon transfer of risk of loss to the customer and the remaining amount upon completion of the installation. On a quarterly basis, we evaluate aged items in the accounts receivable aging report and provide an allowance in an amount we deem adequate for doubtful accounts. If our evaluation of our customers’ financial conditions does not reflect our future ability to collect outstanding receivables, additional provisions may be needed and our operating results could be negatively affected.
Impairment of Investments and Notes Receivable
We recognize an impairment charge when the declines in the fair values of our available-for-sale investments below their cost basis are determined to be other than temporary impairments (“OTTI”). We monitor our available-for-sale investments for possible OTTI on an ongoing basis. When there has been a decline in fair value of a debt security below the amortized cost basis, we recognize OTTI if: (i) we have the intention to sell the security; (ii) it is more likely than not that we will be required to sell the security before recovery of the entire amortized cost basis; or (iii) we do not expect to recover the entire amortized cost basis of the security. We assess the fair value of our available-for-sale securities, which are classified in the level 3 fair value hierarchy based on the income approach by using the discounted cash flow model with key assumptions that include discount rates corresponding to the terms and risks associated with the loans, as well as underlying cash flow assumptions. As of December 29, 2017 , we did not have any available-for-sale investments classified as level 3 in the fair value hierarchy. As of September 29, 2017, we had $47.4 million, which comprised of the fair value our Original CPTC Loans, of available-for-sale investments classified as level 3 in the fair value hierarchy. See Note 4, "Fair Value" and Note 15, "VPT Loans and Securities" of the Notes to the Condensed Consolidated Financial Statements.

We also have investments in privately-held companies, some of which are in the startup or development stages. We monitor these investments for events or circumstances indicative of potential impairment, and we make appropriate reductions in carrying values if we determine that an impairment charge is required, based primarily on the financial condition, near-term

46



prospects and recent financing activities of the investee. These investments are inherently risky because the markets for the technologies or products these companies are developing are typically in the early stages and may never materialize.

At times, we advance notes to third parties, including our customers. We regularly assess these notes for collectability by considering internal factors such as historical experience, credit quality, age of the note balances as well as external factors such as economic conditions that may affect the note holder's ability to pay.

Our ongoing consideration of all the factors described above could result in impairment charges in the future, which could adversely affect our operating results.
Inventories
Our inventories include high technology parts and components that are highly specialized in nature and that are subject to rapid technological obsolescence. We have programs to minimize the required inventories on hand and we regularly review inventory quantities on hand and on order and adjust for excess and obsolete inventory based primarily on historical usage rates and our estimates of product demand and production. Actual demand may differ from our estimates, in which case we may have understated or overstated the provision required for obsolete and excess inventory, which would have an impact on our operating results.
Goodwill, Intangible Assets and Impairment Assessment
Goodwill represents the excess of the purchase price in a business over the fair value of net tangible and intangible assets acquired. The determination of the value of the intangible assets acquired involves certain judgments and estimates. These judgments can include, but are not limited to, the cash flows that an asset is expected to generate in the future and the appropriate discount weighted-average cost of capital ("WACC"). Each period, we evaluate the estimated remaining useful lives of purchased intangible assets and whether events or changes in circumstances warrant a revision to the remaining periods of amortization.
Goodwill is allocated to reporting units expected to benefit from the business combination. We evaluate our reporting units when changes in our operating structure occur, and if necessary, reassign goodwill using a relative fair value allocation approach. Goodwill is tested for impairment at the reporting unit level on an annual basis or whenever events or changes in circumstances indicate its carrying value may not be recoverable. We can opt to perform a qualitative assessment to test a reporting unit’s goodwill for impairment or we can directly perform a quantitative assessment. Various factors are considered in the qualitative assessment, including macroeconomic conditions, industry and market considerations, financial performance and other relevant events affecting the reporting unit. Based on our qualitative assessment, if we determine that the fair value of a reporting unit is more likely than not (i.e., a likelihood of more than 50 percent) to be less than its carrying amount, the quantitative assessment will be performed. The quantitative assessment compares the fair value of a reporting unit against its carrying amount, including the goodwill allocated to each reporting unit. We determine the fair value of our reporting units based on a combination of income and market valuation approaches. The income approach is based on the present value of estimated future cash flows that the reporting unit is expected to generate, and the market approach is based on a market multiple calculated for each reporting unit based on market data of other companies engaged in similar business. Any excess of the reporting unit's carrying value over its fair value will be recorded as an impairment loss.
Determining the fair value of a reporting unit involves the use of significant estimates and assumptions. These estimates and assumptions include revenue growth rates, operating margins and working capital needs to calculate projected future cash flows, WACC, future economic and market conditions, estimation of the long-term rate of growth for our business and determination of appropriate market comparables. We base our fair value estimates on assumptions we believe to be reasonable but that are inherently uncertain. Actual future results related to assumed variables could differ from these estimates. In addition, we make certain judgments and assumptions in allocating assets and liabilities to determine the carrying values for each reporting unit.
We have two reporting units: (i) Oncology Systems and (ii) VPT, with $170.2 million and $53.2 million in goodwill, respectively, as of December 29, 2017 . Based upon the most recent annual goodwill analysis during the fourth quarter of fiscal year 2017, VPT's fair value was 21% in excess of its carrying value, and we believe each of the assumptions used to calculate VPT’s fair value to be reasonable. However, VPT could be at risk for goodwill impairment because adjustments to revenue growth rates, operating margins, WACC and/or our working capital used in the fair value calculation could lead to an impairment.

47



Warranty Obligations
We warrant most of our products for a specific period of time, usually 12 months from installation, against material defects. We provide for the estimated future costs of warranty obligations in cost of revenues when the related revenues are recognized. The accrued warranty costs represent our best estimate at the time of sale of the total costs that we will incur to repair or replace product parts that fail while still under warranty. The amount of accrued estimated warranty costs obligation for established products is primarily based on historical experience as to product failures adjusted for current information on repair costs. For new products, estimates will include historical experience of similar products, as well as reasonable allowance for start-up expenses. Actual warranty costs could differ from the estimated amounts. On a quarterly basis, we review the accrued balances of our warranty obligations and update the historical warranty cost trends, if required. If we were required to accrue additional warranty costs in the future, it would have a negative effect on our operating results.
Loss Contingencies
From time to time, we are a party to or otherwise involved in legal proceedings, claims and government inspections or investigations or other legal matters, both inside and outside the United States, arising in the ordinary course of our business or otherwise. We accrue amounts, to the extent they can be reasonably estimated, that we believe are adequate to address any liabilities related to legal proceedings and other loss contingencies that we believe will result in a probable loss. Such matters are subject to many uncertainties, outcomes are not predictable with assurance, and actual liabilities could significantly exceed our estimates of potential liabilities. In addition, we are subject to a variety of environmental laws around the world. Those laws regulate multiple aspects of our operations, including the handling, storage, transport and disposal of hazardous substances. They impose costs on our operations. In connection with our past and present operations and facilities, we record environmental remediation liabilities when we conclude that environmental assessments or remediation efforts are probable and we believe we can reasonably estimate the costs of those efforts. Our accrued environmental costs represent our best estimate of the total costs of assessments and remediation and the time period over which we expect to incur those costs. We review these accrued balances quarterly. If we were required to increase or decrease the accrued environmental costs in the future, it would adversely or favorably impact our operating results.
Defined Benefit Pension Plans
We sponsor five defined benefit pension plans in Germany, Japan, Switzerland and the United Kingdom covering employees who meet the applicable eligibility requirements in these countries. Several statistical and other factors that attempt to anticipate future events are used in calculating the expenses and liabilities related to the aforementioned plans. These factors include assumptions about the discount rate, expected return on plan assets, and rate of future compensation increases, all of which we determine within certain guidelines. In addition, we also use assumptions, such as withdrawal and mortality rates, to calculate the expenses and liabilities. The actuarial assumptions we use are long-term assumptions and may differ materially from actual experience particularly in the short term due to changing market and economic conditions and changing participant demographics. These differences may have a significant impact on the amount of defined benefit pension plan expenses we record.
The expected rates of return on the various defined benefit pension plans’ assets are based on the asset allocation of each plan and the long-term projected return on those assets. The discount rate enables us to state expected future cash flows at a present value on the measurement date. The discount rates used for defined benefit plans are primarily based on the current effective yield of long-term corporate bonds that are of high quality with satisfactory liquidity and credit rating with durations corresponding to the expected durations of the benefit obligations. A change in the discount rate may cause the present value of benefit obligations to change significantly.
Valuation of Derivative Instruments
We use foreign currency forward contracts to reduce the effects of currency rate fluctuations on sales transactions denominated in foreign currencies and on net monetary assets and liabilities denominated in foreign currencies. These foreign currency forward contracts are derivative instruments and are measured at fair value. There are three levels of inputs that may be used to measure fair value (see Note 4, "Fair Value" of the Notes to the Consolidated Financial Statements). The fair value of foreign currency forward contracts is calculated primarily using Level 2 inputs, which include currency spot and forward rates, interest rate and credit or non-performance risk. The spot rate for each currency is the same spot rate used for all balance sheet translations at the measurement date and sourced from our major trading banks. The forward point values for each currency and the London Interbank Offered Rate (“LIBOR”) to discount assets and liabilities are interpolated from commonly quoted broker services. One-year credit default swap spreads of the counterparty at the measurement date are used to adjust derivative assets, all of which mature in 13 months or less, for non-performance risk. We are required to adjust derivative liabilities to reflect the

48



potential non-performance risk to lenders based on our incremental borrowing rate. Each contract is individually adjusted using the counterparty credit default swap rates (for net assets) or our borrowing rate (for net liabilities). The use of Level 2 inputs in determining fair values requires certain management judgment and subjectivity. Changes to these Level 2 inputs could have a material impact on the valuation of our derivative instruments. There were no transfers of assets or liabilities between fair value measurement levels during the first quarter of fiscal years 2018 and 2017 .
Taxes on Earnings
We are subject to taxes on earnings in both the United States and numerous foreign jurisdictions. As a global taxpayer, significant judgments and estimates are required in evaluating our tax positions and determining our provision for taxes on earnings. We account for uncertainty in income taxes following a two-step approach for recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining whether the weight of available evidence indicates that it is more likely than not that, based on the technical merits, the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. Recognition and measurement are based on management’s best judgment given the facts, circumstances and information available at the end of the accounting period.
Generally, the carrying value of our net deferred tax assets assumes that we will be able to generate sufficient future taxable earnings in the applicable tax jurisdictions to utilize these deferred tax assets. Should we conclude it is more likely than not that we will be unable to recover our deferred tax assets in these tax jurisdictions, we would increase our valuation allowance and our tax provision would increase in the period in which we make such a determination. The Tax Cuts and Jobs Act (the “Act”) was signed into law on December 22, 2017. Among other changes, the Act reduces the U.S. corporate tax rate from 35% to 21%. The reduction in the rate required us to re-measure our net deferred tax assets that were originally recorded assuming a future tax benefit at the 35% rate. During the three months ended December 29, 2017, we recorded a provisional discrete tax expense of $37.8 million related to re-measuring our net deferred tax assets as a result of the rate reduction.
Our foreign earnings are taxed at rates that are, on average, lower than U.S. rates. Our effective tax rate is impacted by existing tax laws in both the United States and in the respective countries in which our foreign subsidiaries do business. In addition, a decrease in the percentage of our total earnings from foreign countries, or a change in the mix of foreign countries among particular tax jurisdictions could increase or decrease our effective tax rate.

As part of the transition to a modified territorial system, the Act imposes a one-time transition tax on the unremitted earnings of our foreign subsidiaries. During the three months ended December 29, 2017, we recorded a provisional discrete tax expense of $169.3 million related to the one-time transition tax. We intend to elect to pay this tax over an eight-year period.
The transition to a modified territorial regime and the one-time transition tax on unremitted earnings has caused us to re-evaluate our intentions with respect to the unremitted earnings of our foreign subsidiaries. In the past, we did not accrue U.S. taxes on certain undistributed profits of certain foreign subsidiaries because the earnings were considered to be indefinitely reinvested. In light of the changes to the taxation of foreign earnings in the Act, we no longer consider the earnings of our foreign subsidiaries to be indefinitely reinvested.

On December 22, 2017, the Securities and Exchange Commission issued Staff Accounting Bulletin No. 118 (“SAB 118”). This guidance allows registrants a “measurement period,” not to exceed one year from the date of enactment, to complete their accounting for the tax effects of the Act. SAB 118 further directs that during the measurement period, registrants who are able to make reasonable estimates of the tax effects of the Act should include those amounts in their financial statements as “provisional” amounts. Registrants should reflect adjustments over subsequent periods as they are able to refine their estimates and complete their accounting for the tax effects of the Act. We have made reasonable estimates and recorded provisional amounts within the meaning of SAB 118. Also, it is expected that the U.S. Treasury will issue regulations and other guidance on the application of certain provisions of the Act. In subsequent periods, but within the measurement period, we will analyze that guidance and other necessary information to refine our estimates and complete our accounting for the tax effects of the Act.
Results of Operations
Fiscal Year
Our fiscal year is the 52- or 53-week period ending on the Friday nearest September 30. Fiscal year 2018 is the 52-week period ending September 28, 2018 , and fiscal year 2017 was the 52-week period that ended on September 29, 2017 . The fiscal quarters ended December 29, 2017 and December 30, 2016 were both 13-week periods.

49



Discussion of Results of Operations for the First Quarter of Fiscal Year 2018 Compared to the First Quarter of Fiscal Year 2017
Total Revenues  
Revenues by sales classification
Three Months Ended
(Dollars in millions)
December 29,
2017
 
December 30,
2016
 
Percent Change
Product
$
365.6

 
$
309.2

 
18
%
Service
312.9

 
292.3

 
7
%
Total Revenues
$
678.5

 
$
601.5

 
13
%
Product as a percentage of total revenues
54
%
 
51
%
 
 
Service as a percentage of total revenues
46
%
 
49
%
 
 
Total product and service revenues increased in the first quarter of fiscal year 2018 , compared to the year-ago period, primarily due to an increase in revenues from Oncology Systems.

Revenues by geographical region
Three Months Ended
(Dollars in millions)
December 29,
2017
 
December 30,
2016
 
Percent Change
 
Constant Currency (1)
Americas
$
356.7

 
$
298.2

 
20
%
 
20
 %
EMEA
193.0

 
184.0

 
5
%
 
(2
)%
APAC
128.8

 
119.3

 
8
%
 
10
 %
Total Revenues
$
678.5

 
$
601.5

 
13
%
 
11
 %
 
 
 
 
 
 
 
 
North America
$
345.6

 
$
282.4

 
22
%
 
22
 %
International (2)
332.9

 
319.1

 
4
%
 
1
 %
Total Revenues
$
678.5

 
$
601.5

 
13
%
 
11
 %
North America as a percentage of total revenues
51
%
 
46
%
 
 
 
 
International as a percentage of total revenues
49
%
 
54
%
 
 
 
 
(1)  
Constant currency is the percent change excluding the effect of foreign currency fluctuations against the U.S. Dollar.
(2)  
We consider international revenues to be revenues outside of North America.
The Americas revenues increased in the first quarter of fiscal year 2018 , compared to the year-ago period, due to an increase in revenues from Oncology Systems in North America and to a lesser extent an increase in revenues from VPT. EMEA revenues increased in the first quarter of fiscal year 2018 , compared to the year-ago period, due to an increase in revenues from Oncology Systems, partially offset by a decrease in revenues from VPT. APAC revenues increased in the first quarter of fiscal year 2018 , compared to the year-ago period, due to an increase in revenues from Oncology Systems, partially offset by a decrease in revenues from VPT.

50



Oncology Systems Revenues  
Revenues by sales classification
Three Months Ended
(Dollars in millions)
December 29,
2017
 
December 30,
2016
 
Percent Change
 
Constant Currency
Product
$
338.3

 
$
282.4

 
20
%
 
18
%
Service
311.1

 
288.8

 
8
%
 
6
%
Total Oncology Systems Revenues
$
649.4

 
$
571.2

 
14
%
 
12
%
Product as a percentage of total Oncology Systems revenues
52
%
 
49
%
 

 
 
Service as a percentage of total Oncology Systems revenues
48
%
 
51
%
 
 
 
 
Oncology Systems revenues as a percentage of total revenues
96
%
 
95
%
 
 
 
 
Oncology Systems product revenues increased in the first quarter of fiscal year 2018 , compared to the year-ago period, primarily due to increases in revenues due to higher volumes of hardware unit shipments.
Oncology Systems service revenues, which now includes performance obligations for installation, training and warranty, increased across all regions in the first quarter of fiscal year 2018 , compared to the year-ago period, primarily due to ongoing customer adoption of service contracts as the warranty periods on our TrueBeam systems expire and an increase in the number of customers as the installed base of our products continues to grow.

Revenues by geographical region
Three Months Ended
(Dollars in millions)
December 29,
2017
 
December 30,
2016
 
Percent Change
 
Constant Currency
Americas
$
337.4

 
$
290.8

 
16
%
 
16
%
EMEA
183.5

 
169.0

 
9
%
 
2
%
APAC
128.5

 
111.4

 
15
%
 
17
%
Total Oncology Systems Revenues
$
649.4

 
$
571.2

 
14
%
 
12
%
 
 
 
 
 
 
 
 
North America
$
326.3

 
$
275.0

 
19
%
 
19
%
International
323.1

 
296.2

 
9
%
 
6
%
Total Oncology Systems Revenues
$
649.4

 
$
571.2

 
14
%
 
12
%
North America as a percentage of total Oncology Systems revenues
50
%
 
47
%
 
 
 
 
International as a percentage of total Oncology Systems revenues
50
%
 
53
%
 
 
 
 
Americas Oncology Systems revenues increased in the first quarter of fiscal year 2018 , compared to the year-ago period, primarily due to higher volumes of hardware unit shipments from hardware products in North America, and to a lesser extent, an increase in revenues from services in North America, partially offset by a decrease in revenues from software licenses and hardware products in Latin America.
EMEA Oncology Systems revenues increased in the first quarter of fiscal year 2018 , compared to the year-ago period, primarily due to an increase in revenues from software licenses and a favorable foreign currency exchange impact.
APAC Oncology Systems revenues increased slightly in the first quarter of fiscal year 2018 , compared to the year-ago period, due to increases related to higher volumes of hardware unit shipments, and to a lesser extent, an increase in revenues from services, partially offset by a decrease in revenues from software licenses.
Variations of higher and lower revenues between the North American and international regions are impacted by regional influences, which recently have included government stimulus programs, economic and political instability in some countries, uncertainty created by health care reform (such as the excise tax on the sale of most medical devices, Medicare reimbursement rates and consolidation of free standing clinics in the United States), and different technology adoption cycles that are consistent with the gross order patterns. See further discussion of orders under “Gross Orders.”

51



Varian Particle Therapy 
Revenues by sales classification
Three Months Ended
(Dollars in millions)
December 29,
2017
 
December 30,
2016
 
Percent Change
Product
$
27.3

 
$
26.8

 
2
 %
Service
1.8

 
3.5

 
(49
)%
Total Varian Particle Therapy Revenues
$
29.1

 
$
30.3

 
(4
)%
VPT revenues as a percentage of total revenues
4
%
 
5
%
 
 
Revenues from VPT decreased in the first quarter of fiscal year 2018 , compared to the year-ago period, primarily due to a decrease in service revenues from certain proton customers.
Gross Margin
Dollars by segment
Three Months Ended
(Dollars in millions)
December 29,
2017
 
December 30,
2016
 
Percent Change
Oncology Systems
$
300.5

 
$
262.1

 
15
 %
Varian Particle Therapy
2.3

 
4.9

 
(52
)%
Gross margin
$
302.8

 
$
267.0

 
13
 %
 
 
 
 
 
 
Percentage by segment
 
 
 
 
 
Oncology Systems
46.3
%
 
45.9
%
 
 
Varian Particle Therapy
8.0
%
 
16.1
%
 
 
Total Company
44.6
%
 
44.4
%
 
 
 
 
 
 
 
 
Percentage by sales classification
 
 
 
 
 
Total Company - Product
38.8
%
 
33.3
%
 
 
Total Company - Service
51.5
%
 
56.1
%
 
 
Oncology Systems product gross margin percentage was 40.8% in the first quarter of fiscal year 2018 , compared to 35.4% for the respective year-ago period. The increase in Oncology Systems product gross margin percentage in the first quarter of fiscal year 2018 , compared to the year-ago period, was due to more revenues from higher margin hardware products and software licenses.
Oncology Systems service gross margin percentage was 52.2% in the first quarter of fiscal year 2018 , compared to 56.2% in the year-ago period. The decrease in service gross margin percentage in the first quarter of fiscal year 2018 , compared to the year-ago period, was primarily due to lower installation revenues and higher costs associated with installation, warranty and entitled training.
VPT gross margin percentage decreased in the first quarter of fiscal year 2018 compared to the year-ago period, primarily due to more revenues from lower margin projects and a decrease in service revenues.
Research and Development
 
Three Months Ended
(Dollars in millions)
December 29,
2017
 
December 30,
2016
 
Percent Change
Research and development
$
55.9

 
$
49.9

 
12
%
Research and development as a percentage of total revenues
8
%
 
8
%
 
 

Research and development expenses increased $6.0 million in the first quarter of fiscal year 2018 , compared to the year-ago period, primarily due to an increase in investments in new product development projects and the enhancement of existing products in Oncology Systems.

52



Selling, General and Administrative and Impairment Charges
 
Three Months Ended
(Dollars in millions)
December 29,
2017
 
December 30,
2016
 
Percent Change
Selling, general and administrative
$
125.5

 
$
161.4

 
(22
)%
Impairment charges

 
38.3

 
n/m

Selling, general and administrative as a percentage of total revenues
18
%
 
27
%
 

Impairment charges as a percentage of total revenues
%
 
6
%
 
 
n/m = not meaningful
Selling, general and administrative expenses decreased $35.9 million in the first quarter of fiscal year 2018 , compared to the year-ago period, primarily due to a $36.6 million decrease in the allowance for doubtful accounts that was mostly for CPTC and another proton center in the first quarter of fiscal year 2017, a $6.1 million decrease in litigation expenses primarily as a result of the settlement with Elekta in April 2017, and a $3.5 million decrease in restructuring charges, partially offset by an $8.8 million increase in employee-related costs largely due to an increase in headcount.
In the first quarter of fiscal year 2017 , we recorded a $38.3 million impairment charge related to our Original CPTC loans. See Note 15, "VPT Loans and Securities" in our Notes to the Condensed Consolidated Financial Statements for additional information.
Interest Income, Net  
 
Three Months Ended
(Dollars in millions)
December 29,
2017
 
December 30,
2016
 
Percent Change
Interest income, net
$
1.1

 
$
1.9

 
(43
)%
Interest income, net of interest expense, decreased in the first quarter of fiscal year 2018 , compared to the year-ago period, primarily due to a decrease in interest income generated from our loans to CPTC partially offset by a decrease in interest expense associated with a decrease in borrowings from our credit facility.
Taxes on Earnings  
 
Three Months Ended
 
December 29,
2017
 
December 30,
2016
 
Percent Change
Effective tax rate
191.5
%
 
58.6
%
 
132.9
%
Our effective tax rate increased in the first quarter of fiscal year 2018 , compared to the year ago period, primarily due to the tax effect of a law change. The first quarter of 2018 reflects the enactment of the Tax Cuts and Jobs Act, which was signed into U.S. law on December 22, 2017. Two provisions of the new law had an immediate impact.

First, the U.S. corporate tax rate was reduced from 35% to 21%. This rate reduction required us to re-measure our net deferred tax assets which were originally recorded assuming a future tax benefit at the 35% rate. We estimate that the total impact of this re-measurement of our net deferred tax assets will be about $47.0 million. The impact to our first quarter is a charge to income tax expense of $37.8 million. As the Company has a September fiscal year end, the change to the lower corporate tax rate will be phased in. As a result of this phase in, the remainder, or about $9.2 million, will be charged to income tax expense over the balance of fiscal year 2018.
Second, as part of the transition to a modified territorial system, the new law imposes a one-time transition tax on the unremitted earnings of our foreign subsidiaries. We estimate the tax effect of this deemed repatriation to be $169.3 million. We intend to elect to pay this tax over an 8-year period.

53



The Securities and Exchange Commission has issued guidance allowing companies a measurement period, not to exceed one-year from the date of enactment, to refine their estimates of the tax impact of the new law. We fully expect that we will true up our estimates of these tax impacts from the new tax legislation over the measurement period.
We adopted the guidance related to employee share-based payments during the period ended December 29, 2017. Under the prior standard, the tax effect of the “excess stock deduction” related to stock-based compensation was recorded to Additional Paid-in Capital in the equity section on the Balance Sheet. For a stock-based compensation instrument, the excess stock deduction is the difference between the amount of the deduction for taxable income and the amount of book expense related to that instrument. Under the new standard, the tax effect of the “excess stock deduction” related to stock-based compensation is recorded as a discrete item to Income Taxes on Earnings in the Statement of Earnings. During the three months ended December 29, 2017, we recorded a discrete tax benefit of $1.5 million related to excess stock deduction activity in the quarter. We expect that the new standard may cause our effective tax rate to be less predictable and more volatile going forward.
Our effective tax rate is impacted by the percentage of our total earnings that come from our international region, the mix of particular tax jurisdictions within our international region, changes in the valuation of our deferred tax assets or liabilities, and changes in tax laws or interpretations of those laws. We also expect that our effective tax rate may experience increased fluctuations from period to period. See Note 14, “Taxes on Earnings” of the Notes to the Consolidated Financial Statements in our 2017 Annual Report.
Discontinued Operations
The following table summarizes the key components of net (loss) earnings from discontinued operations:
 
Three Months Ended  (1)
(In millions)
December 30,
2016
Revenues
$
151.5

Cost of revenues
92.7

Gross margin
58.8

Operating expenses (2)
46.4

Operating earnings
12.4

Taxes on earnings
5.9

Net earnings from discontinued operations
$
6.5

(1)  
There was no activity in net earnings from discontinued operations during the first quarter of fiscal year 2018 .
(2)  
Operating expenses from discontinued operations included separation costs of $14.9 million during the first quarter of fiscal year 2017 . Separation costs include expenses for transaction advisory services, consulting services, restructuring and other expenses.
Diluted Net Earnings (Loss) Per Share
 
Three Months Ended
 
December 29,
2017
 
December 30,
2016
 
Percent Change
Diluted net earnings (loss) per share - continuing operations
$
(1.22
)
 
$
0.08

 
n/m
Diluted net earnings per share - discontinued operations

 
0.07

 
n/m
Total - Diluted net earnings (loss) per share
$
(1.22
)
 
$
0.15

 
n/m
n/m = not meaningful
Diluted net earnings per share from continuing operations decreased in the first quarter of fiscal year 2018 , compared to the year-ago period, primarily due to the Tax Cuts and Jobs Act signed in December 2017, partially offset by an increase in

54



operating earnings from continuing operations and a reduction in the number of diluted shares of common stock outstanding due to share repurchases.
Gross Orders
Total Gross Orders by segment
Three Months Ended
(Dollars in millions)
December 29,
2017
 
December 30,
2016
 
Percent Change
Oncology Systems
$
619.9

 
$
576.7

 
7
%
Varian Particle Therapy
46.2

 
4.3

 
965
%
Total Gross Orders
$
666.1

 
$
581.0

 
15
%
Gross orders are defined as new orders recorded during the period adjusted for any revisions to existing orders during the period. New orders are recorded for the total contractual amount, excluding certain pass-through items, once a written agreement for the delivery of goods or provision of services is in place and, other than VPT, when shipment of the product is expected to occur within two years, so long as any contingencies are deemed perfunctory. For our VPT business, we record orders when construction of the related proton therapy treatment center is reasonably expected to start within two years, but only if any contingencies are deemed perfunctory. We will not record VPT orders if there are major financing contingencies, if a substantial portion of the financing for the project is not reasonably assured or if customer board approval contingencies are pending. We perform a quarterly review to verify that outstanding orders remain valid. If an order is no longer expected to be converted to revenue, we record a backlog adjustment which reduces backlog but does not impact gross orders for the period.
Gross orders in any period may not be directly correlated to the level of revenues in any particular future quarter or period since the timing of revenue recognition will vary significantly based on the delivery requirements of individual orders, acceptance schedules and the readiness of individual customer sites for installation of our products. Moreover, certain types of orders, such as orders for software or newly introduced products in our Oncology Systems segment, typically take more time from order to completion of installation and acceptance than hardware or older products. Because an order for a proton therapy system can be relatively large, an order in one fiscal period will cause gross orders in our VPT business to vary significantly, making comparisons between fiscal periods more difficult.
Oncology Systems Gross Orders
Gross Orders by geographical region
Three Months Ended
(Dollars in millions)
December 29,
2017
 
December 30,
2016
 
Percent Change
 
Constant Currency
Americas
$
299.5

 
$
293.6

 
2
%
 
2
%
EMEA
190.4

 
160.1

 
19
%
 
13
%
APAC
130.0

 
123.0

 
6
%
 
6
%
Total Oncology Systems Gross Orders
$
619.9

 
$
576.7

 
7
%
 
6
%
 


 


 


 
 
North America
$
278.7

 
$
272.2

 
2
%
 
2
%
International
341.2

 
304.5

 
12
%
 
9
%
Total Oncology Systems Gross Orders
$
619.9

 
$
576.7

 
7
%
 
6
%
The Americas Oncology Systems gross orders increased in the first quarter of fiscal year 2018 , compared to the year-ago period, primarily due to growth in North America for our products and services.
EMEA Oncology Systems gross orders increased in the first quarter of fiscal year 2018 , compared to the year-ago period, primarily due to success in large government tenders resulting in increases in gross orders for hardware products, software licenses and services.
APAC Oncology Systems gross orders increased in the first quarter of fiscal year 2018 , compared to the year-ago period, primarily due to an increase in gross orders for services and software licenses.

55



The trailing 12 months' growth in gross orders for Oncology Systems at the end of the first quarter of fiscal year 2018 and at the end of each of the previous three fiscal quarters was:
 
Trailing 12 Months Ended
 
December 29, 2017
 
September 29, 2017
 
June 30, 2017
 
March 31, 2017
Americas
1%
 
1%
 
4%
 
5%
EMEA
14%
 
12%
 
1%
 
—%
APAC
3%
 
7%
 
14%
 
15%
North America
3%
 
4%
 
2%
 
5%
International
7%
 
7%
 
7%
 
6%
Total Oncology Systems Gross Orders
5%
 
5%
 
5%
 
5%
Consistent with the historical pattern, we expect that Oncology Systems gross orders will continue to experience regional fluctuations. In recent years, the percentage of domestic gross orders has increased, but we expect in the long-term international gross orders, specifically from emerging markets, will grow as a percentage of overall orders. Oncology Systems gross orders are affected by foreign currency fluctuations which could impact the demand for our products. In addition, government programs that stimulate the purchase of healthcare products could affect the demand for our products from period to period, and could therefore make it difficult to compare our financial results.
Varian Particle Therapy Gross Orders
VPT gross orders increased in the first quarter of fiscal year 2018 , compared to the year-ago period, primarily due to two proton therapy system orders in the first quarter of fiscal year 2018 versus no proton therapy system orders in the first quarter of fiscal year 2017.
Backlog
Backlog is the accumulation of all gross orders for which revenues have not been recognized and are still considered valid. Backlog is stated at historical foreign currency exchange rates and revenue is released from backlog at current exchange rates, with any difference recorded as a backlog adjustment. Our backlog at December 29, 2017 was $3.0 billion , which includes approximately $340 million in VPT backlog, which was an increase of 10% over the backlog at December 30, 2016 . Our Oncology Systems backlog at December 29, 2017 was 7% higher than the backlog at December 30, 2016 , which reflected an increase of 12% and 3% for the international regions and North America, respectively.
We perform a quarterly review to verify that outstanding orders in the backlog remain valid. Aged orders that are not expected to ultimately convert to revenues are deemed dormant and are reflected as a reduction in the backlog amounts in the period identified. Backlog adjustments are comprised of dormancies, cancellations, foreign currency exchange rate adjustments, backlog acquired from our acquisitions, and other adjustments. Gross orders do not include backlog adjustments. Backlog adjustments totaled $50.0 million in the first quarter of fiscal year 2018 , compared to $18.3 million , in the year-ago period.
Liquidity and Capital Resources
Liquidity is the measurement of our ability to meet potential cash requirements, including ongoing commitments to repay borrowings, acquire businesses or make other investments or loans, repurchase shares of VMS common stock, and fund continuing operations and capital expenditures. Our sources of cash have included operations, borrowings, stock option exercises, and employee stock purchases. Our cash usage is actively managed on a daily basis to ensure the maintenance of sufficient funds to meet our needs.
Cash and Cash Equivalents
The following table summarizes our cash and cash equivalents:
(In millions)
December 29,
2017
 
September 29,
2017
 
Increase
 Total cash and cash equivalents
$
822.6

 
$
716.2

 
$
106.4


56



The increase in cash and cash equivalents in the first quarter of fiscal year 2018 was primarily due to $179.0 million of cash provided by operating activities and $24.2 million in proceeds from the issuance of common stock to employees partially offset by $56.7 million of cash used for the repurchase of shares of VMS common stock, debt repayments, net of borrowings, of $10.0 million under our credit facility agreements, $9.3 million used for purchases of property, plant, and equipment, a $ 6.0 million investment in available-for-sale securities related to the Alabama Proton Therapy Center, and $4.6 million in loans to CPTC.
At December 29, 2017 , we had approximately $112 million , or 14% , of cash and cash equivalents in the United States. Approximately $711 million , or 86% , of cash and cash equivalents was held abroad. As a result of the transition to a modified territorial system and the one-time transition tax on the unremitted earnings of our foreign subsidiaries in the Tax Cuts and Jobs Act, we expect that the cash and cash equivalents held by our foreign subsidiaries will no longer be subject to U.S. federal income tax upon a subsequent actual repatriation to the United States. However, a portion of this cash may still be subject to foreign and state income taxes upon future remittance. In light of the changes to the taxation of foreign earnings in the Act, we no longer consider the earnings of our foreign subsidiaries to be indefinitely reinvested. As a result, we have accrued for the foreign and state income taxes that would be imposed upon a future remittance.
As of December 29, 2017 , most of our cash and cash equivalents that was held abroad was in U.S. Dollars and was primarily held as bank deposits. In addition to cash flows generated from operations, a significant portion of which are generated in the United States, we have used our credit facilities to meet our cash needs from time to time and expect to continue to do so in the future. Borrowings under our credit facilities may be used for working capital, capital expenditures, VMS share repurchases, acquisitions and other corporate purposes.
Cash Flows
 
Three Months Ended
(In millions)
December 29,
2017
 
December 30,
2016
Net cash flow provided by (used in):
 
 
 
Operating activities
$
179.0

 
$
82.2

Investing activities
(25.8
)
 
(31.8
)
Financing activities
(42.8
)
 
(89.6
)
Effects of exchange rate changes on cash and cash equivalents
(4.0
)
 
10.4

Net increase (decrease) in cash and cash equivalents
$
106.4

 
$
(28.8
)
Our primary cash inflows and outflows for the first quarter of fiscal year 2018 , as compared to the first quarter of fiscal year 2017 , were as follows:
In the first quarter of fiscal year 2018 , we generated net cash from operating activities of $179.0 million compared to $82.2 million in the first quarter of fiscal year 2017 . The $96.8 million increase in net cash from operating activities was driven by a $236.8 million increase in the net change from operating assets and liabilities partially offset by a $126.7 million decrease in net earnings and a $13.3 million decrease from non-cash items.
The major contributors to the net change in operating assets and liabilities in the first quarter of fiscal year 2018 were as follows:
Accrued liabilities and other long-term liabilities increased $125.1 million primarily due an increase in a long-term income tax liability that resulted from the tax legislation that was signed into law in the first quarter of fiscal year 2018 .
Trade and unbilled receivables decreased $65.9 million primarily due to higher collections than billings partially offset by an increase in unbilled receivables.
Prepaid and other assets decreased $28.2 million primarily due to a decrease in prepaid income taxes.
Deferred revenues increased $18.6 million primarily due to advance payments received from VPT customers and an increase in deferred service revenues in Oncology Systems.
Inventory increased $11.7 million primarily due an increase in hardware product inventory in Oncology Systems.

57



We expect that cash provided by operating activities may fluctuate in future periods as a result of a number of factors, including fluctuations in our operating results, timing of product shipments, product installation or customer acceptance, trade receivable collections, inventory management, and the timing and amount of tax and other payments. For additional discussion, please refer to the “Risk Factors” in Item 1A.
In the first quarter of fiscal year 2018 , cash used for investing activities was $25.8 million , compared to cash used of $31.8 million in the first quarter of fiscal year 2017 . In the first quarter of fiscal year 2018 , cash used for investing activities primarily included $9.3 million in purchases of property, plant and equipment, $6.0 million in investment in available-for-sale securities, $4.6 million in loans to CPTC, a $2.6 million deposit in an escrow account related to a potential acquisition, and a $2.5 million investment in a privately-held company. In the first quarter of fiscal year 2017 , cash used for investing activities primarily included $17.2 million in purchases of property, plant and equipment, a $11.4 million issuance of a notes receivable, and $3.4 million paid to our deferred compensation plan trust account.
In the first quarter of fiscal year 2018 , cash used in financing activities was $42.8 million compared to $89.6 million used in the first quarter of fiscal year 2017 . In the first quarter of fiscal year 2018 , cash used for financing activities primarily included $56.7 million for the repurchase of VMS common stock, $10.0 million in debt repayments, net of borrowings, partially offset by $24.2 million received from the issuance of common stock to employees. In the first quarter of fiscal year 2017 , cash used for financing activities primarily included $55.0 million in borrowings, net of debt repayments, under our credit facility agreements, $49.5 million for the repurchase of VMS common stock, partially offset by $16.1 million received from the issuance of common stock to employees.
We expect our total fiscal year 2018 capital expenditures, which typically represent construction and/or purchases of facilities, manufacturing equipment, office equipment and furniture and fixtures, as well as capitalized costs related to the implementation of software applications, will be approximately 2% of revenues in fiscal year 2018 .
We entered into an agreement, dated September 1, 2017, ("Credit Agreement") with certain lenders and Bank of America, N.A. (“BofA”) as administrative agent ("Debt Lenders"). The Credit Agreement provides for a five-year revolving credit facility (the "2017 Revolving Credit Facility") in an aggregate principal amount of up to $600.0 million. The 2017 Revolving Credit Facility also includes a $50 million sub-facility for the issuance of letters of credit and permits swing line loans of up to $25 million. We may increase the aggregate commitments under the 2017 Revolving Credit Facility by up to $100 million, plus an amount based on our consolidated leverage ratio on a pro forma basis, subject to certain conditions being met, including lender approval. The Credit Agreement will expire in September 2022. The 2017 Revolving Credit Facility can be prepaid without any premium or penalty. A portion of the proceeds of the 2017 Credit Facility were used to satisfy the outstanding obligation under the prior credit facility. Additional proceeds may be used for working capital, capital expenditures, Company share repurchases, acquisitions and other corporate purposes.
In addition, our Japanese subsidiary (“VMS KK”) has an unsecured uncommitted credit agreement with Sumitomo Mitsui Banking Corporation that enables VMS KK to borrow and have outstanding at any given time a maximum of 3.0 billion Japanese Yen (the “Sumitomo Credit Facility”). The Sumitomo Credit Facility will expire in February 2018 .
The following table summarizes our short-term borrowings:
 
December 29, 2017
 
September 29, 2017
(Dollars in millions)
Amount
 
Weighted-Average Interest Rate
 
Amount
 
Weighted-Average Interest Rate
Short-term borrowings:
 
 
 
 
 
 
 
2017 Revolving Credit Facility
$
340.0

 
2.49
%
 
$
350.0

 
2.36
%
See Note 7, "Borrowings" of the Notes to the Condensed Consolidated Financial Statements for further information regarding the 2017 Revolving Credit Facility and the Sumitomo Credit Facility.

58



The following table provides additional information regarding our short-term borrowings:
(Dollars in millions)
First Quarter of Fiscal Year 2018
Amount outstanding (at end of period)
$
340.0

Weighted average interest rate (at end of period)
2.49
%
Average amount outstanding (during period)
$
257.6

Weighted average interest rate (during period)
2.40
%
Maximum month-end amount outstanding during period
$
340.0

Our liquidity is affected by many factors, some of which result from the normal ongoing operations of our business and some of which arise from uncertainties and conditions in the United States and global economies. Although our cash requirements will fluctuate as a result of the shifting influences of these factors, we believe that existing cash and cash equivalents, cash to be generated from operations, and current or future credit facilities will be sufficient to satisfy anticipated commitments for capital expenditures, and other cash requirements for at least the next 12 months and into the foreseeable future. We currently anticipate that we will continue to utilize our available liquidity and cash flows from operations, as well as borrowed funds, to make strategic acquisitions, invest in the growth of our business, invest in advancing our systems and processes, repurchase VMS common stock, fund loan commitments and other strategic investments.
Total debt as a percentage of total capital increased to 19.6% at December 29, 2017 from 18.7% at September 29, 2017 primarily due to a net loss incurred during the first quarter of fiscal year 2018. The ratio of current assets to current liabilities increased to 1.45 to 1 at December 29, 2017 from 1.40 to 1 at September 29, 2017 .
Days Sales Outstanding
Our Oncology Systems trade and unbilled receivables days sales outstanding (“DSO”) decreased to 107 days at December 29, 2017 compared to 125 days at December 30, 2016 . Our accounts receivable and DSO are impacted by a number of factors, primarily including: the timing of product shipments, product installation or customer acceptance, collections performance, payment terms, the mix of revenues from different regions, and the effects of economic instability. VPT's DSO is not meaningful because it is highly variable. As of December 29, 2017 , approximately 4% of our net trade and unbilled receivables balance was related to customer contracts with remaining terms of more than one year.
Share Repurchase Program
We repurchased shares of VMS common stock under various authorizations during the periods presented as follows:
 
Three Months Ended
(In millions, except per share amounts)
December 29,
2017
 
December 30,
2016
Number of shares
0.5

 
0.5

Average repurchase price per share
$
108.16

 
$
98.98

Total cost
$
56.7

 
$
49.5


In November 2016, the VMS Board of Directors authorized the repurchase of an additional 8.0 million shares of VMS common stock commencing on January 1, 2017. As of December 29, 2017 , approximately 4.7 million shares of VMS common stock remained available for repurchase under the November 2016 authorization.
Stock repurchases may be made in the open market, in privately negotiated transactions (including accelerated share repurchase programs), or under Rule 10b5-1 share repurchase plans, and also may be made from time to time or in one or more larger blocks. All shares that were repurchased under our share repurchase programs have been retired.
For more details see Note 12, "Stockholders' Equity and Noncontrolling Interests" of the Notes to the Condensed Consolidated Financial Statements for further discussion.

59



Contractual Obligations
Long-term income taxes payable includes the liability for uncertain tax positions, including interest and penalties, the noncurrent portion of the one-time transition tax on unremitted foreign earnings under the Tax Cuts and Jobs Act (the "Act"), and may also include other long-term tax liabilities. As of December 29, 2017 , our liability for uncertain tax positions was $59.9 million , of which we do not anticipate making any payments in the next 12 months. We are unable to reliably estimate the timing of the remainder of future payments related to uncertain tax positions; we believe that existing cash and cash equivalents, cash to be generated from operations, and current or future credit facilities will be sufficient to satisfy any payment obligations that may arise related to our liability for uncertain tax positions. The Act allows taxpayers to elect to pay the one-time transition tax over a period of 8 years as follows: 8% per year for each of the first five years and 15%, 20%, and 25%, in years 6 through 8, respectively. As of December 29, 2017 , the noncurrent portion of the one-time transition tax on unremitted foreign earnings is $143.1 million.
As of December 29, 2017 , we had accrued liabilities of $5.8 million for environmental remediation liabilities. The amount accrued represents estimates of anticipated future costs and the timing and amount of actual future environmental remediation costs may vary as the scope of our obligations become more clearly defined. For more details see Note 9, "Commitments and Contingencies" of the Notes to the Condensed Consolidated Financial Statements for further discussion.
As of December 29, 2017 , our outstanding commitment for the GPTC securities was $11.8 million . For more details see Note 15, "VPT Loans and Securities" of the Notes to the Condensed Consolidated Financial Statements for further discussion.
Except for the change in the outstanding balance under our term loan facility and the other items discussed above, there has been no significant change to the other contractual obligations we reported in our 2017 Annual Report.
Subsequent Events

See Note 17, "Subsequent Events" of the Notes to the Condensed Consolidated Financial Statements for a discussion of our subsequent events.

Contingencies
Environmental Remediation Liabilities
For a discussion of environmental remediation liabilities, see Note 9, "Commitments and Contingencies" of the Notes to the Condensed Consolidated Financial Statements, which discussion is incorporated herein by reference.
Other Matters
From time to time, we are a party to or otherwise involved in legal proceedings, claims and government inspections or investigations and other legal matters both inside and outside the United States, arising in the ordinary course of our business or otherwise. Such matters are subject to many uncertainties and outcomes are not predictable with assurance. See Note 9, "Commitments and Contingencies" of the Notes to the Condensed Consolidated Financial Statements, which discussion is incorporated herein by reference.
Off-Balance Sheet Arrangements
In conjunction with the sale of our products in the ordinary course of business, we provide standard indemnification of business partners and customers for losses suffered or incurred for property damages, death and injury and for patent, copyright or any other intellectual property infringement claims by any third parties with respect to our products. The terms of these indemnification arrangements are generally perpetual. Except for losses related to property damages, the maximum potential amount of future payments we could be required to make under these arrangements is unlimited. As of December 29, 2017 , we have not incurred any significant costs since the Spin-offs to defend lawsuits or settle claims related to these indemnification arrangements. As a result, we believe the estimated fair value of these arrangements is minimal.
We have entered into indemnification agreements with our directors and officers and certain of our employees that serve as officers or directors of our foreign subsidiaries that may require us to indemnify our directors and officers and those certain employees against liabilities that may arise by reason of their status or service as directors or officers, and to advance their expenses incurred as a result of any legal proceeding against them as to which they could be indemnified.

60



Recent Accounting Standards or Updates Not Yet Effective
See Note 1, "Summary of Significant Accounting Policies" of the Notes to the Condensed Consolidated Financial Statements for a description of recent accounting standards, including the expected dates of adoption and the estimated effects on our consolidated financial statements.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
We are exposed to three primary types of market risks: credit risk and counterparty risk, foreign currency exchange rate risk and interest rate risk.
Credit Risk and Counterparty Risk
We are exposed to credit loss in the event of nonperformance by counterparties on the foreign currency forward contracts used in hedging activities. These counterparties are large international and regional financial institutions and to date, no such counterparty has failed to meet its financial obligation to us under such contracts.
We are also exposed to credit loss in the event of default by counterparties of our financing receivables and our loans to VPT customers such as:
As of December 29, 2017 , the Term Loan with California Proton Therapy Center ("CPTC") was $53.5 million . The $53.5 million is composed of four Tranches: Tranche A of $2.0 million , Tranche B of $7.2 million , Tranche C of $15.6 million , and Tranche D of $28.7 million (collectively the "Term Loan"). All of the Tranches accrue paid-in-kind interest at 7.5% per annum, except the Tranche B which accrues paid-in-kind interest at 10% per annum. The maturity date of the Term Loan is three years from the Closing Date. The Term Loan is secured by the assets of CPTC.
In addition, the Lenders have committed to lend up to $15.0 million in Revolving Loans. Our share of the funding commitment from the Revolving Loan is $7.2 million and as of December 29, 2017, we have funded $2.4 million. The Revolving Loan accrues paid-in-kind interest at 10% per annum and has a maturity date one year from the Closing Date.
The seniority of these loans is as follows: Revolving Loan, Tranche A, Tranche B, Tranche C and Tranche D. If CPTC is in default the interest of Tranche A, C and D will increase to 9.5% and Tranche B and the Revolving Loan will increase to 12.0%.
As of December 29, 2017 , we have an outstanding loan of $35.0 million to Maryland Proton Treatment Center ("MPTC"). Our subordinated loan is due, with accrued interest, in three annual payments from 2020 to 2022. The interest on the outstanding loan accrues at 12%. We also have $25.1 million as long-term notes receivable related to a deferred payment arrangement with MPTC. The notes receivable carries an interest rate of 15% and is due in September 30, 2018.
We also have loans associated with the New York Proton Center, and Proton International LLC totaling $18.5 million and $2.5 million , respectively.
In July 2017, we purchased the outstanding senior secured debt related to the Rinecker Proton Therapy Center ("RPTC") in Munich, Germany for 21.5 million Euros or $24.5 million. By purchasing the senior secured debt, we have a right to 89 million Euros in claims against all of RPTC's assets. In September 2017, the management of RPTC filed for bankruptcy in Germany. In January 2018, the final insolvency proceedings commenced and it expects the insolvency proceedings to be finalized within the next twelve months. Upon finalization of bankruptcy proceedings, we believe it is probable we will recover its outstanding senior secured debt balance and trade accounts receivable, net.
See Note 15, "VPT Loans and Securities" of the Notes to the Condensed Consolidated Financial Statements for further information on loans to VPT customers.
In addition, cash and cash equivalents held with financial institutions may exceed the Federal Deposit Insurance Corporation insurance limits or similar limits in foreign jurisdictions. We also may need to rely on our credit facilities as described below under “Interest Rate Risk.” Our access to our cash and cash equivalents or ability to borrow could be reduced if one or more financial institutions with which we have deposits or from which we borrow should fail or otherwise be adversely impacted by conditions in the financial or credit markets. Conditions such as those we experienced as a result of the last economic downturn and accompanying contraction in the credit markets heighten these risks. Concerns over economic instability could make it more difficult for us to collect outstanding receivables and could adversely impact our liquidity.

61



Foreign Currency Exchange Rate Risk
As a global entity, we are exposed to movements in foreign currency exchange rates. These exposures may change over time as business practices evolve. Adverse foreign currency rate movements could have a material negative impact on our financial results. Our primary exposures related to foreign currency denominated sales and purchases are in Europe, Asia, Australia and Canada.
We have many transactions denominated in foreign currencies and address certain of those financial exposures through a risk management program that includes the use of derivative financial instruments. We sell products throughout the world, often in the currency of the customer’s country, and may hedge certain of these larger foreign currency sale transactions when they are not transacted in the subsidiaries’ functional currency or in U.S. Dollars. The foreign currency transactions that fit our risk management policy criteria are hedged with foreign currency forward contracts. We may use other derivative instruments in the future. We enter into foreign currency forward contracts primarily to reduce the effects of fluctuating foreign currency exchange rates. We do not enter into foreign currency forward contracts for speculative or trading purposes. The forward contracts range from one to thirteen months in maturity.
We also hedge the balance sheet exposures from our various foreign subsidiaries and business units. We enter into foreign currency forward contracts to minimize the short-term impact of currency fluctuations on assets and liabilities denominated in currencies other than the subsidiaries' functional currency or the U.S. Dollar.
The notional values of our sold and purchased foreign currency forward contracts outstanding as of December 29, 2017 were $475.0 million and $46.9 million , respectively. The notional amounts of foreign currency forward contracts are not a measure of our exposure. The fair value of forward contracts generally reflects the estimated amounts that we would receive or pay to terminate the contracts at the reporting date, thereby taking into account and approximating the current unrealized and realized gains or losses of the open contracts. A move in foreign currency exchange rates would change the fair value of the contracts, and the fair value of the underlying exposures hedged by the contracts would change in a similar offsetting manner.
Interest Rate Risk
Our market risk exposure to changes in interest rates depends primarily on our investment portfolio and borrowings. Our investment portfolio primarily consisted of cash and cash equivalents and available-for-sale investments as of December 29, 2017 . The principal amount of cash and cash equivalents in continuing operations at December 29, 2017 totaled $822.6 million with a weighted average interest rate of 0.36 %. At December 29, 2017 , our available-for-sale investments, $8.0 million in subordinated bonds with a fixed interest rate to finance the Delray Radiation Therapy Center ("DRTC"), $6.0 million Subordinate Revenue Bonds with a fixed interest rate to finance the Alabama Proton Therapy Center ("APTC') and $4.5 million in Senior Capital Appreciation Bonds to finance the Georgia Proton Treatment Center ("GPTC"). The DRTC subordinated bonds and the APTC Subordinate Revenue bear an interest rate of 8.5% per annum and the GPTC Senior Capital Appreciation Bonds bear an interest rate of 8.0% per annum. Our available-for-sale investments are carried at fair value.
Borrowings under the 2017 Revolving Credit Facility accrue interest at either (i) based on the Eurodollar Rate plus a margin of 1.125% to 1.875% based on a leverage ratio involving funded indebtedness and EBITDA, or (ii) based upon a base rate of (a) the federal funds rate plus 0.50% , (b) BofA’s announced prime rate, or (c) the Eurodollar Rate plus 1.00% , whichever is highest, plus a margin of 0.125% to 0.875% based on the same leverage ratio, depending upon instructions from the Company. Borrowings under the 2017 Revolving Credit Facility have a contract repayment date of twelve months , or less, and a final maturity of five years if based on the Eurodollar Rate and all overnight borrowings on the base rate would also have a final maturity of five years.
We are affected by market risk exposure primarily through the effect of changes in interest rates on amounts payable under our 2017 Revolving Credit Facility. As of December 29, 2017 , borrowings under the 2017 Revolving Credit Facility totaled $340.0 million with a weighted average interest rate of 2.49% . If the amount outstanding under our 2017 Revolving Credit Facility remained at this level for an entire year and interest rates increased or decreased by 1%, our annual interest expense would increase or decrease, respectively, by an additional $3.4 million . See Note 7, "Borrowings" of the Condensed Consolidated Financial Statements for a discussion regarding the 2017 Credit Facility.
In addition, the Sumitomo Credit Facility allows VMS KK to borrow up to a maximum amount of 3.0 billion Japanese Yen. Borrowings under the Sumitomo Credit Facility accrue interest based on the basic loan rate announced by the Bank of Japan plus a margin of 0.5% per annum. As of December 29, 2017 , the there was no outstanding balance under the Sumitomo Credit Facility.

62



To date, we have not used derivative financial instruments to hedge the interest rate within our investment portfolio, borrowings, but may consider the use of derivative instruments in the future. In addition, although payments under certain of our operating leases for our facilities are tied to market indices, these operating leases do not expose us to material interest rate risk.
Item 4. Controls and Procedures
(a)
Disclosure controls and procedures. Based on the evaluation of our disclosure controls and procedures (as defined in the Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) required by Exchange Act Rules 13a-15(b) or 15d-15(b), our principal executive officer and principal financial officer have concluded that as of the end of the period covered by this report, our disclosure controls and procedures were effective to ensure that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms, and include controls and procedures designed to ensure that information required to be disclosed by us in such reports is accumulated and communicated to our management, including the principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.
(b)
Changes in internal control over financial reporting. Beginning September 30, 2017, we implemented ASC 606, Revenue from Contracts with Customers. As a result, we implemented changes to our processes related to revenue recognition, the control activities within them, and the key system functionalities to enable the preparation of financial information. This included the development of new policies based on the five-step model provided in the new revenue standard. There were no other changes in our internal control over financial reporting that occurred during the first quarter of fiscal year 2018 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

63




PART II
OTHER INFORMATION
Item 1. Legal Proceedings
We are subject to various legal proceedings and claims that are discussed in Note 9, "Commitments and Contingencies" to the Condensed Consolidated Financial Statements, which discussion is incorporated by reference into this item.
Item 1A. Risk Factors

There were no material changes during the period covered in this report to the risk factors previously disclosed in Part I, Item 1A, of our 2017 Annual Report on Form 10-K, except as follows:
The Tax Cuts and Jobs Act of 2017, the enactment of legislation implementing changes in taxation of international business activities, and the adoption of other tax legislation and policies could materially impact our financial position and results of operations.
The Tax Cuts and Jobs Act of 2017 (the “Act”) is expected to have a significant impact on our financial position and results of operations. The Act reduced the U.S. corporate income tax rate from 35% to 21%. This rate reduction requires us to re-measure our net deferred tax assets which were originally recorded assuming a future tax benefit at the 35% rate. We estimate the impact of this re-measurement is a charge to our income tax expense of approximately $47 million, with approximately $37.8 million charged in the first quarter of 2018, and the remainder of $9.2 million over the balance of fiscal year 2018.
In addition, as part of the transition to a modified territorial system, the new law imposes a one-time transition tax on the unremitted earnings of our foreign subsidiaries. We currently estimate the tax effect of this deemed repatriation to be $169.3 million. We intend to make the election to pay this tax over an eight-year period. The transition to a modified territorial regime and the one-time transition tax on unremitted earnings has also caused us to re-evaluate our intentions with respect to the unremitted earnings of our foreign subsidiaries. In the past, we did not accrue U.S. taxes on certain undistributed profits of certain foreign subsidiaries because the earnings were considered to be indefinitely reinvested. In light of the changes to the taxation of foreign earnings in the Act, we no longer consider the earnings of our foreign subsidiaries to be indefinitely reinvested.
The amounts of the tax effects related to the Act described above represent our reasonable estimates. Also, it is expected that the U.S. Treasury will issue regulations and other guidance on the application of certain provisions of the Act, which could cause us to significantly revise the provisional amounts we have recorded.
On January 22, 2018, a continuing budget resolution was signed into law that included a provision to extend the moratorium on the 2.3% medical device excise tax for two more years, or until January 1, 2020. This tax has had, and may continue to have, a negative impact on our gross margin when the moratorium expires.

A significant portion of our earnings is generated from activity outside the United States. As a result, any substantial changes in international policies regarding corporate taxation or legislative initiatives may materially and adversely affect our business, the amount of taxes we are required to pay and our financial condition and results of operations generally.
The proposed acquisition of Sirtex Medical Limited may not be completed within the expected timeframe, or at all, and the failure to complete the acquisition could adversely affect our business.
On January 30, 2018, we signed an agreement to acquire Sirtex Medical Limited ("Sirtex"), an Australian company that is listed on the Australian Securities Exchange, for A$28 per share or approximately A$1.6 billion (approximately $1.3 billion). Sirtex is an Australian-based global life sciences company focused on interventional oncology therapies.
The transaction, which is expected to close in late May 2018, is subject to the approval of the Sirtex shareholders, the Federal Court of Australia and other customary closing conditions, including applicable regulatory approvals that are beyond our control. There is no guarantee that these conditions will be satisfied in a timely manner or at all. If any of the conditions to the proposed acquisition are not satisfied (or waived by the other party) the acquisition may not be completed. In addition, the Scheme Implementation Deed (the “Agreement”) may be terminated under specified circumstances. Failure to complete the acquisition could adversely affect our business as we could be required to pay a termination fee up to 1% of the total consideration under certain circumstances as described in the Agreement and cause delay in our plan to expand into the

64



interventional oncology market. In addition, our stock price may also suffer as the failure to consummate the acquisition may result in negative perception in the investment community.
Uncertainty associated with the completion of the merger may cause substantial disruptions in our business and Sirtex’s business.
Uncertainty associated with the completion of the acquisition may cause substantial disruptions in our business and Sirtex’s business, which could have an adverse effect on our financial results. Among other things, such uncertainty may affect our relationships with customers, potential customers and suppliers and our ability to recruit prospective employees or to retain and motivate existing employees. Sirtex may face similar disruptions to its business. The adverse effect of such disruptions could be exacerbated by delay in the completion of the acquisition or termination of the Agreement.
Our efforts to integrate acquisitions may not be successful, and this may adversely impact our profitability and sales growth.
As part of our strategy to develop and identify new technologies, products and services, we have made and may continue to acquire new businesses and technologies. Our integration of the operations of acquired businesses requires significant efforts, including the coordination of information technologies, research and development, sales and marketing, operations, manufacturing and finance. In particular, if our proposed acquisition of Sirtex is completed, its success will depend, in part, on our ability to successfully integrate the business and operations and fully realize the anticipated benefits and synergies from combining our businesses and Sirtex’s business If we are not able to achieve these objectives following the acquisition, the anticipated benefits and synergies of the transactions may not be realized fully or at all or may take longer to realize than expected. Our efforts to successfully integrate acquisitions may result in additional expenses and divert significant amounts of management’s time from other projects.
Our failure to manage successfully and coordinate the growth of the acquired companies could also have an adverse impact on our business. In addition, there is no guarantee that some of the businesses we acquire will become profitable or remain so. If our acquisitions do not meet our initial expectations, we may record impairment charges.
Factors that will affect the success of our acquisitions include:
our ability to retain key employees of the acquired company;
the performance of the acquired business, technology, product or service;
our ability to integrate operations, financial and other systems;
the ability of the combined company to achieve synergies among its constituent companies, such as increasing sales of the combined company’s products and services, achieving expected cost savings and effectively combining technologies to develop new products and services;
any disruption in order fulfillment or loss of sales due to integration processes;
the presence or absence of adequate internal controls and/or significant fraud in the financial systems of acquired companies;
any decrease in customer and distributor loyalty and product orders caused by dissatisfaction with the acquired companies’ product lines and sales and marketing practices, including price increases; and
our assumption of known contingent liabilities that are realized, known liabilities that prove greater than anticipated, or unknown liabilities that come to light, to the extent that the realization of any of these liabilities increases our expenses or adversely affects our business or financial position.




65



Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
(a)
Not applicable
(b)
Not applicable
(c)
The following table provides information with respect to the shares of common stock repurchased by us during the first quarter of fiscal year 2018 (in millions, except per share amounts):
Period
Total Number of
Shares Purchased
 
Average Price
Paid Per Share
 
Total Number of
Shares Purchased as
Part of Publicly
Announced Plans or
Programs
 
Maximum Number
of Shares that May
Yet Be Purchased
Under the Plans or
Programs
  (1)
September 30, 2017 - October 27, 2017

 
$

 

 
5.2

October 28, 2017 - November 24, 2017
0.3

 
$
106.29

 
0.3

 
4.9

November 25, 2017 - December 29, 2017
0.2

 
$
111.18

 
0.2

 
4.7

Total
0.5

 
$
108.16

 
0.5

 
4.7

(1)
In November 2016, the VMS Board of Directors authorized the repurchase of an additional 8.0 million shares of VMS common stock commencing on January 1, 2017. Share repurchases may be made in the open market, in privately negotiated transactions (including accelerated share repurchase programs), or under Rule 10b5-1 share repurchase plans, and also may be made from time to time or in one or more larger blocks. All shares that were repurchased under the Company's share repurchase programs have been retired.
The preceding table excludes an immaterial number of shares of VMS common stock that were withheld by VMS in satisfaction of tax withholding obligations upon the vesting of restricted stock units granted under our employee stock plans.
Item 3. Defaults Upon Senior Securities
None.
Item 4. Mine Safety Disclosures
Not applicable.
Item 5. Other Information

As the Company completed its adoption of ASC 606 in the first quarter of fiscal year 2018, certain balance sheet adjustments were necessary from the Preliminary Condensed Consolidated Balance Sheets as of December 29, 2017 and September 29, 2017 that were filed in the Company’s 8-K on January 24, 2018 announcing its fiscal year 2018 first quarter results. The impact of these adjustments was to increase both unbilled receivables and deferred revenue by $25.8 million and $78.5 million as of December 29, 2017 and September 29, 2017, respectively, which results in Oncology Systems accounts receivable days sales outstanding, or DSO, of 107 days at December 29, 2017 and 125 days at December 30, 2016. There has been no change to the Company’s Condensed Consolidated Statements of Earnings.

66



Item 6. Exhibits
The exhibits listed below are filed or incorporated by reference as part of this Form 10-Q:
Exhibit
No.
  
Description
 
 
 
2.1 *
 
 
 
 
4.1
 
 
 
 
4.2
 
 
 
 
10.1
 
 
 
 
10.2
 
.
 
 
 
10.3
 
.
 
 
 
10.4
 
.
 
 
 
15.1*
  
 
 
 
31.1*
  
 
 
 
31.2*
  
 
 
 
32.1*
  
 
 
 
32.2*
  
 
 
 
101.INS
  
XBRL Instance Document
 
 
 
101.SCH
  
XBRL Taxonomy Extension Schema Document
 
 
 
101.CAL
  
XBRL Taxonomy Extension Calculation Linkbase Document
 
 
 
101.DEF
  
XBRL Taxonomy Extension Definition Linkbase Document
 
 
 
101.LAB
  
XBRL Taxonomy Extension Label Linkbase Document
 
 
 
101.PRE
  
XBRL Taxonomy Extension Presentation Linkbase Document
 
 
 
 
 
 
 
 
 
 
 
 
*
 
Filed herewith

67



SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
 
 
 
VARIAN MEDICAL SYSTEMS, INC.
 
 
 
 
(Registrant)
 
 
 
 
 
Dated:
February 7, 2018
By:
 
/s/ GARY E. BISCHOPING JR.
 
 
 
 
Gary E. Bischoping Jr.
 
 
 
 
Senior Vice President and
 
 
 
 
Chief Financial Officer
 
 
 
 
(Duly Authorized Officer and
 
 
 
 
Principal Financial Officer)

68

 
VARIANSCHEMEIMPLDEEDW_IMAGE1.JPG
Scheme Implementation Deed

 
Sirtex Medical Limited
(ABN 35 078 166 122)

Varian Medical Systems, Inc.



































 
Watson Mangioni Lawyers Pty Limited
Corporate and Commercial Lawyers
Level 23, 85 Castlereagh Street
SYDNEY NSW 2000
Tel: (02) 9262 6666
Fax: (02) 9262 2626
Email: mail@wmlaw.com.au  
Ref: CSC 217 7345










Table of Contents

1.
Definitions and Interpretation
1
 
 
 
2.
Agreement to Proceed with the Transaction
8
 
 
 
3.
Conditions Precedent and Pre-implementation Steps
8
 
 
 
4.
Transaction Steps
12
 
 
 
5.
Implementation
13
 
 
 
6.
Representations and Warranties
18
 
 
 
7.
Releases
19
 
 
 
8.
Public Announcements
20
 
 
 
9.
Exclusivity
21
 
 
 
10.
Reimbursement Fees
23
 
 
 
11.
Termination
27
 
 
 
12.
Confidentiality
28
 
 
 
13.
GST
28
 
 
 
14.
Duty, Costs and Expenses
29
 
 
 
15.
Notices
29
 
 
 
16.
General
31
 
 
 
Annexure A
Indicative Timetable
 
 
 
 
Annexure B
Scheme of Arrangement
 
 
 
 
Annexure C
Deed Poll
 










This Scheme Implementation Deed is made on 30 January 2018.

Parties:
1.
Sirtex Medical Limited (ABN 35 078 166 122) of Level 33, 101 Miller Street, North Sydney NSW 2060, Australia ( Sirtex );
2.
Varian Medical Systems, Inc. of 3100 Hansen Way, Palo Alto, CA 94304-1038, United States ( Bidder ).
Recitals:
A.
Sirtex and the Bidder have agreed to propose and implement a scheme of arrangement under Part 5.1 of the Corporations Act between Sirtex and its shareholders.
B.
At the request of the Bidder, Sirtex has agreed to propose the Scheme and issue the Scheme Booklet.

1. Definitions and Interpretation
1.1.      Definitions
dIn this deed:
Adviser means, in relation to an entity:
(a)
a financier to the entity in connection with the Transaction; or
(b)
a financial, corporate, legal, technical or other expert adviser or consultant, who provides advisory or consultancy services in a professional capacity in the ordinary course of its business and has been engaged in that capacity in connection with the Transaction by the entity.
AIFRS means the International Financial Reporting Standards as adopted in Australia.
ASIC means the Australian Securities and Investments Commission.
ASX means ASX Limited (ABN 98 008 624 691) or the securities market operated by it, as the context requires.
ASX Listing Rules means the official listing rules of the ASX.
Bidder Group means the Bidder and each of its subsidiaries (excluding, at any time, Sirtex and its subsidiaries to the extent that Sirtex and its subsidiaries are subsidiaries of the Bidder at that time) and a reference to a member of the Bidder Group is to the Bidder or any such subsidiary.
Bidder Information means information about the Bidder Group provided or approved by the Bidder or any of its Advisers for inclusion in the Scheme Booklet.
Bidder Nominee means any wholly-owned subsidiary of the Bidder nominated by the Bidder to acquire Scheme Shares under the Scheme in accordance with clause 2.2.
Bidder Parties means the members of the Bidder Group and their respective officers, employees and Advisers.
Bidder Representations and Warranties means the representations and warranties set out in Schedule 1.
Board means the board of directors of Sirtex.






Business Day means a business day as defined in the ASX Listing Rules.
Claim includes, in relation to a person, a demand, claim, action or proceeding made or brought by or against the person, however arising and whether present, unascertained, immediate, future or contingent.
Class Actions means the following proceedings:
(a)
Todd Hayward v Sirtex Medical Limited (File number: VID91/2017) filed in the Victorian Registry of the Federal Court of Australia on 9 February 2017; and
(b)
Pawel Kuterba v Sirtex Medical Limited (ACN 78 166 122) (File number: VID1375/2017) filed in the Victorian Registry of the Federal Court of Australia on 15 December 2017,
and any other proceedings in any way related to those proceedings or their subject matter.
Competing Proposal means any proposal or transaction (including by way of takeover bid, scheme of arrangement, capital reduction, sale of assets, sale or issue of securities or joint venture) which, if completed, would mean a Third Party, whether alone or together with any associate, would:
(a)      (other than as custodian, nominee or bare trustee) acquire an interest in, or a relevant interest in, 20% or more of the Sirtex Shares or the shares of any material subsidiary of Sirtex other than pursuant to the exception in item 9 of section 611 of the Corporations Act;
(b)      acquire (whether directly or indirectly) or become the holder of, or otherwise acquire, have a right to acquire or have an economic interest in assets of the Sirtex Group with an aggregate book value representing 20% or more of the total assets of the Sirtex Group as set out in Sirtex’s consolidated balance sheet as at 30 June 2017;
(c)      acquire control of Sirtex or any material subsidiary of Sirtex; or
(d)      otherwise acquire or merge or amalgamate with Sirtex or any material subsidiary of Sirtex,
whether by way of takeover bid, scheme of arrangement, shareholder approved acquisition, capital reduction or share buy-back, sale or purchase of shares, securities or assets, global assignment of assets and liabilities, incorporated or unincorporated joint venture, dual-listed company (or other synthetic merger), or other transaction or arrangement. For the purposes of paragraphs (a) and (c) above, a subsidiary of Sirtex will be a material subsidiary if:
(1)
the business or property of the subsidiary contributes more than 20% of the consolidated net profit after tax of Sirtex; or
(2)
the business or property of the subsidiary represents more than 20% of the total consolidated assets of the Sirtex.
Conditions Precedent means the conditions precedent set out in clause 3.1.
Confidentiality Deed means the confidentiality deed between Sirtex and the Bidder dated on or about 30 November 2017.
Corporations Act means the Corporations Act 2001 (Cth) .
Corporations Regulations means the Corporations Regulations 2001 (Cth).
Court means the Federal Court of Australia (NSW registry) or such other court of competent jurisdiction under the Corporations Act agreed to in writing between the parties.
Deed Poll means a deed poll in favour of all Scheme Shareholders in the form of Annexure C (or such other form agreed to in writing between the parties).
Disclosed means fairly disclosed:
(a)    in the Disclosure Materials; or






(b)    in any announcement made by Sirtex on ASX in the 2 years before entry into this deed.
Disclosure Materials means:
(a)      the documents and information contained in the Ansarada online data room to which the Bidder and its Representatives were given access before entry into this deed; and
(b)      any written answers to requests for further information made by Bidder and its Representatives as contained in that online data room before entry into this deed.
Effective means the coming into effect under section 411(10) of the Corporations Act of the order of the Court made under section 411(4)(b) in relation to the Scheme.
Effective Date means the date on which the Scheme becomes Effective.
End Date means 31 July 2018 or such other date as is agreed in writing between the parties.
Exclusivity Period means the period from and including the date of this deed to the earlier of:
(a)    the termination of this deed; and
(b)    the End Date.
FATA means the Foreign Acquisitions and Takeovers Act 1975 (Cth).
First Court Date means the first day on which an application made to the Court for orders under section 411(1) of the Corporations Act that the Scheme Meeting be convened is heard or, if the application is adjourned or subject to appeal for any reason, the day on which the adjourned application is heard.
Government Agency means any government or any governmental, semi-governmental, statutory or judicial entity, agency or authority, whether in Australia, the United States of America or elsewhere, including any self-regulatory organisation established under statute or otherwise discharging substantially public or regulatory functions, and the ASX or any other stock exchange.
Implementation Date means the fifth Business Day after the Record Date or such other date as agreed in writing between the parties.
Incoming Directors means the persons nominated in writing to Sirtex by the Bidder no later than 5 Business Days before the Implementation Date.
Independent Expert means the independent expert in respect of the Scheme appointed by Sirtex.
Independent Expert’s Report means the report (including any updates to such report) of the Independent Expert stating whether or not in its opinion the Scheme is in the best interests of Sirtex Shareholders.
Insolvency Event means, in the case of any entity:
(a)
it ceases, suspends, or threatens to cease or suspend the conduct of all or a substantial part of its business or disposes of or threatens to dispose of all or a substantial part of its assets;
(b)
it stops or suspends or threatens to stop or suspend payment of all or a class of its debts;
(c)
it is, or under legislation is presumed or taken to be, insolvent (other than as the result of a failure to pay a debt or claim the subject of a good faith dispute);
(d)
it has an administrator, controller or similar officer appointed, or any step preliminary to the appointment of such an officer is taken;
(e)
an application or an order is made, proceedings are commenced, a resolution is passed or proposed in a notice of meeting, an application to a court or other steps are taken for:






(i)
its winding up, dissolution or administration; or
(ii)
it entering into an arrangement, compromise or composition with or assignment for the benefit of its creditors or a class of them,
(other than frivolous or vexatious applications, orders, proceedings, notices or steps);
(f)
any of:
(i)
a receiver, receiver and manager, administrative receiver or similar officer is appointed to;
(ii)
a security interest becomes enforceable or is enforced over; or
(iii)
a distress, attachment or other execution is levied or enforced or applied for over,
all or a substantial part of its assets; or
(g)
anything analogous to anything referred to in the above paragraphs, or which has substantially similar effect, occurs with respect to it, including under any foreign law.
Material Adverse Change means any event, occurrence or matter that occurs after the date of this deed that individually or when aggregated with all such events, occurrences or matters has, has had or would be reasonably likely to have the effect of:
(a)
a diminution in the consolidated net assets of the Sirtex Group (calculated on the basis of AIFRS as at the date of this deed) of at least $25 million compared to the consolidated net assets of the Sirtex Group as at 31 December 2017; or
(b)
a permanent and recurring diminution in the annual consolidated earnings before interest expense, tax, depreciation and amortisation and significant and non-recurring items of the Sirtex Group of at least $10 million,
other than events, occurrences or matters:
(c)
required or permitted by this deed or the Scheme (including those comprising, or undertaken pursuant to, the settlement of any Class Action in compliance with clause 5.3(a)(x));
(d)
which do not relate specifically to the Sirtex Group and which are beyond the control of the Sirtex Group, including those that arise from:
(i)
changes in exchange rates or interest rates;
(ii)
general economic, political, regulatory or business conditions in Australia or elsewhere; or
(iii)
changes to accounting standards or laws in Australia or elsewhere,
but excluding any such event, change, circumstance, occurrence, matter or thing which has a materially disproportionate effect on the Sirtex Group, taken as a whole, as compared to the equivalent operations of other participants in the industry or industries in which the Sirtex Group operates;
(e)
to the extent Disclosed (including the Class Actions and potential damages payable under them and the costs to be incurred by Sirtex in relation to the Transaction); or
(f)
to the extent any losses or liabilities arising from such event, occurrence or matter are covered by insurance which Sirtex’s insurers have agreed to pay.
Outgoing Directors means the directors of Sirtex advised in writing to Sirtex by the Bidder no later than 5 Business Days before the Implementation Date.
Prescribed Occurrence means any of the occurrences set out in Schedule 3.






Record Date means 7pm on the fifth Business Day following the Effective Date or such other date as Sirtex and the Bidder agree.
Regulator’s Draft means the draft of the Scheme Booklet in a form acceptable to Sirtex and the Bidder which is provided to ASIC for its review pursuant to section 411(2) of the Corporations Act.
Regulatory Approvals means:
(a)
any approval, consent, authorisation, registration, filing, lodgement, permit, franchise, agreement, notarisation, certificate, permission, licence, direction, declaration, authority or exemption from, by or with a Government Agency; or
(b)
in relation to anything that would be fully or partly prohibited or restricted by law if a Government Agency intervened or acted in any way within a specified period after lodgement, filing, registration or notification, the expiry of that period without notification.
Regulatory Review Period means the period from the date on which the Regulator’s Draft is submitted to ASIC to the date on which ASIC confirms that it does not intend to make any submissions at the Court hearing on the First Court Date or otherwise object to the Scheme.
Reimbursement Fee means the amount equal to 1% of the total Scheme Consideration payable for all the Scheme Shares under the Scheme.
Representative means, in relation to the Bidder or Sirtex:
(a)    each other member of the Bidder Group or the Sirtex Group (as applicable);
(b)    an officer of a member of the Bidder Group or the Sirtex Group (as applicable); or
(c)    an Adviser to a member of the Bidder Group or the Sirtex Group (as applicable).
RG 60 means Regulatory Guide 60 issued by ASIC.
Scheme means the scheme of arrangement under Part 5.1 of the Corporations Act between Sirtex and the Scheme Shareholders in the form attached as Annexure B (or such other form agreed to in writing by the parties).
Scheme Booklet means the information described in clause 5.1(a) to be approved by the Court and despatched to the Sirtex Shareholders and which must include the Scheme, an explanatory statement (complying with the requirements of the Corporations Act, the Corporations Regulations, RG 60 and the ASX Listing Rules), the Independent Expert’s Report, the notice of Scheme Meeting and a proxy form for the Scheme Meeting.
Scheme Consideration means the consideration per Scheme Share to be provided by the Bidder (or the Bidder Nominee) in consideration for the transfer of the Scheme Share to the Bidder (or the Bidder Nominee), being the cash amount of $28.00 per Scheme Share.
Scheme Meeting means the meeting of Sirtex Shareholders ordered by the Court to be convened under section 411(1) of the Corporations Act.
Scheme Share means a Sirtex Share held by a Scheme Shareholder.
Scheme Shareholders means Sirtex Shareholders as at the Record Date.
Second Court Date means the first day on which an application made to the Court for an order under section 411(4)(b) of the Corporations Act approving the Scheme is heard or, if the application is adjourned or subject to appeal for any reason, the day on which the adjourned application is heard.
Share Register means the register of members of Sirtex maintained in accordance with the Corporations Act.
Sirtex Group means Sirtex and each of its subsidiaries and a reference to a Sirtex Group Member or a member of the Sirtex Group is to Sirtex or any of its subsidiaries.






Sirtex Parties means members of the Sirtex Group and their respective officers, employees and Advisers.
Sirtex Right means a performance right or a contractual right to be granted a performance right, which performance right confers the right to acquire one unissued Sirtex Share pursuant to the Sirtex Rights Plan.
Sirtex Rights Plan means the Sirtex Executive Rights Plan approved by Sirtex Shareholders at the 2015 annual general meeting held on 27 October 2015 (as amended).
Sirtex Registry means Link Market Services Limited (ABN 54 083 214 537).
Sirtex Representations and Warranties means the representations and warranties of Sirtex set out in Schedule 2.
Sirtex Share means a fully paid ordinary share in the capital of Sirtex.
Sirtex Shareholder means each person who is registered in the Share Register as the holder of Sirtex Shares.
Superior Proposal means a bona fide Competing Proposal received after the date of this deed that the Board determines, acting in good faith and in order to satisfy what the Board considers to be its fiduciary or statutory duties (having taken advice from its external financial and legal advisers):
(a)      is reasonably capable of being valued and implemented, taking into account all aspects of the Competing Proposal; and
(b)      would, if completed substantially in accordance with its terms, be more favourable to Sirtex Shareholders (as a whole) than the Scheme, taking into account all terms and conditions of the Competing Proposal.
Third Party means a person other than the Bidder Parties and their associates.
Timetable means the indicative timetable for the implementation of the Transaction set out in Annexure A.
Transaction means the acquisition of Sirtex by the Bidder (or, if applicable, the Bidder Nominee) through implementation of the Scheme in accordance with the terms of this deed.
1.2.      Interpretation
In this deed, headings are for convenience only and do not affect interpretation and, unless the context requires otherwise:
(a)      words importing the singular include the plural and vice versa;
(b)      words importing a gender include any gender;
(c)      other parts of speech and grammatical forms of a word or phrase defined in this deed have a corresponding meaning;
(d)      a reference to a person includes an individual, the estate of an individual, a corporation, an authority, an association or a joint venture, a partnership, a trust and any Government Agency;
(e)      a reference to a clause, party, attachment, exhibit or schedule is a reference to a clause of, and a party, attachment, exhibit and schedule to this deed, and a reference to this deed includes any attachment, exhibit and schedule;
(f)      a reference to a statute, regulation, proclamation, ordinance or by law includes all statutes, regulations, proclamations, ordinances or by laws amending, consolidating or replacing it, whether passed by the same or another Government Agency with legal power to do so, and a reference to a statute includes all regulations, proclamations, ordinances and by laws issued under that statute;






(g)      a reference to any document (including this deed) is to that document as varied, novated, ratified or replaced from time to time;
(h)      the word “includes” in any form is not a word of limitation;
(i)      a reference to “$”, “A$” or “dollar” is to Australian currency;
(j)      a reference to any time is, unless otherwise indicated, a reference to the time in Sydney, New South Wales, Australia;
(k)      a period of time dating from a given day or the day of an act or event, is to be calculated exclusive of that day;
(l)      a day is to be interpreted as the period of time commencing at midnight and ending 24 hours later;
(m)      a reference to “associate”, “control” (by an entity of another entity), “officer”, “related body corporate”, “subsidiary”, “relevant interest” or “voting power” is to that term as defined in the Corporations Act;
(n)      a reference to the ASX Listing Rules includes any variation, consolidation or replacement of these rules and is to be taken to be subject to any waiver or exemption granted to the compliance of those rules by a party.
1.3.      Business Day
Where the day on or by which any thing is to be done is not a Business Day, that thing must be done on or by the next Business Day.
1.4.      Listing requirements included as law
A listing rule or business rule of a securities exchange will be regarded as a ”law”, and a reference to such a rule is to be taken to be subject to any waiver or exemption granted to the compliance of those rules by a party.
1.5.      Statements on the basis of knowledge
Any statement made by Sirtex on the basis of its knowledge is made on the basis that its knowledge is limited to the knowledge which any of Andrew McLean, Darren Smith and any member of the Board has or would have if they had made all reasonable enquiries of the officers and employees of any member of the Sirtex Group with responsibility for the matters to which the statement relates.
2.      Agreement to Proceed with the Transaction
2.1.      Sirtex to propose Scheme
Sirtex agrees to propose the Scheme on and subject to the terms of this deed.
2.2.      Nomination of acquirer subsidiary
At any time prior to the Business Day before the First Court Date, the Bidder may nominate any wholly-owned subsidiary of the Bidder to acquire Scheme Shares under the Scheme by providing a written notice which sets out the details of Bidder Nominee to Sirtex. If the Bidder decides to nominate a Bidder Nominee to acquire Scheme Shares:
(a)      the parties must procure that the Scheme Shares transferred under the Scheme are transferred to the Bidder Nominee rather than the Bidder;
(b)      the Bidder must procure that the Bidder Nominee complies with all of the relevant obligations of the Bidder under this deed and the Deed Poll; and






(c)      any such nomination will not relieve the Bidder of its obligations under this deed, including the obligation to pay (or procure the payment by the Bidder Nominee of) the Scheme Consideration in accordance with the terms of the Scheme.
2.3.      Agreement to implement the Scheme
The parties agree to implement the Scheme on and subject to the terms of this deed.
3.      Conditions Precedent and Pre-implementation Steps
3.1.      Conditions Precedent
Subject to this clause 3, the Scheme will not become Effective, and the obligations of the Bidder under clause 4.3 will not become binding, unless each of the following Conditions Precedent is satisfied or waived in accordance with clauses 3.2 and 3.5:
Conditions Precedent for benefit of all parties
(a)      Shareholder approval : Sirtex Shareholders approve the Scheme by the requisite majorities under section 411(4)(a)(ii) of the Corporations Act at the Scheme Meeting;
(b)      FIRB approval : before 8am on the Second Court Date, the Treasurer of the Commonwealth of Australia (or his delegate) either:
(i)
gives the Bidder written advice, which is unconditional or subject only to conditions that are acceptable to the Bidder acting reasonably, that the Commonwealth Government does not object under FATA or its foreign investment policy to the Transaction; or
(ii)
is or, by passage of time, becomes precluded from making an order under FATA in respect of the Transaction, and remains so precluded until that time;
(c)      other Regulatory Approvals :
(i)
all applicable waiting periods (and any extensions thereof) under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 expire or are otherwise terminated;
(ii)
the German Federal Cartel Office confirms that does not object to, or does not propose to intervene in, the Transaction pursuant to the German Act Against Restraints of Competition (Gesetz gegen Wettbewerbsbeschränkungen);
(d)      ASIC or ASX consents : before 8am on the Second Court Date, ASIC and ASX issue or provide such consents or approvals or have done such other acts which Sirtex and the Bidder agree are reasonably necessary or desirable to implement the transaction contemplated by clause 4;
(e)      restraints : no temporary restraining order, preliminary or permanent injunction or other order issued by any court of competent jurisdiction in, or Government Agency of, Australia, the United States of America, Germany, Italy, Belgium, the United Kingdom or Ireland preventing or imposing any legal restraint on the Transaction (excluding any such order or injunction that is issued in relation to, or is otherwise connected with or related to, any of the Regulatory Approvals or Government Agencies referred to in clauses 3.1(b) and 3.1(c) or any other Government Agencies responsible for such Regulatory Approvals) is in effect in each case as at 8am on the Second Court Date;
(f)      Court approval : the Court approves the Scheme in accordance with section 411(4)(b) of the Corporations Act;
Conditions Precedent for benefit of the Bidder only
(g)      no Material Adverse Change : no Material Adverse Change occurs or is discovered, announced, disclosed or otherwise becomes known to the Bidder between the date of this deed and 8am on the Second Court Date;






(h)      no Prescribed Occurrence : no Prescribed Occurrence occurs between the date of this deed and 8am on the Second Court Date;
Conditions Precedent for benefit of Sirtex only
(i)      Independent Expert : the Independent Expert issues a report which concludes that the Scheme is in the best interests of Sirtex Shareholders before the time when the Scheme Booklet is registered with ASIC and the Independent Expert has not publicly withdrawn or qualified this conclusion before 8am on the Second Court Date; and
(j)      Bidder Insolvency Event : the Bidder does not suffer an Insolvency Event between the date of this deed and 8am on the Second Court Date.
3.2.      Reasonable endeavours
(a)      The Bidder and Sirtex must:
(i)
use reasonable endeavours to procure that the Conditions Precedent in clauses 3.1(a), 3.1(d), 3.1(e) and 3.1(f) are satisfied; and
(ii)
provide reasonable assistance in satisfying the other Conditions Precedent and ensure that there is no occurrence within the control of a member of the Bidder Group or the Sirtex Group (as the context requires) that would prevent any Condition Precedent being satisfied.
(b)      The Bidder must use reasonable endeavours to procure that the Conditions Precedent in clauses 3.1(b), 3.1(c) and 3.1(j) are satisfied.
(c)      Sirtex must use reasonable endeavours to procure that the Conditions Precedent in clauses 3.1(g), 3.1(h) and 3.1(i) are satisfied.
(d)      The Bidder and Sirtex must:
(i)
consult and co-operate fully with the other party in relation to the satisfaction of the Conditions Precedent, including in relation to all material communications with Government Agencies in relation to Regulatory Approvals;
(ii)
promptly provide to the other party all material communications with Government Agencies in relation to Regulatory Approvals;
(iii)
promptly notify the other if it becomes aware that any Condition Precedent has been satisfied; and
(iv)
promptly notify the other of any failure to satisfy a Condition Precedent or of any fact or circumstance that will result in a Condition Precedent becoming incapable of being satisfied or that may result in a Condition Precedent not being satisfied in accordance with its terms (having regard to the obligations of the parties under this clause).
(e)      Without limiting this clause:
(i)
Sirtex must provide the Bidder with all information reasonably requested in connection with the Bidder's applications for each Regulatory Approval referred to in clauses 3.1(b) and 3.1(c); and
(ii)
the Bidder must consult with Sirtex, and Sirtex must consult with the Bidder, as applicable, in relation to the submission of and progress of obtaining each Regulatory Approval referred to in clauses 3.1(b) and 3.1(c).
(f)      The Bidder and Sirtex must:
(i)
give the Court on the Second Court Date a certificate confirming (in respect of matters within its knowledge) whether or not the Conditions Precedent (other than the Condition Precedent in clause 3.1(f)) have been satisfied or waived; and






(ii)
give the other a draft of its certificate by 5pm on the Business Day before the Second Court Date.
3.3.      Regulatory matters
(a)      Without limiting clause 3.2:
(i)
the Bidder must promptly apply for all relevant Regulatory Approvals contemplated by the Conditions Precedent in clauses 3.1(b) and 3.1(c) and promptly provide a copy of all such applications and associated correspondence to Sirtex (provided that any commercially sensitive information may be redacted from the copies provided);
(ii)
each party must take all steps it is responsible for as part of the applicable approval or consent process in respect of the relevant Regulatory Approvals, including responding to requests for information at the earliest practicable time;
(iii)
each party acknowledges and agrees that the other party has the right to be represented and make submissions at any meeting with any Regulatory Authority relating to a Regulatory Approval;
(iv)
each party must consult with the other party in advance in relation to all material communications (whether written or oral, and whether direct or via a Representative) with any Government Agency relating to any Regulatory Approval and, without limitation:
(A)
provide the other party with drafts of any material written communications to be sent to a Government Agency and take any reasonable comments made by the other party into account in good faith when making any amendments; and
(B)
provide copies of any material written communications sent to or received from a Government Agency to the other party promptly upon despatch or receipt (as the case may be), in each case to the extent it is reasonable, and not in breach of any law or requirement of the relevant Government Agency, to do so; and
(v)
subject to the terms of the applicable Condition Precedent, each party must promptly offer to the relevant Government Agency, and agree or accept, all undertakings, commitments and conditions reasonably necessary or appropriate in order to obtain the approval, confirmation or consent (as the case may be) as soon as possible, unless it would be unreasonable to do so and, without limiting this clause 3.3(a)(v), in relation to the confirmation referred to in clause 3.1(c)(ii), the Bidder must offer to the relevant Government Agency, and agree to accept, all undertakings, commitments and conditions reasonably necessary or appropriate in order to obtain the confirmation at phase 1 (or equivalent).
(b)      The Bidder indemnifies Sirtex against, and must pay to Sirtex on demand the amount of, any reasonable third party cost or expense incurred by Sirtex arising out of or in connection with any action taken by Sirtex under:
(i)
clause 3.3(a)(ii); and
(ii)
clause 3.2(a),
in so far as it relates to the Conditions Precedent in clauses 3.1(b), 3.1(c) and 3.1(e).
3.4.      FIRB conditions
The parties acknowledge that the standard tax conditions issued by the Foreign Investment Review Board from time to time are acceptable if included in the “no objections” notifications.
3.5.      Waiver of Conditions Precedent






(a)      The Conditions Precedent in clauses 3.1(a), 3.1(b) and 3.1(f) cannot be waived.
(b)      The Conditions Precedent in clauses 3.1(c), 3.1(d) and 3.1(e) are for the benefit of the Bidder and Sirtex and may only be waived by both of them in writing.
(c)      The Conditions Precedent in clauses 3.1(g) and 3.1(h) are for the benefit of the Bidder and may only be waived by the Bidder in writing.
(d)      The Conditions Precedent in clauses 3.1(i) and 3.1(j) are for the benefit of Sirtex and may only be waived by Sirtex in writing.
(e)      A party entitled to waive a Condition Precedent may do so conditionally or unconditionally in its absolute discretion.
(f)      If a party waives the breach or non-fulfilment of any of the Conditions Precedent that waiver precludes that party from suing the other party for any breach of this deed arising as a result of the non-fulfilment of the Condition Precedent that was waived or arising from the same event which gave rise to the non-fulfilment of the Condition Precedent.
3.6.      If a Condition Precedent is not fulfilled or waived
If a Condition Precedent cannot be fulfilled (or has not been fulfilled or waived) by the time or date specified in this deed for satisfaction of the Condition Precedent, or the Scheme has not become Effective by the End Date, Sirtex and the Bidder must consult in good faith to determine whether:
(a)      the Scheme may proceed by way of alternative means or methods and, if so, agree on the terms of such alternative means or methods;
(b)      to extend the relevant time for satisfaction of the Condition Precedent;
(c)      to adjourn or change the date of the Scheme Meeting; or
(d)      to extend the End Date.
Without limiting the foregoing, if a Condition Precedent is not satisfied by the date contemplated in the Timetable as the Second Court Date, Sirtex and the Bidder agree (unless there is no reasonable prospect that the Condition Precedent will be satisfied) that the Second Court Date be deferred until such date (not later than the Business Day before the End Date) as reasonably required to enable more time to satisfy the Condition Precedent.
3.7.      Termination on failure of Condition Precedent
(a)      If:
(i)
the Scheme has not become Effective by the End Date; or
(ii)      any event occurs which would, or in fact does, prevent a Condition Precedent being satisfied and that Condition Precedent is not waived by Sirtex or the Bidder or both (as applicable) in accordance with clause 3.5,
then, subject to clause 3.7(b), the Bidder or Sirtex may terminate this deed without any liability to the other party because of that termination (except for any obligation of a party to pay a Reimbursement Fee in accordance with clause 10).
(b)      A party will not be entitled to terminate this deed pursuant to clause 3.7(a) if the relevant occurrence, or the failure of the satisfaction of a Condition Precedent, or of the Scheme becoming Effective, arises out of, or is caused by:
(i)
a breach of this deed (including clause 3.2) by that party; or
(ii)
a deliberate act or omission of that party.






(c)      Subject to any rights or obligations arising under or pursuant to clauses that are expressed to survive termination of this deed, on termination of this deed no party will have any rights against or obligations to any other party under this deed except for those rights and obligations which accrued before termination.
4.      Transaction Steps
4.1.      Scheme
Sirtex must propose a scheme of arrangement under which:
(a)      all of the Scheme Shares will be transferred to the Bidder (or, if applicable, the Bidder Nominee); and
(b)      the Scheme Shareholders will be entitled to receive the Scheme Consideration.
4.2.      Scheme Consideration
Subject to and in accordance with this deed and the Scheme, each Scheme Shareholder is entitled to receive the Scheme Consideration in respect of each Scheme Share held by that Scheme Shareholder.
4.3.      Payment of Scheme Consideration
The Bidder undertakes to Sirtex (in its own right and as trustee on behalf of the Scheme Shareholders) that, in consideration for the transfer to the Bidder (or, if applicable, the Bidder Nominee) of each Scheme Share, on the Implementation Date it will:
(a)      accept (or, if applicable, procure the Bidder Nominee to accept) that transfer; and
(b)      before 12 noon, pay or procure the payment of the Scheme Consideration for each Scheme Share to or at the direction of Sirtex as trustee for the Scheme Shareholders for payment to Scheme Shareholders in accordance with the Scheme and the Deed Poll.
4.4.      No amendment to the Scheme without consent
Sirtex must not consent to any modification of, or amendment to, or the making or imposition by the Court of any condition in respect of, the Scheme without the prior written consent of Bidder (not to be unreasonably withheld or delayed in relation to procedural or administrative matters that do not relate to the value of the Scheme Consideration or the Scheme Shares).
5.      Implementation
5.1.      Sirtex’s obligations
Sirtex must take all necessary steps to propose and implement the Scheme as soon as is reasonably practicable and, without limiting the foregoing, must use reasonable endeavours to ensure that each step in the Timetable is met by the date set out beside that step (and must consult with the Bidder on a regular basis about its progress in that regard), including by doing any acts it is authorised and able to do on behalf of Sirtex Shareholders and each of the following:
(a)      preparation of Scheme Booklet : subject to clause 5.1(b), prepare the Scheme Booklet in accordance with all applicable laws and in particular with the Corporations Act, the Corporations Regulations, RG 60 and the ASX Listing Rules. The Scheme Booklet must include a statement that:
(i)
other than the Bidder Information and the Independent Expert’s Report, the Scheme Booklet has been prepared by Sirtex and is the responsibility of Sirtex, and that no Bidder Party assumes any responsibility for the accuracy or completeness of the Scheme Booklet (other than the Bidder Information); and






(ii)
the Bidder Information has been provided by Bidder and is the responsibility of Bidder, and that no Sirtex Party assumes any responsibility for the accuracy or completeness of the Bidder Information.
The Scheme Booklet must also include the recommendation and statement required under clause 5.5;
(b)      consultation with Bidder : consult with the Bidder as to the content and presentation of the Scheme Booklet including:
(i)
providing to the Bidder successive drafts of the Scheme Booklet and allowing the Bidder a reasonable opportunity to review and comment on those draft documents before lodgement of the Scheme Booklet with ASIC;
(ii)
considering in good faith all comments made by the Bidder and its Representatives for the purpose of amending the Scheme Booklet; and
(iii)
obtaining the Bidder’s consent to the inclusion of the Bidder Information (including in respect of the form and context in which the Bidder Information appears in the Scheme Booklet);
(c)
information : prepare and promptly provide to the Bidder any information regarding the Sirtex Group that the Bidder reasonably requires to prepare the Bidder Information for inclusion in the Scheme Booklet;
(d)      Independent Expert : promptly appoint the Independent Expert and provide all assistance and information reasonably requested by the Independent Expert to enable the Independent Expert to prepare the Independent Expert’s Report as soon as practicable;
(e)      ASIC and ASX review : during the Regulatory Review Period, promptly provide to the Bidder, and include in the Scheme Booklet, any new information not included in the Regulator’s Draft which is required by the Corporations Act, Corporations Regulations, RG 60 or the ASX Listing Rules to be included and keep the Bidder informed of any material matters raised by ASIC or ASX in relation to the Scheme Booklet or the Transaction, and use reasonable endeavours to take into consideration in resolving such matters any issues raised by the Bidder;
(f)      application for no appearance letter and section 411(17)(b) statement : apply to ASIC for the production of:
(i)
an indication of intent letter stating that it does not intend to make any submissions at the Court hearing on the First Court Date or otherwise object to the Scheme; and
(ii)
a statement under section 411(17)(b) of the Corporations Act that ASIC has no objection to the Scheme;
(g)      Court direction : apply to the Court for orders pursuant to section 411(1) of the Corporations Act directing Sirtex to convene the Scheme Meeting and consult with the Bidder as to the content of all relevant originating process, affidavits, submissions and draft minutes of Court orders;
(h)      ASIC registration : request ASIC to register the explanatory statement included in the Scheme Booklet in relation to the Scheme in accordance with section 412(6) of the Corporations Act;
(i)      despatch Scheme Booklet: send the Scheme Booklet to Sirtex Shareholders as soon as practicable after the Court orders Sirtex to convene the Scheme Meeting;
(j)      Sirtex Rights : procure that all outstanding Sirtex Rights are vested or lapsed and the relevant resultant Sirtex Shares are issued or agreed to be issued before the Record Date;
(k)      update Scheme Booklet : if it becomes aware of information after the Scheme Booklet has been sent to Sirtex Shareholders that is material for disclosure to Sirtex Shareholders in deciding whether to approve the Scheme or that is required to be disclosed to Sirtex Shareholders under any applicable law, inform Sirtex Shareholders of the information in an appropriate and timely manner, in






accordance with applicable law, after consulting with the Bidder as to the content and presentation of that information;
(l)      Share Registry information : provide all information, or procure that the Sirtex Registry provides all information, in each case in a form reasonably requested by the Bidder, about the Scheme, the Scheme Shareholders, the Sirtex Shareholders and the Share Register (including any sub register) to the Bidder and its Representatives which the Bidder reasonably requests in order to solicit votes at the Scheme Meeting and facilitate the provision by, or on behalf of, the Bidder (or, if applicable, the Bidder Nominee) of the Scheme Consideration;
(m)      Scheme Meeting : convene the Scheme Meeting to agree to the Scheme in accordance with the orders made by the Court pursuant to section 411(1) of the Corporations Act;
(n)      Court approval : (subject to all Conditions Precedent in clause 3.1, other than the condition in clause 3.1(f) being satisfied or waived in accordance with this deed) apply to the Court for orders approving the Scheme and consult with the Bidder as to the content of all relevant affidavits, submissions and draft minutes of Court orders;
(o)      lodge copy of Court order : lodge with ASIC an office copy of the Court order in accordance with section 411(10) of the Corporations Act approving the Scheme as soon as possible after the Court approves the Scheme, and in any event by 5.00pm on the first Business Day after the day on which the Court approves the Scheme;
(p)      Scheme Consideration : close the Share Register as at the Record Date and determine entitlements to the Scheme Consideration in accordance with the Scheme and the Deed Poll;
(q)      registration : subject to the Bidder satisfying its obligations under clause 4.3, register all transfers of Sirtex Shares held by Scheme Shareholders to the Bidder (or, if applicable, the Bidder Nominee) on the Implementation Date; and
(r)      ASX listing : take all reasonable steps to maintain Sirtex’s listing on the ASX notwithstanding any suspension of the quotation of Sirtex Shares up to and including the Implementation Date, including making appropriate applications to ASX.
5.2.      Bidder’s obligations
The Bidder must take (or, if applicable, cause the Bidder Nominee to take) all necessary steps to implement the Scheme as soon as is reasonably practicable and, without limiting the foregoing, must use reasonable endeavours to ensure that each step in the Timetable is met by the date set out beside that step (and consult with Sirtex on a regular basis about its progress in that regard), including by doing each of the following:
(a)      Bidder Information : prepare and promptly provide to Sirtex the Bidder Information for inclusion in the Scheme Booklet to comply with all applicable laws, including the Corporations Act, the Corporations Regulations, RG 60 and the ASX Listing Rules and consult with Sirtex as to the content and presentation of the Bidder Information in the Scheme Booklet, such consultation to include allowing Sirtex a reasonable opportunity to review and make comments on successive drafts of the Bidder Information before lodgement of the Scheme Booklet with ASIC;
(b)      review of Scheme Booklet : review the drafts of the Scheme Booklet prepared by Sirtex and provide comments, if any, as soon as practicable;
(c)      confirmation of Bidder Information : before the Scheme Booklet is provided to ASIC pursuant to section 411(2) of the Corporations Act, either:
(i)
confirm in writing to Sirtex that the Bidder Information in the form and context in which it appears in the Scheme Booklet is not misleading or deceptive in any material respect and does not contain any material omission; or
(ii)
provide to Sirtex the changes required to ensure that the Bidder Information in the form and context in which it appears in the Scheme Booklet is not misleading or deceptive in any material respect and does not contain any material omission;






(d)      assist Independent Expert : provide all assistance and information reasonably requested by the Independent Expert to enable the Independent Expert to prepare the Independent Expert’s Report as soon as practicable;
(e)      update Bidder Information : if at anytime after the despatch of the Scheme Booklet, the Bidder becomes aware:
(i)
of new information which, were it known at the time of despatch, should have been included in any Bidder Information provided previously to Sirtex; or
(ii)
that any part of the Bidder Information provided previously to Sirtex is misleading or deceptive in any material respect (whether by omission or otherwise),
it must advise Sirtex so that Sirtex can determine whether supplementary disclosure to Sirtex Shareholders is required;
(f)      Deed Poll : by not later than the Business Day prior to the First Court Date, enter into the Deed Poll in favour of the Scheme Shareholders to perform their obligations under the Scheme and deliver it to Sirtex;
(g)      Court representation : procure that it is represented by counsel at the Court hearings referred to in clauses 5.1(g) and 5.1(n), at which, through its counsel, the Bidder will undertake (if requested by the Court) to do all such things and take all such steps within its power as are necessary in order to ensure the fulfilment of its obligations under this deed and the Scheme;
(h)      Share transfer : if the Scheme becomes Effective, accept (or, if applicable, procure the Bidder Nominee to accept) a transfer of the Sirtex Shares as contemplated by clause 4.3(a); and
(i)      Scheme Consideration : if the Scheme becomes Effective, pay or procure the payment of the Scheme Consideration in the manner and amount contemplated by clause 4.3(b) and the terms of the Scheme.
5.3.      Conduct of business pre-implementation
(a)      From the date of this deed up until and including the Implementation Date, Sirtex must ensure that, except for any action which:
(i)
is required or permitted by this deed or the Scheme;
(ii)
has been Disclosed;
(iii)
is required by law or a Government Agency;
(iv)
has been consented to in writing by the Bidder (and the Bidder will consider in good faith, acting reasonably, any request for consent from Sirtex where Sirtex has provided reasonable details of the matter (including any material terms) in writing to the Bidder and must not unreasonably withhold or delay its consent to any such request); or
Sirtex and the other members of the Sirtex Group:
(v)
conduct their businesses in the ordinary course consistent with business plans and budgets Disclosed and otherwise in a manner generally consistent with the manner in which such businesses have been conducted in the 12 months prior to the date of this deed;
(vi)
use all reasonable endeavours to maintain and preserve their relationships with customers, suppliers, Government Agencies, landlords, licensors, licensees and others having business dealings with them, including by using reasonable endeavours to obtain their consent to the Transaction to the extent required under any material agreement with such third parties; and






(vii)
do not enter any lines of business or other activities in which members of the Sirtex Group are not engaged at the date of this deed;
(viii)
conduct their businesses and operations substantially in accordance with all applicable laws and regulations;
(ix)
where reasonably requested, consult with the Bidder and provide updates as to the progress of their business and operations;
(x)
do not settle the Class Actions, or any part of them, or take any other step that compromises the members of the Sirtex Group’s rights in respect of the Class Actions;
(xi)
do not incur any additional financial indebtedness by way of borrowings and other financial facilities including operating and finance leases (except for draw-downs on existing banking facilities or utilisation of existing securitisation programs) or guarantee or indemnify the obligations of any person other than a member of the Sirtex Group, other than in the usual and ordinary course of business and consistent with past practice; and
(xii)
do not make any material change to the terms of employment of any director, executive or senior manager (except as required by law, publicly disclosed prior to the date of this deed or as provided in an existing contract in place as at the date of this deed).
(b)      From the date of this deed up until and including the Implementation Date, Sirtex must not declare or pay a dividend.
(c)      For the avoidance of doubt, nothing in this clause 5.3 restricts the ability of Sirtex to respond to a Competing Proposal in accordance with clause 9.
5.4.      Appointment and resignation of directors
On the Implementation Date, but subject to the Bidder having paid the Scheme Consideration in accordance with clause 4.3(b) and receipt by Sirtex of signed consents to act, Sirtex must use its reasonable endeavours to:
(a)      cause the appointment of each Incoming Director to the Board; and
(b)      procure that each of the Outgoing Directors retires from the Board and provides written notice to the effect that they have no claim outstanding for loss of office, remuneration or otherwise against Sirtex (provided that nothing in this clause 5.4 requires any Outgoing Director to forego any rights they may have under any deed of access and indemnity or policy of insurance),
in each case, in accordance with Sirtex’s constitution, the Corporations Act and the ASX Listing Rules.
5.5.      Board recommendation
(a)      Subject to clause 5.5(b), Sirtex must use its reasonable endeavours to procure that:
(i)
the Board unanimously recommends (including in the Scheme Booklet) that, in the absence of a superior proposal and subject to the Independent Expert concluding that the Transaction is in the best interests of Sirtex Shareholders, Sirtex Shareholders vote in favour of the Scheme at the Scheme Meeting; and
(ii)
the Scheme Booklet will include a statement by the Board to that effect and to the effect that each director of Sirtex will, in the absence of a superior proposal and subject to the Independent Expert concluding that the Transaction is in the best interests of Sirtex Shareholders, vote (or procure the voting) of all Sirtex Shares held or controlled by them in favour of the Scheme at the Scheme Meeting.
(b)      Sirtex must use its reasonable endeavours to procure that no director of Sirtex changes, withdraws or modifies their recommendation that Sirtex Shareholders vote in favour of the Scheme at the Scheme Meeting or their statement that they will vote (or procure the voting) of all Sirtex Shares






held or controlled by them in favour of the Scheme at the Scheme Meeting or make a recommendation or statement that is inconsistent with such recommendation or statement, unless:
(i)
the Independent Expert concludes in the Independent Expert’s Report (or any update or variation to that report) that the Scheme is not in the best interests of Sirtex Shareholders, or adversely changes its previously given opinion in the Independent Expert’s Report (or any update or variation to that report) that the Scheme is in the best interests of Sirtex Shareholders;
(ii)
Sirtex receives a Competing Proposal and the Board, acting in good faith, determines (after consultation with its financial advisers) that the Competing Proposal constitutes a Superior Proposal; or
(iii)
that director, acting in good faith, determines (after taking written advice from Sirtex’s or their own external financial and legal advisers) that a failure by them or the Board to change, withdraw or modify such recommendation or make a recommendation or statement that is inconsistent with it would be reasonably likely to constitute a breach of their fiduciary or statutory obligations.
5.6.      Promotion of Scheme
During the Exclusivity Period, provided that the Board has not changed its recommendation in accordance with clause 5.5, Sirtex must use reasonable endeavours to procure that the senior executives of the Sirtex Group participate in efforts to promote the merits of the Scheme, including (as determined by Sirtex):
(a)      meeting with key Sirtex Shareholders;
(b)      communicating with Sirtex Group employees, customers, and suppliers; and
(c)      communicating with the public to promote the merits of the Scheme.
5.7.      Conduct of Court proceedings
(a)      Sirtex and the Bidder (or, if applicable, the Bidder Nominee) are entitled to separate representation at all Court proceedings affecting the Transaction.
(b)      This deed does not give:
(i)
Sirtex any right or power to give undertakings to the Court for or on behalf of the Bidder (or, if applicable, the Bidder Nominee); or
(ii)
the Bidder (or, if applicable, the Bidder Nominee) any right or power to give undertakings to the Court for or on behalf of Sirtex, in each case, without the relevant party’s written consent.
6.      Representations and Warranties
6.1.      Bidder representations
The Bidder represents and warrants to Sirtex (in its own right and separately as trustee or nominee for each of the other Sirtex Parties) that each of the Bidder Representations and Warranties is true and correct.
6.2.      Sirtex’s representations
(a)      Subject to clause 6.2(b), Sirtex represents and warrants to the Bidder (in its own right and separately as trustee or nominee for each of the other Bidder Parties) that each of the Sirtex Representations and Warranties is true and correct.
(b)      Each Sirtex Representation and Warranty is subject to matters that:






(i)
are required to be done under this deed or the Scheme;
(ii)
took place with the prior written consent of the Bidder;
(iii)
have been Disclosed; or
(iv)
as at the date of this deed are within the actual knowledge of Bidder or the Bidder’s Representatives.
(c)      The Bidder acknowledges that prior to the execution of this deed it conducted due diligence investigations in relation to the Sirtex Group and that as at the date of this deed it is not aware, as a consequence of having conducted those due diligence investigations, of any information or matter that would give it a right to terminate this deed or would constitute a breach of any Sirtex Representation and Warranty.
6.3.      Timing of representations and warranties
Unless expressed to be given at a particular time (in which case it is given at that time), each Bidder Representation and Warranty and each Sirtex Representation and Warranty is given:
(a)      at the date of this deed; and
(b)      at all times up until 8am on the Second Court Date.
6.4.      Survival of representations and warranties
Each Bidder Representation and Warranty and Sirtex Representation and Warranty:
(a)      is severable; and
(b)      survives the termination of this deed (but does not survive, and will be taken to have no further force or effect following, implementation of the Scheme).
7.      Releases
7.1.      Sirtex Parties
(a)      The Bidder releases, and shall procure that each member of the Bidder Group releases, its rights against, and agrees with Sirtex that it will not make a Claim against, any Sirtex Party (other than Sirtex) in connection with:
(i)
any breach of any representation, covenant or warranty of Sirtex in this deed;
(ii)
any disclosure made by any Sirtex Party that contains any statement which is false or misleading whether in content or by omission, except to the extent that the relevant Sirtex Party has not acted in good faith or has engaged in wilful misconduct.
(b)      Clause 7.1(a) is subject to any Corporations Act restriction and will (if and to the extent required) be read down accordingly.
(c)      Sirtex receives and holds the benefit of this clause 7.1 as agent and trustee on behalf of each other Sirtex Party.
7.2.      Bidder Parties
(a)      Sirtex releases, and shall procure that each member of the Sirtex Group releases, its rights against, and agrees with the Bidder that it will not make a Claim against, any Bidder Party (other than the Bidder and the Bidder Nominee (if any)) in connection with:
(i)
any breach of any representation, covenant or warranty of the Bidder in this deed;






(ii)
any disclosure made by any Bidder Party that contains any statement which is false or misleading whether in content or by omission, except to the extent that the relevant Bidder Party has not acted in good faith or has engaged in wilful misconduct.
(b)      Clause 7.2(a) is subject to any Corporations Act restriction and will (if and to the extent required) be read down accordingly.
(c)      The Bidder receives and holds the benefit of this clause 7.2 as agent and trustee on behalf of each other Bidder Party.
7.3.      Deeds of indemnity and insurance
(a)      Subject to the Scheme becoming Effective, the Bidder undertakes in favour of Sirtex and each other person who is a Sirtex Party that it will:
(i)
for a period of not less than 7 years from the Implementation Date, ensure that the constitutions of Sirtex and each other member of the Sirtex Group continue to contain such rules as are contained in those constitutions at the date of this deed that provide for each company to indemnify each of its current and former directors and officers against any liability incurred by that person in their capacity as a director or officer of the company to any person other than a member of the Sirtex Group; and
(ii)
procure that Sirtex and each other member of the Sirtex Group complies with any deeds of indemnity, access and insurance made by them in favour of their respective directors and officers from time to time and, without limiting the foregoing, ensure that directors’ and officers’ run-off insurance cover for those directors and officers is maintained (with the same level of cover, and on the same terms, as maintained by the Sirtex Group at the date of this deed or with a higher level of cover or on terms more favourable to those directors and officers) for a period of not less than 7 years from the retirement date of each director and officer.
(b)      The undertakings contained in clause 7.3(a) are subject to any Corporations Act restriction and will (if and to the extent required) be read down accordingly.
(c)      Sirtex receives and holds the benefit of clause 7.3(a) to the extent it relates to each director and officer of a member of the Sirtex Group as agent and trustee on behalf of each of them.
(d)      The Bidder acknowledges that, notwithstanding any other provision of this deed, Sirtex may, prior to the Implementation Date, enter into arrangements to secure directors and officers run-off insurance for up to 7 years after the Implementation Date, and that any actions to facilitate that insurance or in connection therewith will not be a Prescribed Occurrence or breach any provision of this deed.
8.      Public Announcements
8.1.      Announcement of the Transaction
Immediately after the execution of this deed, Sirtex and the Bidder must issue public announcements in a form previously agreed to in writing between them. The Sirtex announcement must include:
(a)
a unanimous recommendation by the directors of Sirtex to Sirtex Shareholders consistent with that set out in clause 5.5(a)(i); and
(b)      a statement consistent with that set out in clause 5.5(a)(ii).
8.2.      Other public announcements
Subject to clause 8.3, any further public announcement or disclosure of or in relation to the Transaction or any other transaction the subject of this deed or the Scheme may only be made with the approval by writing by each party (each party acting reasonably and in good faith) to the timing, form and






content of that announcement or disclosure. Subject to any applicable law or rules of a relevant stock exchange, the parties agree to make all public announcements in relation to the Transaction outside the trading hours of ASX.
8.3.      Required disclosure
Where a party is required by applicable law or the ASX Listing Rules to make any announcement or to make any disclosure in connection with the Transaction or any other transaction the subject of this deed or the Scheme, it may do so but must use reasonable endeavours, to the extent practicable and lawful, to consult with the other party to the fullest extent possible before making the relevant disclosure and must give the other party as much notice as reasonably practical.
8.4.      Statements on termination
The parties must act in good faith and use all reasonable endeavours to issue agreed statements in respect of any termination of this deed and, to that end but without limitation, clauses 8.2 and 8.3 apply to any such statements or disclosures.
9.      Exclusivity
9.1.      Termination of existing discussions
(a)      Sirtex warrants that, as at the time of execution of this deed, it is not, and must ensure that none of its Representatives are, in any negotiations or discussions, and that it has, and its Representatives have, ceased any existing negotiations or discussions, in respect of any Competing Proposal (or which may reasonably be expected to lead to a Competing Proposal) with any person.
(b)      Sirtex agrees that if, in the six months before the date of this deed, it has provided any confidential information to a Third Party (or to any current or former adviser to Sirtex or a Third Party, other than Sirtex’s advisers in relation to the Transaction) in relation to a possible Competing Proposal, Sirtex has requested or will promptly request in writing the immediate return or destruction by the Third Party (and any relevant adviser) of such confidential information.
9.2.      No shop restriction
During the Exclusivity Period, except with the prior written consent of the Bidder, Sirtex must ensure that neither it nor any of its Representatives directly or indirectly solicits, invites, encourages or initiates any Competing Proposal or any enquiries, negotiations or discussions with any Third Party in relation to, or that may reasonably be expected to lead to, a Competing Proposal, or communicate any intention to do any of those things.
9.3.      No talk restriction
During the Exclusivity Period, except with the prior written consent of the Bidder, Sirtex must ensure that neither it nor any of its Representatives directly or indirectly enters into, continues or participates in negotiations or discussions with, or enters into any agreement or understanding with, any Third Party in relation to, or that may reasonably be expected to lead to, a Competing Proposal, even if:
(a)      the Competing Proposal was not directly or indirectly solicited, invited, encouraged or initiated by Sirtex; or
(b)      the Competing Proposal has been publicly announced.
9.4.      No due diligence
Without limiting the general nature of clause 9.3, during the Exclusivity Period Sirtex must ensure that neither it nor any of its Representatives make available to any Third Party, or permit any Third Party, to receive any non public information relating to any member of the Sirtex Group in connection with such Third Party formulating, developing or finalising, or assisting in the formulation, development or finalisation of, a Competing Proposal.
9.5.      Exceptions






Clause 9.3 and 9.4 do not apply to the extent that they restrict Sirtex or the Board from taking or refusing to take any action with respect to a genuine Competing Proposal (which was not solicited, invited, encouraged or initiated by Sirtex or its Representatives in contravention of clause 9.2) if the Board, acting in good faith, determines:
(a)      after consultation with its financial advisers, that the Competing Proposal is or may reasonably be expected to lead to a Superior Proposal having regard to the steps which the Board proposes to take; and
(b)      after receiving written advice from its legal advisers, that failing to respond to that Competing Proposal would be reasonably likely to constitute a breach of the Board's fiduciary or statutory obligations.
9.6.      Normal provision of information
Nothing in this deed prevents Sirtex from:
(a)      providing information to its Representatives;
(b)      providing information to any Government Agency;
(c)      providing information to its auditors, customers, financiers, joint venturers and suppliers acting in that capacity in the ordinary course of business;
(d)      providing information required to be provided by law, including to satisfy its obligations of disclosure under the ASX Listing Rules or to any Government Agency; or
(e)      making presentations to, and to responding to enquiries from, brokers, portfolio investors and analysts in the ordinary course in relation to the Scheme or its business generally.
9.7.      Notice of unsolicited approach
During the Exclusivity Period, Sirtex must inform the Bidder if:
(a)      it is approached, directly or indirectly, by any Third Party to take any action of a kind referred to in clauses 9.3 or 9.4, and must disclose to the Bidder:
(i)
the fact that such an approach has been made;
(ii)
the identity of the Third Party who has made the approach, and the identity of the person making or proposing any Competing Proposal; and
(iii)
all material terms of any Competing Proposal (to the extent known by Sirtex),
as soon as reasonably practicable, and in any event by no later than 24 hours after such approach was received; or
(b)      it proposes to take any action of a kind referred to in clauses 9.3 or 9.4 (for the avoidance of doubt, such notice being given before the taking of the relevant action).
9.8.      Matching right
Without limiting clauses 9.2 and 9.3, during the Exclusivity Period, Sirtex:
(a)      must not enter into any legally binding agreement, arrangement or understanding pursuant to which a Third Party, Sirtex or both proposes or propose to undertake or give effect to a Competing Proposal; and
(b)      must use its reasonable endeavours to procure that none of its directors changes, withdraws or modifies their recommendation that Sirtex Shareholders vote in favour of the Scheme at the Scheme Meeting or otherwise makes a public statement to endorse or recommend a Competing Proposal,
unless:






(c)      the Competing Proposal is a Superior Proposal;
(d)      Sirtex has provided the Bidder with the material terms and conditions of the Competing Proposal;
(e)      Sirtex has given the Bidder at least 5 Business Days after the date of the provision of the information referred to in clause 9.8(d) to provide a matching or superior proposal to the terms of the Competing Proposal; and
(f)      the Bidder has not provided a matching or superior proposal to the terms of the Competing Proposal to the Board by the expiry of the 5 Business Day period referred to in clause 9.8(e).
Sirtex acknowledges and agrees that each successive modification of any Competing Proposal will constitute a new Competing Proposal for the purposes of the requirements under clause 9.8 and accordingly Sirtex must comply with clauses 9.8(a) and 9.8(b) in respect of any new Competing Proposal unless clauses 9.8(c) to 9.8(f) (inclusive) apply.
9.9.      Bidder counterproposal
If the Bidder proposes to Sirtex, or announces amendments to the Scheme or a new proposal that constitute a matching or superior proposal to the terms of the Competing Proposal ( Bidder Counterproposal ) by the expiry of the 5 Business Day period referred to in clause 9.8(e), Sirtex must procure that the Board considers the Bidder Counterproposal and if the Board, acting in good faith, determines that the Bidder Counterproposal would provide an equivalent or superior outcome for Sirtex Shareholders as a whole compared with the Competing Proposal, taking into account the material terms and conditions of the Bidder Counterproposal, then:
(a)      Sirtex and the Bidder must use their reasonable endeavours to agree the amendments to this deed and, if applicable, the Scheme and Deed Poll that are reasonably necessary to reflect the Bidder Counterproposal and to implement the Bidder Counterproposal, in each case as soon as reasonably practicable; and
(b)      Sirtex must use its reasonable endeavours to procure that each of the directors of Sirtex recommends the Scheme (as modified by the Bidder Counterproposal) to Sirtex Shareholders in the absence of a superior proposal.
9.10.      Legal advice
Sirtex and the Bidder acknowledge that they each have received legal advice on this deed and the operation of this clause 9.
10.      Reimbursement Fees
10.1.      Background
This clause has been agreed in circumstances where:
(a)      the Bidder and Sirtex believe that the Scheme will provide significant benefits to the Bidder, Sirtex and their respective shareholders, and the Bidder and Sirtex acknowledge that, if they enter into this deed and the Scheme is subsequently not implemented, the Bidder will incur significant costs, including those set out in clause 10.6;
(b)      the Bidder and Sirtex have each requested that provision be made for the Reimbursement Fee to be payable to it, without which neither the Bidder nor Sirtex would not have entered into this deed;
(c)      the boards of both parties believe that it is appropriate for both parties to agree to the payments referred to in this clause to secure the other party’s entry into this deed and participation in the Scheme; and
(d)      both parties have received legal advice on this deed and the operation of this clause.






10.2.      Payments by Sirtex to the Bidder
Subject to clauses 10.4, 10.5, 10.7 and 10.8, Sirtex agrees to pay the Reimbursement Fee to the Bidder without withholding or set off if the Scheme does not proceed because:
(a)      Competing Proposal : during the Exclusivity Period a Competing Proposal is announced by a Third Party and, within 12 months of such announcement, the Third Party or an associate of the Third Party:
(i)
completes in all material respects a transaction of the kind referred to in paragraph (b), (c) or (d) of the definition of Competing Proposal; or
(ii)
without limiting clause 10.2(a)(i) above, has a relevant interest in at least 50% of Sirtex Shares,
except where the Independent Expert concludes in the Independent Expert’s Report (or any update or variation to that report) that the Scheme is not in the best interests of Sirtex Shareholders, or adversely changes its previously given opinion in the Independent Expert’s Report (or any update or variation to that report) that the Scheme is in the best interests of Sirtex Shareholders (except in circumstances where the Independent Expert reaches that conclusion or makes that change as a result of a Competing Proposal having been announced or made public);
(b)      change of recommendation : at any time on or before the Scheme Meeting:
(i)
a majority of the members of the Board make a public statement withdrawing or adversely changing or modifying their recommendation that Sirtex Shareholders vote in favour of the Scheme at the Scheme Meeting or their statement that they will vote (or procure the voting) of all Sirtex Shares held or controlled by them in favour of the Scheme at the Scheme Meeting (including by attaching qualifications to such recommendation or statement) or make a recommendation or statement that is inconsistent with such recommendation or statement; or
(ii)
without limiting the foregoing, a majority of members of the Board make a public statement indicating that they no longer support the Scheme or that they support a Competing Proposal,
excluding any member of the Board who withdraws their recommendation:
(iii)
due to the Independent Expert concluding in the Independent Expert’s Report (or any update or variation to that report) that the Scheme is not in the best interests of Sirtex Shareholders, or adversely changing its previously given opinion in the Independent Expert’s Report (or any update or variation to that report) that the Scheme is in the best interests of Sirtex Shareholders (except in circumstances where the Independent Expert reaches that conclusion or makes that change as a result of a Competing Proposal having been announced or made public); or
(iv)
in circumstances where Sirtex is entitled to terminate this deed in accordance with clause 11.1(a) or clause 11.1(b);
(c)      Independent Expert : Sirtex validly terminates this deed in accordance with clause 11.1(f) due to the Independent Expert concluding in the Independent Expert’s Report (or any update or variation to that report) that the Scheme is not in the best interests of Sirtex Shareholders, or adversely changing its previously given opinion in the Independent Expert’s Report (or any update or variation to that report) that the Scheme is in the best interests of Sirtex Shareholders, where the reason for that conclusion or change is a Competing Proposal; or
(d)      termination by the Bidder : the Bidder validly terminates this deed in accordance with clause 11.1(a) or clause 11.1(c).
10.3.      Payment by the Bidder to Sirtex






Subject to clauses 10.4, 10.5, 10.7 and 10.8, the Bidder agrees to pay the Reimbursement Fee to Sirtex without withholding or set off if the Scheme does not proceed because:
(a)      failure to achieve Regulatory Approvals or restraint applying : this deed is terminated in accordance with clause 3.7(a) as a result of any of the Conditions Precedent in clause 3.1(b) or 3.1(c) not being satisfied or waived in accordance with clause 3.5 (or as a result of the Condition Precedent in clause 3.1(f) not being satisfied as a result of the failure to satisfy or waive any of the Conditions Precedent in clause 3.1(b) or 3.1(c)); or
(b)      termination by Sirtex : Sirtex validly terminates this deed in accordance with clause 11.1(a) or clause 11.1(b).
10.4.      No amount payable if Scheme becomes Effective
(a)      Notwithstanding the occurrence of any event in clause 10.2 or clause 10.3, if the Scheme becomes Effective:
(i)
no amount is payable by any party under those clause; and
(ii)
if any amount has already been paid under those clauses it must be refunded by the recipient within 20 Business Days after the Scheme becomes Effective.
(b)      A party can only ever be liable to pay the Reimbursement Fee once.
10.5.      Timing of payment
If the Reimbursement Fee is payable under clause 10.2 or clause 10.3, Sirtex or the Bidder (as applicable) must pay the Reimbursement Fee without withholding or set off within 20 Business Days of receipt of a demand for payment from the other party.
10.6.      Nature of payment
The amount payable by a party to the other party under clauses 10.2 and 10.3 is an amount to compensate the other party for:
(a)      advisory costs;
(b)      costs of management and directors’ time;
(c)      out-of-pocket expenses;
(d)      the distraction of the Bidder’s management from conducting the Bidder’s business as usual caused by pursuing the Scheme;
(e)      reasonable opportunity costs incurred in pursuing the Transaction or in not pursuing alternative acquisitions or strategic initiatives which could have developed to further the other party’s business and objectives; and
(f)      damage to the other party’s reputation associated with a failed transaction and the implications of that damage to the other party’s business.
The parties agree that the costs incurred are of a nature that they cannot be accurately quantified and that a genuine pre-estimate of the costs would equal or exceed the amount payable under clause 10.2 or clause 10.3 (as applicable).
10.7.      Limitation of liability
(a)      Notwithstanding any other provision of this deed but subject to clauses 10.7(b) and 10.8:
(i)
the maximum liability of a party to the other party under or in connection with this deed including in respect of any breach of this deed will be the Reimbursement Fee and in no event will the aggregate liability of a party under or in connection with a breach of this deed exceed an amount equal to the Reimbursement Fee; and






(ii)
the payment by a party to the other party of the Reimbursement Fee represents the sole and absolute amount of liability of that party to the other party under or in connection with this deed and no further damages, fees, expenses or reimbursements of any kind will be payable by that party to the other party in connection with this deed.
(b)      Nothing in clause 10.7(a) in any way:
(i)
prevents a party (in its own right or as agent or trustee on behalf of any person contemplated by this deed) from seeking orders from a court of competent jurisdiction for the specific performance by the other party of any obligations under this deed; or
(ii)
extinguishes or limits the liability of a party for any breach of this deed arising from criminal acts or fraud by the other party or a Representative of the other party.
10.8.      Compliance with law
(a)      If it is finally determined following the exhaustion of all reasonable avenues of appeal to the Takeovers Panel or a court that all or any part of the amount payable under clause 10.2:
(i)
is unlawful or would if performed be, unlawful;
(ii)
involves a breach of the duties of the Board; or
(iii)
constitutes unacceptable circumstances within the meaning of the Corporations Act,
then Sirtex’s obligation to pay the applicable amount or part of the amount payable under clause 10.2 does not apply and if the Bidder has received any such part of the payment due under clause 10.2 it must refund it within 20 Business Days of such final determination.
(b)      The parties must not make or cause or permit to be made any application to a court, arbitral tribunal or the Takeovers Panel for or in relation to a determination referred to in this clause 10.8.
11.      Termination
11.1.      Termination events
This deed may be terminated:
(a)      material breach of document : by either Sirtex or the Bidder at any time prior to 8am on the Second Court Date, if the other is in material breach of a term of this deed (other than a breach of representation and warranty, which is dealt with in clause 11.1(c) or 11.1(b), as applicable), taken in the context of the Scheme as a whole, provided that Sirtex or the Bidder (as the case may be) has, if practicable, given notice to the other setting out the relevant circumstances and the relevant circumstances continue to exist 10 Business Days (or any shorter period ending at 8am on the Second Court Date) after the time such notice is given;
(b)      material breach of Bidder Representations and Warranties : by Sirtex if the Bidder Representations and Warranties are not true and accurate in all material respects, provided that:
(i)
Sirtex has given written notice to the Bidder setting out the relevant circumstances and stating an intention to terminate this deed or to allow the Scheme to lapse;
(ii)
the relevant breach or circumstances have not been remedied within 10 Business Days after such notice is given (or any shorter period ending at 8am on the Second Court Date); and
(iii)
the relevant breach of the Bidder Representations and Warranties is material in the context of the scheme taken as a whole;
(c)      material breach of Sirtex Representations and Warranties : by the Bidder if the Sirtex Representations and Warranties are not true and accurate in all material respects, provided that:






(i)
the Bidder has given written notice to Sirtex setting out the relevant circumstances and stating an intention to terminate this deed or to allow the Scheme to lapse;
(ii)
the relevant breach or circumstances have not been remedied within 10 Business Days after such notice is given (or any shorter period ending at 8am on the Second Court Date); and
(iii)
the relevant breach of the Sirtex Representations and Warranties is material in the context of the Scheme taken as a whole;
(d)      change of recommendation of Board : by the Bidder if a majority of the members of the Board have changed, withdrawn or modified their recommendation that Sirtex Shareholders vote in favour of the Scheme at the Scheme Meeting as permitted under clause 5.5;
(e)      recommendation of Competing Proposal : by Sirtex if, at any time before 8am on the Second Court Date, a majority of the Board publicly recommends a Competing Proposal that is a Superior Proposal, and provided that the Competing Proposal was not connected with a breach of Sirtex’s obligations in clause 9;
(f)      Independent Expert : by Sirtex if the Independent Expert concludes in the Independent Expert’s Report (or any update or variation to that report) that the Scheme is not in the best interests of Sirtex Shareholders, or adversely changes its previously given opinion in the Independent Expert’s Report (or any update or variation to that report) that the Scheme is in the best interests of Sirtex Shareholders;
(g)      failure of Conditions Precedent : in accordance with and pursuant to clause 3.7(a); and
(h)      by agreement : if agreed to in writing by Sirtex and the Bidder.
11.2.      Termination
Where a party has a right to terminate this deed, that right for all purposes will be validly exercised if the party delivers a notice in writing to the other party stating that it terminates this deed.
11.3.      Effect of Termination
If this deed is terminated by either party, or if this deed otherwise terminates in accordance with its terms, then in either case all further obligations of the parties under this deed, other than the obligations set out in this clause and in clauses 7, 8, 10 and 12 to 16 (inclusive) will immediately cease to be of further force and effect without further liability of any party to the other, provided that nothing in this clause releases any party from liability for any pre-termination breach of this deed.
12.      Confidentiality
12.1.      Confidentiality Deed
Sirtex and the Bidder acknowledge and agree that they continue to be bound by the Confidentiality Deed after the date of this deed.
12.2.      Survival of obligations
The rights and obligations of the parties under the Confidentiality Deed survive termination of this deed.
13.      GST
13.1.      Definitions and interpretation
For the purposes of this clause:
(a)      GST Act means the A New Tax System (Goods and Services Tax) Act 1999 (Cth);






(b)      a term which has a defined meaning in the GST Act has the same meaning when used in this clause, unless the contrary intention appears; and
(c)      each periodic or progressive component of a supply to which section 156-5(1) of the GST Act applies will be treated as if it were a separate supply.
13.2.      GST exclusive
Unless this deed expressly states otherwise, all consideration to be provided under this deed is exclusive of GST.
13.3.      Payment of GST
(a)      If GST is payable, or notionally payable, on a supply in connection with this deed, the party providing the consideration for the supply agrees to pay to the supplier an additional amount equal to the amount of GST payable on that supply ( GST Amount ).
(b)      Subject to the prior receipt of a tax invoice, the GST Amount is payable at the same time as the GST-exclusive consideration for the supply, or the first part of the GST-exclusive consideration for the supply (as the case may be), is payable or is to be provided.
(c)      This clause does not apply to the extent that the consideration for the supply is expressly stated to include GST or the supply is subject to a reverse-charge.
13.4.      Adjustment events
If an adjustment event arises for a supply made in connection with this deed, the GST Amount must be recalculated to reflect that adjustment. The supplier or the recipient (as the case may be) agrees to make any payments necessary to reflect the adjustment and the supplier agrees to issue an adjustment note.
13.5.      Reimbursements
Any payment, indemnity, reimbursement or similar obligation that is required to be made in connection with this deed which is calculated by reference to an amount paid by another party must be reduced by the amount of any input tax credits which the other party (or the representative member of any GST group of which the other party is a member) is entitled. If the reduced payment is consideration for a taxable supply, clause 13.3 will apply to the reduced payment.
13.6.      No merger
This clause 13 will not merge on termination of this deed.
14.      Duty, Costs and Expenses
14.1.      Stamp duty and registration fees
The Bidder:
(a)      must pay all stamp duties, registration fees and similar taxes payable or assessed as being payable in connection with this deed or the Scheme or the steps to be taken under this deed or the Scheme (including any fees, fines, penalties and interest in connection with any of those amounts); and
(b)      indemnifies Sirtex against any liability incurred by Sirtex arising from a failure to comply with clause 14.1(a).
14.2.      Costs and expenses
Except as otherwise provided in this deed, each party must pay its own costs and expenses in connection with the negotiation, preparation, execution and performance of this deed and the proposed, attempted or actual implementation of this deed and the Transaction.






15.      Notices
15.1.      Form
(a)      Unless this deed expressly states otherwise, all notices, demands, certificates, consents, approvals, waivers and other communications in connection with this deed must be in writing and signed by the sender (if an individual) or a person duly authorised by the sender.
(b)      All communications (other than email communications) must also be marked for the attention of the person referred to in clause 15.3 (or, if the recipient has notified otherwise, then marked for attention in the way last notified).
(c)      Email communications must state the first and last name of the sender and are taken to be signed by the named sender.
15.2.      Delivery
(a)      Communications must be:
(i)
delivered by hand to the address of the party referred to in clause 15.3;
(ii)
sent by regular ordinary post (airmail if sent from one country to another) to the address of the party referred to in clause 15.3; or
(iii)
sent by email to the email address of the party referred to in clause 15.3.
(b)      If the intended recipient has notified changed contact details, then communications must be sent to the changed contact details.
15.3.      Notice details
The notice details of:
(a)      Sirtex are:
Name:
Sirtex Medical Limited
Address:
Level 33, 101 Miller Street, North Sydney NSW 2060, Australia
Attention:
Andrew McLean
Email:
andrew.mclean@sirtex.com

With a copy to:
Name:
Watson Mangioni
Address:
Level 23, 85 Castlereagh Street, Sydney NSW 2000, Australia
Attention:
Chris Clarke
Email:
cclarke@wmlaw.com.au

(b)      the Bidder are:
Name:
Varian Medical Systems, Inc.
Address:
3100 Hansen Way, Palo Alto, CA 94304-1038, United States
Attention:
Mike Dunn
Email:
Mike.Dunn@varian.com

With a copy to:






Name:
Norton Rose Fulbright
Address:
Level 18, Grosvenor Place, 225 George Street, Sydney NSW 2000
Attention:
Shaun Clyne / Jeremy Wickens
Email:
shaun.clyne@nortonrosefulbright.com / jeremy.wickens@nortonrosefulbright.com

or as specified to the sender by the other party by notice.
15.4.      When effective
Communications take effect from the time they are received or taken to be received under clause 15.5 (whichever happens first) unless a later time is specified in the communication.
15.5.      When taken to be received
Subject to clause 15.6, communications are taken to be received:
(a)      if delivered by hand, when delivered;
(b)      if sent by post, 5 Business Days after posting (if posted to an address in the same country) or 10 Business Days after posting (if posted to an address in a different country);
(c)      if sent by email:
(i)
when the sender receives an automated message confirming delivery; or
(ii)
4 hours after the time sent (as recorded on the device from which the sender sent the email) unless the sender receives an automated message that delivery failed,
whichever happens first.
15.6.      Receipt outside business hours
Despite anything else in this clause 15, if communications are received or taken to be received under clause 15.5 after 5pm on a working day or on a day that is not a working day, they are taken to be received at 9am on the next working day. For the purposes of this clause, “working day” means a day that is not a Saturday, Sunday or public holiday and on which banks are open for business generally, in the place to which the communication is posted, sent or delivered).
16.      General
16.1.      Variation
This deed may only be varied by a deed signed by or on behalf of each of the parties.
16.2.      Assignment
Subject to clause 2.2, a party may not assign, novate, charge, encumber or otherwise transfer any of its rights or obligations under this deed without the prior written consent of the other party.
16.3.      Entire agreement
This deed and the Confidentiality Deed contain the entire agreement between the parties with respect to their subject matter. They set out the only conduct relied on by the parties and supersede all earlier conduct and prior agreements and understandings between the parties in connection with their subject matter.
16.4.      Counterparts






(a)      This deed may consist of a number of copies, each signed by one or more parties to it. If so, the signed copies are treated as making up a single document and the date on which the last counterpart is executed is the date of the deed.
(b)      This deed may be executed on the basis of an exchange of facsimile copies or electronic images (such as scanned copies or digital photos), and execution of this deed by such means is a valid and sufficient execution.
16.5.      Further action
Each party will do all things and execute all further documents necessary to give full effect to this deed.
16.6.      No merger
The rights and obligations of the parties do not merge on completion of the Transaction. They survive the execution and delivery of any assignment or other document entered into for the purpose of implementing the Transaction.
16.7.      Severability
If the whole or any part of a provision of this deed is void, unenforceable or illegal in a jurisdiction it is severed for that jurisdiction. The remainder of this deed has full force and effect and the validity or enforceability of that provision in any other jurisdiction is not affected. This clause has no effect if the severance alters the basic nature of this deed or is contrary to public policy.
16.8.      No third party beneficiary
This deed shall be binding on and inure solely to the benefit of each party to it and each of their respective permitted successors and assigns, and nothing in this deed, express or implied, is intended to or shall confer on any other person, other than the Bidder Parties and the Sirtex Parties (including, for the avoidance of doubt, each member of the Board), to the extent set forth in clause 6 and clause 7, any third party beneficiary rights.
16.9.      Waivers
(a)      Failure to exercise or enforce, a delay in exercising or enforcing, or the partial exercise or enforcement of any right, power or remedy provided by law or under this deed by any party does not in any way preclude, or operate as a waiver of, any exercise or enforcement, or further exercise or enforcement, of that or any other right, power or remedy provided by law or under this deed.
(b)      Any waiver or consent given by any party under this deed is only effective and binding on that party if it is given or confirmed in writing by that party.
(c)      No waiver of a breach of any term of this deed operates as a waiver of another breach of that term or of a breach of any other term of this deed.
16.10.      Consents
If the doing of any act, matter or thing under this deed is dependent on the consent or approval of a party or is within the discretion of a party, the consent or approval may be given or the discretion may be exercised conditionally or unconditionally or withheld by the party in its absolute discretion unless expressly provided otherwise.
16.11.      No representation or reliance
(a)      Each party acknowledges that no party (nor any person acting on its behalf) has made any representation or other inducement to it to enter into this deed, except for representations or inducements expressly set out in this deed and (to the maximum extent permitted by law) all other representations, warranties and conditions implied by statute or otherwise in relation to any matter relating to this deed, the circumstances surrounding the parties’ entry into it and the transactions contemplated by it are expressly excluded.






(b)      Each party acknowledges that it has performed its own searches, enquiries, investigations and evaluations prior to entering into this deed and has formed its own views on the Transaction, with no targets, projections, forecasts or other forward looking statements having been relied on by that party.
(c)      Each party acknowledges and confirms that it does not enter into this deed in reliance on any representation or other inducement by or on behalf of any other party, except for any representation or inducement expressly set out in this deed.
16.12.      Rules of construction
No term or condition of this deed will be construed adversely to a party solely on the ground that the party was responsible for the preparation of this deed or a provision of it.
16.13.      Governing law and jurisdiction
(a)      This deed is governed by the laws of New South Wales, Australia.
(b)      Each party irrevocably submits to the non-exclusive jurisdiction of the courts of New South Wales and courts competent to hear appeals from those courts.
16.14.      Service of process
(a)      Without preventing any other mode of service, any document in an action (including any writ of summons or other originating process or any third or other party notice) may be served on any party by being delivered to or left for that party at its address for service of notices under clause 15.
(b)      The Bidder irrevocably appoints Norose Notices Australia Pty Ltd ACN 158 029 586 of Level 16, ‘Grosvenor Place’, 225 George Street, Sydney, NSW 2000 as its process agent to receive any document in any action in connection with this deed and agrees that failure by a process agent to notify the Bidder of any document in an action in connection with this deed does not invalidate the action concerned.
(c)      If Norose Notices Australia Pty Ltd ceases to be able to act as such, the Bidder agrees to appoint a new process agent in Australia and deliver to Sirtex within 1 Business Day a copy of a written acceptance of appointment by the process agent, upon receipt of which the new appointment becomes effective for the purpose of this deed. The Bidder must inform Sirtex in writing of any change in the address of its process agent within 1 Business Day of the change.









Schedule 1
Bidder Representations and Warranties

(a)      status : the Bidder and the Bidder Nominee (if any) has been incorporated or formed in accordance with the laws of its place of incorporation;
(b)      power : the Bidder has power to enter into this deed, to comply with its obligations under it and exercise its rights under it;
(c)      corporate authorisations : the Bidder has taken all necessary corporate action to authorise the entry into and the performance of this deed and to carry out the transactions contemplated by this deed;
(d)      no contravention : the entry by the Bidder into, its compliance with its obligations and the exercise of its rights under, this deed do not and will not conflict with:
(i)      its constituent documents or cause a limitation on its powers or the powers of its directors to be exceeded; or
(ii)      any law binding on it;
(e)      authorisations : the Bidder has in full force and effect each authorisation necessary for it to enter into this deed, to comply with its obligations and exercise its rights under it, and to allow them to be enforced;
(f)      validity of obligations : the obligations of the Bidder under this deed are valid and binding and are enforceable against it in accordance with its terms;
(g)      reliance : the Bidder Information provided to Sirtex for inclusion in the Scheme Booklet will be provided in good faith and on the understanding that Sirtex and its directors will rely on that information for the purposes of preparing the Scheme Booklet and proposing and implementing the Scheme in accordance with the Corporations Act;
(h)      Bidder Information : the Bidder Information provided in accordance with this deed and included in the Scheme Booklet, as at the date of the Scheme Booklet, will not contain any statement which is misleading or deceptive in any material respect nor contain any material omission having regard to applicable disclosure requirements and will comply in all material respects with the requirements of the Corporations Act, the Listing Rules and all relevant regulatory guides and other guidelines and requirements of ASIC;
(i)      information provided to the Independent Expert : all information provided by the Bidder to the Independent Expert will be provided in good faith and on the understanding that the Independent Expert will rely on that information for the purposes of preparing the Independent Expert’s Report for inclusion in the Scheme Booklet;
(j)      opinions : any statement of opinion or belief contained in the Bidder Information or provided by the Bidder to the Independent Expert is honestly held and there are reasonable grounds for holding the opinion or belief;
(k)      insolvency event : no member of the Bidder Group is subject to, or has suffered, an Insolvency Event;
(l)      Sirtex Shareholding : neither the Bidder nor any of its associates has a relevant interest in any Sirtex Shares;
(m)      no dealing with Sirtex Shareholders : neither the Bidder nor any of its associates has any agreement, arrangement or understanding with any Sirtex Shareholder under which that Sirtex Shareholder (or an associate of that Sirtex Shareholder) would be entitled to receive consideration for their Sirtex Shares different from the Scheme Consideration or under which the Sirtex Shareholder agrees to vote in favour of the Scheme or against any Competing Proposal;




2



(n)      reasonable basis : it has a reasonable basis to expect that it will, by the Implementation Date, have available to it sufficient cash amounts (whether from internal cash reserves or external funding arrangements, including equity and debt financing or a combination of both) to satisfy Bidder’s obligations to pay the Scheme Consideration in accordance with its obligations under this deed, the Scheme and the Deed Poll;
(o)      regulatory approvals : no regulatory approval is required to be obtained by Bidder in order for it to execute, deliver and perform this deed, other than those approvals set out in clause 3.1, and as at the date of this deed no regulatory action of any nature has been taken that would prevent or restrict its ability to fulfil its obligations under this deed; and
(p)      Bidder Nominee : if the Bidder has nominated a Bidder Nominee, the Bidder Nominee is a wholly owned subsidiary of the Bidder.











Schedule 2
Sirtex Representations and Warranties

(a)      status : it has been incorporated or formed in accordance with the laws of its place of incorporation;
(b)      power : it has power to enter into this document, to comply with its obligations under it and exercise its rights under it;
(c)      corporate authorisations : Sirtex has taken all necessary corporate action to authorise the entry into and the performance of this deed and to carry out the transactions contemplated by this deed;
(d)      no contravention : the entry by it into, its compliance with its obligations and the exercise of its rights under, this document do not and will not conflict with:
(i)      its constituent documents or cause a limitation on its powers or the powers of its directors to be exceeded; or
(ii)      any law binding on it;
(e)      authorisations : it has in full force and effect each authorisation necessary for it to enter into this document, to comply with its obligations and exercise its rights under it, and to allow them to be enforced;
(f)      validity of obligations : its obligations under this document are valid and binding and are enforceable against it in accordance with its terms;
(g)      reliance : the Sirtex Information contained in the Scheme Booklet will be included in good faith and on the understanding that Bidder and its directors will rely on that information for the purposes of considering and approving the Bidder Information in the Scheme Booklet before it is despatched, approving the entry into the Deed Poll and implementing the Scheme;
(h)      Sirtex Information : the Sirtex Information provided in accordance with this document and included in the Scheme Booklet as at the date of the Scheme Booklet will not contain any statement which is misleading or deceptive in any material respect nor contain any material omission having regard to applicable disclosure requirements and will comply in all material respects with the requirements of the Corporations Act, the Listing Rules and all relevant regulatory guides and other guidelines and requirements of ASIC;
(i)      Information provided to the Independent Expert : all information provided by Sirtex to the Independent Expert will be provided in good faith and on the understanding that the Independent Expert will rely on that information for the purpose of preparing the Independent Expert’s Report for inclusion in the Scheme Booklet;
(j)      opinions : any statement of opinion or belief contained in the Sirtex Information or provided by Sirtex to the Independent Expert is honestly held and there are reasonable grounds for holding the opinion or belief;
(k)      compliance : the Sirtex Group has complied in all material respects with all Australian and foreign laws and regulations applicable to them and orders of Australian and foreign governmental agencies having jurisdiction over it and has all material licenses, permits and franchises necessary for it to conduct its businesses as presently being conducted;
(l)      insolvency event : no member of the Sirtex Group is subject to, or has suffered, an Insolvency Event;
(m)      capital structure : Sirtex’s capital structure (including all issued securities) as at the date of this deed is as set out in Schedule 4 and, as at the date of this deed, it has not issued or agreed to issue any other securities, options, performance rights or instruments which are still outstanding or which may convert into Sirtex Shares other than as set out in Schedule 4;




2



(n)      continuous disclosure : Sirtex has complied in all material respects with its continuous disclosure obligations under ASX Listing Rule 3.1. There is no information that Sirtex is withholding pursuant to a carve-out under ASX Listing Rule 3.1 (other than the fact of its discussions with the Bidder in relation to the ownership of Sirtex) that has not been disclosed to the Bidder or its Representatives; and
(o)      disclosure : the Disclosure Materials were prepared, compiled and made available to Bidder and its Representatives in good faith and to the best of Sirtex’s knowledge the Disclosure Materials are not misleading or deceptive in any material respect (whether by way of omission or otherwise).










Schedule 3

Prescribed Occurrences

(a)      Sirtex converts all or any of its shares into a larger or smaller number of shares;
(b)      a member of the Sirtex Group resolves to reduce its share capital in any way;
(c)      a member of the Sirtex Group:
(i)      enters into a buy-back agreement; or
(ii)      resolves to approve the terms of a buy-back agreement under the Corporations Act;
(d)      a member of the Sirtex Group issues shares, or grants an option over its shares, or agrees to make such an issue or grant such an option, other than the issue of up to 825,954 fully paid ordinary shares to the holders as at the date of this deed of Sirtex Rights in accordance with the terms of those Sirtex Rights (including as a result of an exercise of a discretion vested in Sirtex or the Board in those terms);
(e)      a member of the Sirtex Group issues, or agrees to issue, convertible notes;
(f)      a member of the Sirtex Group disposes, or agrees to dispose, of the whole, or a substantial part, of its business or property;
(g)      a member of the Sirtex Group grants, or agrees to grant, a security interest in the whole, or a substantial part, of its business or property;
(h)      a member of the Sirtex Group pays, or agrees to pay, any of its directors, officers, employees or contractors a termination or retention payment (other than in accordance with contractual arrangements in effect on the date of this deed which have been Disclosed);
(i)      a member of the Sirtex Group resolves to be wound up;
(j)      a liquidator or provisional liquidator of a member of a member of the Sirtex Group is appointed;
(k)      a court makes an order for the winding up of a member of the Sirtex Group;
(l)      an administrator of a member of the Sirtex Group is appointed under sections 436A, 436B or 436C of the Corporations Act;
(m)      a member of the Sirtex Group executes a deed of company arrangement; or
(n)      a receiver, or a receiver and manager, is appointed in relation to the whole, or a substantial part, of a member of the Sirtex Group.










Schedule 4

Sirtex Capital Structure

Security
Number on issue at date of this deed
Sirtex Shares
55,773,045
Sirtex Rights
825,954, comprising:
•     129,744 Sirtex Rights issued in CY15 (with a vesting date of 30 June 2018);
•     206,686 Sirtex Rights issued in CY16 (with a vesting date of 30 June 2019); and
•     489,524 Sirtex Rights issued in CY17 (with a vesting date of 30 June 2020).









EXECUTED by the parties as a deed:
SIGNED, SEALED & DELIVERED by
Sirtex Medical Limited
(ABN 35 078 166 122)
in accordance with section 127 of the Corporations Act:
)
)
)
)
)
 
/s/ John A. Eady
 
/s/ Andrew McLean
Director/Secretary
 
Director
John A. Eady
 
Andrew McLean
Name (please print)
 
Name (please print)



SIGNED, SEALED & DELIVERED by
Varian Medical Systems, Inc.
by its duly authorised representative in the presence of:
)
)
)
)
 
/s/ Gary E. Bischoping
 
/s/ Dow R. Wilson
Witness
 
Authorised Representative
Gary E. Bischoping
 
Dow R. Wilson
Name (please print)
 
Name (please print)











Annexure A
Indicative Timetable

Event
 
Target date
Announcement
 
30 January 2018
First complete draft of Scheme Booklet (including expert’s report)
 
5 March 2018
Scheme Booklet complete and provided to ASIC
 
12 March 2018
First Court hearing
 
29 March 2018
Mailing of Scheme Booklet complete
 
5 April 2018
Scheme Meeting
 
7 May 2018
Second Court hearing
 
9 May 2018
Effective Date
 
10 May 2018
Record Date
 
17 May 2018
Implementation Date
 
24 May 2018





Annexure B
Scheme of Arrangement
 
VARIANSCHEMEIMPLDEEDW_IMAGE1.JPG
Scheme of Arrangement

Dated
 
Sirtex Medical Limited
(ABN 35 078 166 122)

Scheme Shareholders





































 
Watson Mangioni Lawyers Pty Limited
Corporate and Commercial Lawyers
Level 23, 85 Castlereagh Street
SYDNEY NSW 2000
Tel: (02) 9262 6666
Fax: (02) 9262 2626
Email: mail@wmlaw.com.au  
Ref: CSC 217 7345






Table of Contents

1.
Definitions and Interpretation
 
2.
Preliminary
 
3.
Conditions Precedent
 
4.
Scheme
 
5.
Implementation of Scheme
 
6.
Scheme Consideration
 
7.
Dealings in Scheme Shares
 
8.
Quotation of Sirtex Shares
 
9.
General Scheme Provisions
 







Scheme of Arrangement under Part 5.1 of the Corporations Act 2001 (Cth).

Parties:
1.
Sirtex Medical Limited (ABN 35 078 166 122) of Level 33, 101 Miller Street, North Sydney NSW 2060, Australia ( Sirtex );
2.
Each person registered as a holder of fully paid ordinary shares in Sirtex as at the Record Date ( Scheme Shareholders ).

1.
Definitions and Interpretation

1.1
Definitions

In this Scheme:
ASIC means the Australian Securities and Investments Commission.
ASX means ASX Limited (ABN 98 008 624 691) or the securities market operated by it, as the context requires.
ASX Listing Rules means the official listing rules of the ASX.
Bidder means Varian Medical Systems, Inc. of 3100 Hansen Way, Palo Alto, CA 94304-1038, United States.
Bidder Nominee has the meaning given to that term in clause 2.3(a) of this Scheme.
Business Day means a business day as defined in the ASX Listing Rules.
CHESS means the clearing house electronic subregister system of share transfers operated by ASX Settlement Pty Limited (ABN 49 008 504 532).
Corporations Act means the Corporations Act 2001 (Cth) .
Court means the Federal Court of Australia (NSW registry) or such other court of competent jurisdiction under the Corporations Act agreed to in writing between Sirtex and the Bidder.
Deed Poll means the deed poll dated [ insert ] 2018 executed by the Bidder substantially in the form of Annexure C of the Scheme Implementation Deed or as otherwise agreed by Sirtex and the Bidder under which the Bidder covenants in favour of each Scheme Shareholder to perform its obligations under this Scheme.
Effective means the coming into effect under section 411(10) of the Corporations Act of the order of the Court made under section 411(4)(b) in relation to this Scheme.
Effective Date means the date on which the Scheme becomes Effective.
Encumbrance means any security for payment of money or performance of obligations, including a mortgage, lien, charge, pledge, trust, power or title retention or flawed deposit arrangement and any “security interest” as defined in sections 12(1) or 12(2) of the Personal Property Securities Act 2009 (Cth) or any agreement to create any of them or allow them to exist.
End Date means 31 July 2018 or such other date as is agreed in writing between Sirtex and the Bidder.
Government Agency means any government or any governmental, semi-governmental, statutory or judicial entity, agency or authority, whether in Australia, the United States of America or elsewhere, including any self-regulatory organisation established under statute or otherwise discharging substantially public or regulatory functions, and the ASX or any other stock exchange.
Implementation Date means the fifth Business Day after the Record Date or such other date as agreed in writing between Sirtex and the Bidder.
Record Date means 7pm on the fifth Business Day following the Effective Date or such other date as Sirtex and the Bidder agree.
Registered Address means, in relation to a Sirtex Shareholder, the address shown in the Share Register.






Scheme means this scheme of arrangement between Sirtex and the Scheme Shareholders under which all of the Scheme Shares will be transferred to the Bidder (or if applicable, the Bidder Nominee) under Part 5.1 of the Corporations Act as described in clause 6 of this Scheme, in consideration for the Scheme Consideration, subject to any amendments or conditions made or required by the Court pursuant to section 411(6) of the Corporations Act to the extent they are approved in writing by Sirtex and the Bidder in accordance with clause 9.2 of this Scheme.
Scheme Consideration means $28.00 cash per Scheme Share.
Scheme Implementation Deed means the scheme implementation deed dated 30 January 2018 between Sirtex and the Bidder under which, amongst other things, Sirtex has agreed to propose this Scheme to Sirtex Shareholders and each of the Bidder and Sirtex has agreed to take certain steps to give effect to this Scheme.
Scheme Meeting means the meeting of Sirtex Shareholders ordered by the Court to be convened under section 411(1) of the Corporations Act at which Sirtex Shareholders will vote on this Scheme.
Scheme Share means a Sirtex Share held by a Scheme Shareholder at the Record Date.
Scheme Share Transfer means, for each Scheme Shareholder, a duly completed and executed proper instrument of transfer of the Scheme Shares held by that Scheme Shareholder for the purposes of section 1071B of the Corporations Act, which may be a master transfer of all Scheme Shares.
Scheme Shareholders means Sirtex Shareholders at the Record Date.
Second Court Date means the first day on which an application made to the Court for an order under section 411(4)(b) of the Corporations Act approving the Scheme is heard or, if the application is adjourned or subject to appeal for any reason, the day on which the adjourned application is heard.
Share Register means the register of members of Sirtex maintained in accordance with the Corporations Act.
Sirtex Registry means     Link Market Services Limited (ABN 54 083 214 537).
Sirtex Share means a fully paid ordinary share in the capital of Sirtex.
Sirtex Shareholder means each person who is registered in the Share Register as the holder of Sirtex Shares.
Trust Account means the trust account operated by or on behalf of Sirtex to hold the Scheme Consideration on trust for the purpose of paying the Scheme Consideration to the Scheme Shareholders in accordance with clause 6.1 of this Scheme.
1.2
Interpretation
In this Scheme, headings are for convenience only and do not affect interpretation and, unless the context requires otherwise:
(a)
words importing the singular include the plural and vice versa;
(b)
words importing a gender include any gender;
(c)
other parts of speech and grammatical forms of a word or phrase defined in this Scheme have a corresponding meaning;
(d)
a reference to a person includes an individual, the estate of an individual, a corporation, an authority, an association or a joint venture, a partnership, a trust and any Government Agency;
(e)
a reference to a clause, party, attachment, exhibit or schedule is a reference to a clause of, and a party, attachment, exhibit and schedule to this Scheme, and a reference to this Scheme includes any attachment, exhibit and schedule;
(f)
a reference to a statute, regulation, proclamation, ordinance or by law includes all statutes, regulations, proclamations, ordinances or by laws amending, consolidating or replacing it, whether passed by the same or another Government Agency with legal power to do so, and a reference to a statute includes all regulations, proclamations, ordinances and by laws issued under that statute;
(g)
a reference to any document (including this Scheme) is to that document as varied, novated, ratified or replaced from time to time;
(h)
the word “includes” in any form is not a word of limitation;






(i)
a reference to “$”, “A$” or “dollar” is to Australian currency;
(j)
a reference to any time is, unless otherwise indicated, a reference to the time in Sydney, New South Wales, Australia;
(k)
a period of time dating from a given day or the day of an act or event, is to be calculated exclusive of that day;
(l)
a day is to be interpreted as the period of time commencing at midnight and ending 24 hours later;
(m)
a reference to “associate”, “control” (by an entity of another entity), “officer”, “related body corporate”, “subsidiary”, “relevant interest” or “voting power” is to that term as defined in the Corporations Act;
(n)
a reference to the ASX Listing Rules includes any variation, consolidation or replacement of these rules and is to be taken to be subject to any waiver or exemption granted to the compliance of those rules by a party.

1.3
Business Day

Where the day on or by which any thing is to be done is not a Business Day, that thing must be done on or by the next Business Day.
1.4    Listing requirements included as law
A listing rule or business rule of a securities exchange will be regarded as a ”law”, and a reference to such a rule is to be taken to be subject to any waiver or exemption granted to the compliance of those rules by a party.

2.    Preliminary
2.1    Sirtex
(a)    Sirtex is:
(i)
a public company limited by shares;
(ii)
incorporated in Australia and registered in Western Australia; and
(iii)
admitted to the official list of the ASX and Sirtex Shares are officially quoted on the stock market conducted by ASX.
(b)    As at [ date ] 2018, [ insert ] Sirtex Shares were on issue.
2.2
The Bidder
The Bidder is a company incorporated in Delaware, United States.
2.3
Bidder Nominee
(a)
Pursuant to clause 2.2 of the Scheme Implementation Deed, the Bidder may nominate a wholly owned Subsidiary of the Bidder ( Bidder Nominee ) to pay the Scheme Consideration and to which the Scheme Shares are to be transferred in accordance with clause 5 of this Scheme.
(b)
If the Bidder nominates a Bidder Nominee, then clause 2.2 of the Scheme Implementation Deed provides that:
(i)
the Bidder must procure that the Bidder Nominee complies with the Scheme Implementation Deed as if the Bidder Nominee were a party to it in place of the Bidder; and
(ii)
any such nomination will not relieve the Bidder of its obligations under the Scheme Implementation Deed, including the obligation to pay (or procure the payment by Bidder Nominee of) the Scheme Consideration as contemplated by the terms of this Scheme.
2.4
If Scheme becomes Effective
If this Scheme becomes Effective:






(a)
in consideration of the transfer of each Scheme Share to the Bidder (or if applicable, the Bidder Nominee), the Bidder will provide (or procure the Bidder Nominee to provide) the Scheme Consideration to Sirtex on behalf of each Scheme Shareholder in accordance with the terms of this Scheme;
(b)
all Scheme Shares will be transferred to the Bidder (or if applicable, the Bidder Nominee) on the Implementation Date; and
(c)
Sirtex will enter the name of the Bidder (or if applicable, the Bidder Nominee) in the Share Register in respect of all Scheme Shares transferred to the Bidder (or if applicable, the Bidder Nominee) in accordance with the terms of this Scheme.
2.5    Scheme Implementation Deed
Sirtex and the Bidder have agreed by executing the Scheme Implementation Deed to implement the terms of this Scheme.
2.6    Deed Poll
The Bidder has executed the Deed Poll for the purpose of covenanting in favour of the Scheme Shareholders to perform (or procure the performance of) its obligations as contemplated by this Scheme, including to provide (or procure the provision of) the Scheme Consideration.

3.    Conditions Precedent
3.1    Conditions precedent to Scheme
This Scheme is conditional on, and will not become Effective until, the satisfaction of each of the following conditions precedent:
(a)
as at 8am on the Second Court Date, neither the Deed Poll nor the Scheme Implementation Deed have been terminated in accordance with their terms;
(b)
all of the conditions precedent in clause 3.1 of the Scheme Implementation Deed having been satisfied or waived (other than the condition precedent in clause 3.1(c) of this Scheme) in accordance with the terms of the Scheme Implementation Deed by 8am on the Second Court Date;
(c)
the Court having approved this Scheme, with or without any modification or condition, pursuant to section 411(4)(b) of the Corporations Act, and if applicable, Sirtex and the Bidder having accepted in writing any modification or condition made or required by the Court under section 411(6) of the Corporations Act; and
(d)
the coming into effect, pursuant to section 411(10) of the Corporations Act, of the orders of the Court made under section 411(4)(b) of the Corporations Act (and, if applicable, section 411(6) of the Corporations Act) in relation to this Scheme.
3.2    Conditions precedent and operation of clause 5
The satisfaction of each condition of clause 3.1 of this Scheme is a condition precedent to the operation of clause 5 of this Scheme.
3.3    Certificate in relation to conditions precedent
(a)
Each of Sirtex and the Bidder must provide to the Court on the Second Court Date a certificate confirming (in respect of matters within their knowledge) whether or not all of the conditions precedent set out in clause 3.1 of this Scheme (other than the conditions precedent in clause 3.1(c) and clause 3.1(d) of this Scheme) have been satisfied or waived as at 8am on the Second Court Date.
(b)
The certificates referred to in clause 3.3(a) will constitute conclusive evidence of whether the conditions precedent referred to in clause 3.1 of this Scheme (other than the conditions precedent in clause 3.1(c) and 3.1(d) of this Scheme) have been satisfied or waived as at 8am on the Second Court Date.






4.    Scheme
4.1    Effective Date
Subject to clause 4.2, this Scheme will come into effect pursuant to section 411(10) of the Corporations Act on and from the Effective Date.
4.2    Termination and End Date
Without limiting any rights under the Scheme Implementation Deed, if:
(a)
the Scheme Implementation Deed or the Deed Poll is terminated in accordance with its terms before the Scheme becomes Effective; or
(b)    the Effective Date does not occur on or before the End Date,
then each of the Bidder (and if applicable the Bidder Nominee) and Sirtex are released from any further obligation to take steps to implement the Scheme.

5.    Implementation of Scheme
5.1    Lodgement of Court orders with ASIC
If the conditions precedent set out in clause 3.1 of this Scheme (other than the condition precedent in clause 3.1(d) of this Scheme) are satisfied, Sirtex must lodge with ASIC in accordance with section 411(10) of the Corporations Act an office copy of the Court order approving this Scheme as soon as possible, and in any event by no later than 5pm on the first Business Day after the day on which the Court approves this Scheme or such later time as the Bidder and Sirtex agree in writing.
5.2    Transfer and registration of Sirtex Shares
On the Implementation Date, but subject to the payment of the Scheme Consideration for the Scheme Shares into the Trust Account in accordance with clause 6.1(a) of this Scheme and the Bidder having provided Sirtex with written confirmation thereof:
(a)
the Scheme Shares, together with all rights and entitlements attaching to the Scheme Shares as at the Implementation Date, will be transferred to the Bidder (or if applicable, the Bidder Nominee) without the need for any further act by any Scheme Shareholder (other than acts performed by Sirtex as attorney and agent for Scheme Shareholders under clause 9.1 of this Scheme) by:
(iv)
Sirtex delivering to the Bidder (or if applicable, the Bidder Nominee) a duly completed and executed Scheme Share Transfer executed on behalf of the Scheme Shareholders; and
(v)
the Bidder (or if applicable, the Bidder Nominee) duly executing the Scheme Share Transfer, attending to the stamping of the Scheme Share Transfer (if required) and delivering it to Sirtex for registration; and
(b)
as soon as practicable after receipt of the duly executed Scheme Share Transfer, Sirtex must enter, or procure the entry of, the name of the Bidder (or if applicable, the Bidder Nominee) in the Share Register in respect of all Scheme Shares transferred to the Bidder (or if applicable, the Bidder Nominee) in accordance with the terms of this Scheme.
5.3    Entitlement to Scheme Consideration
On the Implementation Date, in consideration for the transfer to the Bidder (or if applicable, the Bidder Nominee) of the Scheme Shares, each Scheme Shareholder will be entitled to receive the Scheme Consideration in respect of each of their Scheme Shares in accordance with clause 6 of this Scheme.
5.4    Title and rights in Sirtex Shares
Subject to the provision of the Scheme Consideration for the Scheme Shares as contemplated by clause 6 of this Scheme, on and from the Implementation Date, the Bidder (or if applicable, the Bidder Nominee) will be beneficially entitled to the Scheme Shares transferred to it under the Scheme, pending registration by Sirtex of the Bidder (or if applicable, the Bidder Nominee) in the Share Register as the holder of the Scheme Shares.






5.5    Scheme Shareholders’ agreements
Under this Scheme, each Scheme Shareholder agrees to the transfer of their Scheme Shares, together with all rights and entitlements attaching to those Scheme Shares, in accordance with the terms of this Scheme.
5.6    Warranty by Scheme Shareholders
Each Scheme Shareholder warrants to the Bidder (or if applicable, the Bidder Nominee), and is deemed to have authorised Sirtex to warrant to the Bidder as agent and attorney for the Scheme Shareholder by virtue of this clause 5.6, that:
(a)
all their Scheme Shares (including any rights and entitlements attaching to those Scheme Shares) transferred to the Bidder (or if applicable, the Bidder Nominee) under the Scheme will, as at the date of the transfer, be fully paid and free from all Encumbrances; and
(b)
they have full power and capacity to sell and to transfer their Scheme Shares (including any rights and entitlements attaching to those Scheme Shares) to the Bidder (or if applicable, the Bidder Nominee) under the Scheme.
5.7    Transfer free of Encumbrances
To the extent permitted by law, all Sirtex Shares (including any rights and entitlements attaching to those Scheme Shares) which are transferred to the Bidder (or if applicable, the Bidder Nominee) under this Scheme will, at the date of the transfer of them to the Bidder (or if applicable, the Bidder Nominee), vest in the Bidder (or if applicable, the Bidder Nominee) free from all Encumbrances and interests of third parties of any kind, whether legal or otherwise, and free from any restrictions on transfer of any kind not referred to in this Scheme.
5.8    Appointment of the Bidder as sole proxy
Subject to the provision of the Scheme Consideration for the Scheme Shares as contemplated by clause 6.1 of this Scheme, on and from the Implementation Date until Sirtex registers the Bidder (or if applicable, the Bidder Nominee) as the holder of all of the Sirtex Shares in the Share Register, each Scheme Shareholder:
(a)
irrevocably appoints Sirtex as attorney and agent (and directs Sirtex in such capacity) to appoint the Bidder (or if applicable, the Bidder Nominee) and each of its directors from time to time (jointly and each of them individually) as its sole proxy and where applicable, corporate representative, to attend shareholders’ meetings, exercise the votes attaching to Sirtex Shares registered in its name and sign any shareholders resolution, and no Scheme Shareholder may itself attend or vote at any of those meetings or sign any resolutions, whether in person, by proxy or by corporate representative (other than pursuant to this clause 5.8(a));
(b)
must take all other actions in the capacity of the registered holder of Sirtex Shares as the Bidder (or if applicable, the Bidder Nominee) reasonably directs;
(c)
acknowledges and agrees that in exercising the powers referred to in this clause 5.8(a), the Bidder and any director, officer or agent nominated under this clause 5.8(a) may act in the best interests of the Bidder as the intended registered holder of the Scheme Shares.
Sirtex undertakes in favour of each Scheme Shareholder that it will appoint the Bidder (or if applicable, the Bidder Nominee) and each of its directors from time to time (jointly and each of them individually) as that Scheme Shareholder’s proxy or, where applicable, corporate representative in accordance with clause 5.8(a) of this Scheme.

6.    Scheme Consideration
6.1    Payment of Scheme Consideration
(a)
The Bidder must (pursuant to its obligations under the Deed Poll), by no later than the Business Day before the Implementation Date, deposit (or procure the deposit) in cleared funds the aggregate amount of the Scheme Consideration payable to all Scheme Shareholders into the Trust Account.
(b)
On the Implementation Date, subject to receipt of the Scheme Consideration from or on behalf of the Bidder (or the Bidder Nominee) in accordance with clause 6.1(a) of this Scheme, Sirtex






must pay from the Trust Account to each Scheme Shareholder an amount equal to the Scheme Consideration for each Scheme Share transferred to the Bidder (or if applicable, the Bidder Nominee) on the Implementation Date by that Scheme Shareholder, which obligation will be satisfied by Sirtex:
(i)
where a Scheme Shareholder has, before the Record Date, made an election in accordance with the requirements of the Share Register to receive dividend payments from Sirtex by electronic funds transfer to a bank account nominated by the Scheme Shareholder, paying, or procuring the payment of, the relevant amount in Australian currency by electronic means in accordance with that election; or
(ii)
whether or not a Scheme Shareholder has made an election referred to in clause 6.1(b)(i), dispatching, or procuring the dispatch of, a cheque drawn on an Australian bank in Australian currency for the relevant amount to the Scheme Shareholder by pre-paid ordinary post (or, if the address of the Scheme Shareholder in the Share Register is outside Australia, by pre-paid airmail post) to their Registered Address at the Record Date, such cheque being drawn in the name of the Scheme Shareholder (or in the case of joint holders, in accordance with clause 6.5).
(c)
If there is any surplus in the amount held by Sirtex in the Trust Account, that surplus must be paid by Sirtex to the Bidder following the satisfaction of Sirtex’s obligations under this clause.
6.2
Cancellation and re-issue of cheques
(a)    Sirtex may cancel a cheque issued under clause 6.1 of this Scheme if the cheque:
(i)    is returned to Sirtex; or
(ii)
has not been presented for payment within 6 months after the date on which the cheque was sent.
(b)
During the period of one year commencing on the Implementation Date, on request from a Scheme Shareholder (which request may not be made until the date which is 5 Business Days after the Implementation Date), Sirtex must reissue a cheque that was previously cancelled under this clause 6.2.
(c)
Sirtex must maintain appropriate records of all payments made in accordance with this clause 6 of this Scheme, including (amongst other things) the amounts paid (including the method of payment in accordance with clause 6.1(b)), the persons paid and any cancelled cheques pursuant to this clause 6.2.
6.3    Unclaimed monies
(a)
The Unclaimed Money Act 1995 (NSW) will apply in relation to any Scheme Consideration which becomes “unclaimed money” (as defined in section 7 of the Unclaimed Money Act 1995 (NSW)).
(b)
Any interest or other benefit accruing from unclaimed Scheme Consideration will be to the benefit of the Bidder.
6.4    Orders of a court
In the case of notice having been given to Sirtex (or the Sirtex Registry) of an order or direction made by a court of competent jurisdiction or by a Government Agency:
(a)
which requires payment to a third party of a sum in respect of Scheme Shares held by a particular Scheme Shareholder, which would otherwise be payable to that Scheme Shareholder in accordance with clause 6.1 of this Scheme, then Sirtex shall procure that payment is made in accordance with that order; or
(b)
which would prevent Sirtex from dispatching payment to any particular Scheme Shareholder in accordance with clause 6.1 of this Scheme, or such payment is otherwise prohibited by applicable law, Sirtex will be entitled to retain an amount, in Australian dollars, equal to the number of Scheme Shares held by that Scheme Shareholder multiplied by the Scheme Consideration until such time as payment in accordance with clause 6.1 of this Scheme is permitted by law.
6.5    Joint holders
In the case of Scheme Shares held in joint names, any bank cheque required to be paid to Scheme Shareholders by or on behalf of the Bidder must be payable to the joint holders and be forwarded to the holder whose name appears first in the Share Register as at the Record Date.







7.    Dealings in Scheme Shares
7.1    Determination of Scheme Shareholders
To establish the identity of the Scheme Shareholders, dealings in Scheme Shares will only be recognised by Sirtex if:
(a)    in the case of dealings of the type to be effected using CHESS, the transferee is registered in the Share Register as the holder of the relevant Scheme Shares on or before the Record Date; and
(b)    in all other cases, registrable transmission applications or transfers in registrable form in respect of those dealings are received on or before the Record Date at the place where the Share Register is kept.
7.2    Share Register
Sirtex must register any registrable transmission applications or transfers of the Scheme Shares received in accordance with clause 7.1(b) of this Scheme on or before the Record Date, provided that nothing in this clause 7.2 requires Sirtex to register a transfer that would result in a Sirtex Shareholder holding a parcel of Sirtex Shares that is less than a “marketable parcel” (as defined in the operating rules of ASX).
7.3    No disposals after Effective Date
(a)
If this Scheme becomes Effective, a holder of Scheme Shares (and any person claiming through that holder) must not dispose of or purport or agree to dispose of any Scheme Shares or any interest in them after the Effective Date in any way except as set out in this Scheme and any such disposal will be void and of no legal effect whatsoever.
(b)
Sirtex will not accept for registration or recognise for any purpose any transmission, application or transfer in respect of Scheme Shares received after the Record Date (except a transfer to the Bidder (or if applicable, the Bidder Nominee) pursuant to this Scheme and any subsequent transfer by the Bidder (or if applicable, the Bidder Nominee) or its successors in title) or received prior to the Record Date but not in registrable or actionable form.
7.4    Maintenance of Share Register
For the purpose of determining entitlements to the Scheme Consideration, Sirtex will maintain the Share Register in accordance with the provisions of this clause 7 until the Scheme Consideration has been paid to the Scheme Shareholders and the Bidder (or if applicable, the Bidder Nominee) has been entered in the Share Register as the holder of all the Scheme Shares. The Share Register in this form will solely determine entitlements to the Scheme Consideration.
7.5    Effect of certificates and holding statements
Subject to provision of the Scheme Consideration and registration of the transfer to the Bidder (or if applicable, the Bidder Nominee) contemplated in clauses 5.2 and 6.1 of this Scheme, any statements of holding in respect of Scheme Shares will cease to have effect after the Record Date as documents of title in respect of those Scheme Shares (other than statements of holding in favour of the Bidder (or if applicable, the Bidder Nominee) and its successors in title). After the Record Date, each entry current on the Share Register as at the Record Date (other than entries in respect of the Bidder (or if applicable, the Bidder Nominee) or its successors in title) will cease to have effect except as evidence of entitlement to the Scheme Consideration.
7.6    Details of Scheme Shareholders
Within 3 Business Days after the Record Date Sirtex will ensure that details of the names, Registered Addresses and holdings of Scheme Shares for each Scheme Shareholder, as shown in the Share Register at the Record Date, are available to the Bidder and its Bidder Nominee (if applicable) in such form as the Bidder reasonably requires.

8.    Quotation of Sirtex Shares
(a)
Suspension of trading on ASX in Sirtex Shares will occur from the close of trading on ASX on the Effective Date.
(b)    After the Scheme has been fully implemented, Sirtex will apply:






(i)    for termination of the official quotation of Sirtex Shares on the ASX; and
(ii)    to have itself removed from the official list of the ASX,
in each case with effect on and from the close of trading day immediately following, or shortly after, the Implementation Date, as determined by the Bidder.

9.    General Scheme Provisions
9.1    Power of attorney
Each Scheme Shareholder, without the need for any further act by any Scheme Shareholder, irrevocably appoints Sirtex and each of its directors and secretaries (jointly and each of them individually) as its attorney and agent for the purpose of:
(a)
executing any document necessary or expedient to give effect to this Scheme including the Scheme Share Transfer;
(b)
enforcing the Deed Poll against the Bidder (or if applicable, the Bidder Nominee), and Sirtex accepts such appointment.
9.2    Variations, alterations and conditions
Sirtex may, with the consent of the Bidder (or if applicable, the Bidder Nominee) (which cannot be unreasonably withheld), by its counsel or solicitor consent on behalf of all persons concerned to any variations, alterations or conditions to this Scheme which the Court thinks fit to impose.
9.3    Further action by Sirtex
Sirtex will execute all documents and do all things (on its own behalf and on behalf of each Scheme Shareholder) necessary or expedient to implement, and perform its obligations under, this Scheme.
9.4    Authority and acknowledgement
Each of the Scheme Shareholders:
(a)
irrevocably consents to Sirtex and the Bidder (or if applicable, the Bidder Nominee) doing all things necessary or expedient for or incidental to the implementation of this Scheme; and
(b)
acknowledges that this Scheme binds Sirtex and all Scheme Shareholders (including those who do not attend the Scheme Meeting or do not vote at that meeting or vote against the Scheme at the Scheme Meeting) and, to the extent of any inconsistency and to the extent permitted by law, overrides the constitution of Sirtex.
9.5    No liability when acting in good faith
Neither Sirtex nor the Bidder (and if applicable, the Bidder Nominee), nor any of their respective officers, will be liable for anything done or omitted to be done in the performance of this Scheme in good faith.
9.6    Enforcement of Deed Poll
Sirtex undertakes in favour of each Scheme Shareholder to enforce the Deed Poll against the Bidder on behalf of and as agent and attorney for the Scheme Shareholders.
9.7    Stamp duty and registration fees
The Bidder will:
(a)
pay all stamp duties, registration fees and similar taxes payable or assessed as being payable in connection with this Scheme or the Deed Poll (including any fees, fines, penalties and interest in connection with those amounts); and
(b)
indemnify each Scheme Shareholder against any liability incurred by the Scheme Shareholder arising from its failure to comply with clause 9.7(a).
9.8    Notices
(a)
If a notice, transfer, transmission application, direction or other communication referred to in this Scheme is sent by post to Sirtex, it will not be taken to be received in the ordinary course of post or on a date and time other than the date and time (if any) on which it is actually received at Sirtex’s registered office or at the office of the Registry.






(b)
The accidental omission to give notice of the Scheme Meeting or the non-receipt of such a notice by any Sirtex Shareholder shall not, unless so ordered by the Court, invalidate the Scheme Meeting or the proceedings of the Scheme Meeting.
9.9    Governing law and jurisdiction
(a)    This Scheme is governed by the law in force in New South Wales.
(b)    Each party irrevocably and unconditionally:
(i)    submits to the non-exclusive jurisdiction of the courts of that place; and
(ii)
waives, without limitation, any claim or objection based on absence of jurisdiction or inconvenient forum.






Annexure C
Deed Poll
 
VARIANSCHEMEIMPLDEEDW_IMAGE1.JPG
Deed Poll

Dated
 
Given by
Varian Medical Systems, Inc.

In favour of
Scheme Shareholders





Table of Contents

1.
Definitions and Interpretation
 
2.
Conditions Precedent and Termination
 
3.
Performance of Obligations Generally
 
4.
Scheme Consideration
 
5.
Representations and Warranties
 
6.
Continuing Obligations
 
7.
Notices
 
8.
General
 





This Deed Poll is made on     2018

Made by:
Varian Medical Systems, Inc. of 3100 Hansen Way, Palo Alto, CA 94304-1038, United States ( Bidder );
In favour of:
Each person registered as a holder of fully paid ordinary shares in Sirtex as at the Record Date ( Scheme Shareholders ).
Recitals:
A.
The directors of Sirtex have resolved that Sirtex should propose the Scheme.
B.      The effect of the Scheme will be that all Scheme Shares will be transferred to the Bidder (or if applicable, the Bidder Nominee).
C.      Sirtex and the Bidder have entered into the Scheme Implementation Deed.
D.      In the Scheme Implementation Deed, the Bidder has agreed (amongst other things) to provide the Scheme Consideration to Sirtex on behalf of the Scheme Shareholders, subject to the satisfaction of certain conditions.
E.      The Bidder is entering into this deed poll for the purpose of covenanting in favour of Scheme Shareholders to perform its obligations in relation to the Scheme.

1.      Definitions and Interpretation
1.1.      Definitions
In this deed poll:
(a)      Scheme means the proposed scheme of arrangement between Sirtex and the Scheme Shareholders under which all of the Scheme Shares will be transferred to the Bidder (or if applicable, the Bidder Nominee) under Part 5.1 of the Corporations Act, substantially in the form of Annexure A to this deed poll, or as otherwise agreed by Sirtex and the Bidder, subject to any amendments or conditions made or required by the Court pursuant to section 411(6) of the Corporations Act to the extent they are approved in writing by Sirtex and the Bidder in accordance with clause 9.2 of the Scheme;
(b)      Scheme Implementation Deed means the scheme implementation deed dated 30 January 2018 between Sirtex and the Bidder under which, amongst other things, Sirtex has agreed to propose the Scheme to Sirtex Shareholders and each of the Bidder and Sirtex has agreed to take certain steps to give effect to this Scheme; and
(c)      all other words and phrases used in this deed poll have the same meaning as given to them in the Scheme.
1.2.      Interpretation



Clauses 1.2, 1.3 and 1.4 of the Scheme apply to the interpretation of this deed poll except that references to “this Scheme” in that clause are to be read as references to “this deed poll” and any reference to “party” are taken to include the Scheme Shareholders.
1.3.      Nature of deed poll
The Bidder acknowledges and agrees that:
(a)      this deed poll may be relied on and enforced by any Scheme Shareholder in accordance with its terms even though the Scheme Shareholders are not party to it; and
(b)      under the Scheme, each Scheme Shareholder irrevocably appoints Sirtex and each of its directors, officers and secretaries (jointly and each of them severally) as its agent and attorney to enforce this deed poll against the Bidder.
2.      Conditions Precedent and Termination
2.1.      Conditions precedent
The Bidder’s obligations under clause 4 are subject to the Scheme becoming Effective.
2.2.      Termination
The Bidder’s obligations under this deed poll will automatically terminate and the terms of this deed poll will be of no further force or effect if:
(a)      the Scheme has not become Effective on or before the End Date; or
(b)      the Scheme Implementation Deed is terminated in accordance with its terms.
2.3.      Consequences of termination
If this deed poll is terminated under clause 2.2, then, in addition and without prejudice to any other rights, powers or remedies available to Scheme Shareholders:
(a)      the Bidder is released from its obligations to further perform this deed poll except those obligations contained in clause 8.1 and any other obligations which by their nature survive termination; and
(b)      each Scheme Shareholder retains the rights, powers or remedies they have against the Bidder in respect of any breach of this deed poll which occurs before it is terminated.
3.      Performance of Obligations Generally
The Bidder must comply with its obligations under the Scheme Implementation Deed and do all acts and things necessary or desirable on its part to give full effect to the Scheme.
4.      Scheme Consideration
4.1.      Scheme Consideration
Subject to clause 2, the Bidder undertakes in favour of each Scheme Shareholder to pay, or to procure the payment of, the Scheme Consideration to the Trust Account on behalf of each Scheme Shareholder subject to and in accordance with the terms of the Scheme.
4.2.      Manner of payment



Subject to clause 4.3, the Bidder’s obligation to provide, or procure the provision of, the Scheme Consideration to Sirtex on behalf of each Scheme Shareholder is satisfied by the Bidder (or if applicable, the Bidder Nominee), no later than the Business Day before the Implementation Date, depositing in cleared funds the aggregate amount of the Scheme Consideration payable to all Scheme Shareholders into the Trust Account (except that the amount of any interest (less bank fees and other charges) on the amount deposited will be to the Bidder’s account).
4.3.      Joint holders
In the case of Scheme Shares held in joint names, any bank cheque required to be paid to Scheme Shareholders by the Bidder (or if applicable, the Bidder Nominee) must be payable to the joint holders and be forwarded to the holder whose name appears first in the Share Register as at the Record Date.
5.      Representations and Warranties
The Bidder represents and warrants that:
(a)      it is a corporation validly existing under the laws of its place of registration;
(b)      it has the corporate power to enter into and perform its obligations under this deed poll and to carry out the transactions contemplated by this deed poll;
(c)      it has taken all necessary corporate action to authorise its entry into this deed poll and has taken or will take all necessary corporate action to authorise the performance of this deed poll and to carry out the transactions contemplated by this deed poll;
(d)      this deed poll is valid and binding upon the Bidder and enforceable against the Bidder in accordance with its terms;
(e)      this deed poll does not conflict with, or result in the breach of or default under, any provision of its constitution, or any writ, order or injunction, judgment, law, rule or regulation to which it is a party or subject or by which it is bound; and
(f)      it is solvent and no resolutions have been passed nor has any other step been taken or legal action or proceedings commenced or threatened against it for its winding up or dissolution or for the appointment of a liquidator, receiver, administrator or similar officer over any or all of its assets.
6.      Continuing Obligations
Subject to clause 8.3, this deed poll is irrevocable and, subject to clause 2, remains in full force and effect until:
(a)      the Bidder has fully performed its obligations under this deed poll; or
(b)      the earlier termination of this deed poll under clause 2.2.
7.      Notices
7.1.      Form
Unless this deed expressly states otherwise, all notices, demands, certificates, consents, approvals, waivers and other communications to the Bidder in connection with this deed must be in writing and signed by the sender (if an individual) or a person duly authorised by the sender.
7.2.      Delivery



Communications to the Bidder must be:
(a)      delivered by hand to the address of the Bidder referred to in clause 7.3;
(b)      sent by regular ordinary post (airmail if sent from one country to another) to the address of the Bidder referred to in clause 7.3; or
(c)      given in any other way permitted by law.
7.3.      Notice details
The notice details of the Bidder are:
Name:
Varian Medical Systems, Inc.
Address:
3100 Hansen Way, Palo Alto, CA 94304-1038, United States
Attention:
Mike Dunn
Email:
Mike.Dunn@varian.com

7.4.      When effective
Communications take effect from the time they are received or taken to be received under clause 7.5 (whichever happens first) unless a later time is specified.
7.5.      When taken to be received
Subject to clause 7.6, communications are taken to be received:
(a)      if delivered by hand, when delivered; or
(b)      if sent by post, 5 Business Days after posting (if posted to an address in the same country) or 10 Business Days after posting (if posted to an address in a different country).
7.6.      Receipt outside business hours
Despite clauses 7.4 and 7.5, if communications are received or taken to be received under clause 7.5 after 5pm on a Business or on a non-Business Day, they are taken to be received at 9am on the next Business Day and take effect from that time unless a later time is specified.
8.      General
8.1.      Stamp duty
The Bidder must:
(a)      pay all stamp duty, registration fees and similar taxes payable or assessed as being payable on or in connection with this deed poll, the performance of this deed poll, or any instruments entered into under this deed poll and in respect of a transaction effected by or made under the Scheme and this deed poll (including any fees, fines, penalties and interest in connection with any of those amounts);
(b)      pay other costs in respect of the Scheme (including, in connection with the transfer of Scheme Shares to the Bidder (or if applicable, the Bidder Nominee) in accordance with the terms of the Scheme); and
(c)      indemnify on demand each Scheme Shareholder against any liability arising from failure to comply with clauses 8.1(a) or 8.1(b).



8.2.      Waiver
(a)      A waiver of any right arising from a breach of this deed poll or of any right, power, authority, discretion or remedy arising upon default under this deed poll must be in writing and signed by the party giving the waiver.
(b)      A failure or delay in exercise, or partial exercise, of:
(i)      a right arising from a breach of this deed poll; or
(ii)      a right, power, authority, discretion or remedy created or arising upon default under this deed poll,
does not result in a waiver of that right, power, authority, discretion or remedy.
(c)      A party is not entitled to rely on a delay in the exercise or non-exercise of a right, power, authority, discretion or remedy arising from a breach of this deed poll or on a default under this deed poll as constituting a waiver of that right, power, authority, discretion or remedy.
(d)      A party may not rely on any conduct of another party as a defence to exercise of a right, power, authority, discretion or remedy by that other party.
8.3.      Variation
A provision of this deed poll or any right created under it may not be varied, altered or otherwise amended unless:
(a)      if before the First Court Date (as defined in the Scheme Implementation Deed), the variation is agreed to by Sirtex and the Bidder in writing; and
(b)      if on or after the First Court Date (as defined in the Scheme Implementation Deed), the variation is agreed to by Sirtex and the Bidder in writing and the Court indicates that the variation, alteration or amendment would not itself preclude approval of the Scheme,
in which event the Bidder must enter into a further deed poll in favour of the Scheme Shareholders giving effect to the variation, alteration or amendment.
8.4.      Remedies cumulative
The rights, powers and remedies of the Bidder and the Scheme Shareholders under this deed poll are cumulative and are in addition to, and do not exclude any, other rights, powers and remedies given by law independently of this deed poll.
8.5.      Assignment
The rights and obligations of the Bidder and each Scheme Shareholder under this deed poll are personal and must not be assigned, encumbered or otherwise dealt with at law or in equity and no person may attempt or purport to do so without the prior written consent of the Bidder and Sirtex.
8.6.      Governing law and jurisdiction
This deed poll is governed by the law in force in New South Wales, Australia. The Bidder irrevocably and unconditionally submits to the non-exclusive jurisdiction of the courts of that place.
8.7.      Further action



The Bidder must execute all deeds and other documents and do all things (on its own behalf or on behalf of each Scheme Shareholder) necessary or expedient to give full effect to this deed poll and the transactions contemplated by it.
8.8.      Service of process
(a)      Without preventing any method of service allowed under any relevant law, the Bidder:
(i)      irrevocably appoints Norose Notices Australia Pty Ltd ACN 158 029 586 as its process agent to receive any document in an action in connection with this deed poll; and
(ii)      agrees that failure by a process agent to notify the Bidder of any document in an action in connection with this deed poll does not invalidate the action concerned.
(b)      If for any reason Norose Notices Australia Pty Ltd ceases to be able to act as process agent, the Bidder agrees to appoint another person as its process agent in the place referred to in clause 8.8 and ensure that the replacement process agent accepts its appointment and confirms its appointment to the Bidder.
(c)      The Bidder agrees that service of documents on its process agent at the following address is sufficient service on it:
Name:
Norose Notices Australia Pty Ltd
Address:
Level 16, ‘Grosvenor Place’, 225 George Street, Sydney, NSW 2000
Attention:
Shaun Clyne / Jeremy Wickens
Email:
shaun.clyne@nortonrosefulbright.com / jeremy.wickens@nortonrosefulbright.com

EXECUTED by the party as a deed poll:

SIGNED, SEALED & DELIVERED by
Varian Medical Systems, Inc.
by its duly authorised representative in the presence of:
)
)
)
)
 
 
 
 
Witness
 
Authorized Representative
 
 
 
Name (please print)
 
Name (please print)







Exhibit 15.1


February 7, 2018


Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549


Commissioners:

We are aware that our report dated February 7, 2018 on our review of interim financial information of Varian Medical Systems, Inc. for the three month periods ended December 29, 2017 and December 30, 2016 and included in the Company's quarterly report on Form 10-Q for the quarter ended December 29, 2017 is incorporated by reference in its Registration Statements on Form S-3 (No. 333-221763) and Form S‑8 (No. 333-220078, No.333-188693, No.333-168444, No. 333-168443, No. 333-146176, No. 333-130001, No. 333-152903, No. 333-123778, No. 333-75531, No. 333-57006, No. 333-57008, No. 333-57010, and No. 333-161307).

Very truly yours,


/S/ PRICEWATERHOUSECOOPERS LLP
PricewaterhouseCoopers LLP


PricewaterhouseCoopers LLP, 488 Almaden Boulevard, Suite 1800, San Jose, CA 95110
T: (408) 817 3700, F: (408) 817 5050, www.pwc.com/us




Exhibit 31.1
CERTIFICATION OF CHIEF EXECUTIVE OFFICER
PURSUANT TO EXCHANGE ACT RULE 13a-14(a)/15d-14(a)
AS ADOPTED PURSUANT TO SECTION 302
OF THE SARBANES-OXLEY ACT OF 2002
I, Dow R. Wilson, certify that:
1.
I have reviewed this Quarterly Report on Form 10-Q of Varian Medical Systems, Inc. (the “registrant”);
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth quarter in the case of an annual report) that has materially affected, or is reasonable likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Dated:
February 7, 2018
/s/
Dow R. Wilson
 
 
 
Dow R. Wilson
 
 
 
President
 
 
 
and Chief Executive Officer





Exhibit 31.2
CERTIFICATION OF CHIEF FINANCIAL OFFICER
PURSUANT TO EXCHANGE ACT RULE 13a-14(a)/15d-14(a)
AS ADOPTED PURSUANT TO SECTION 302
OF THE SARBANES-OXLEY ACT OF 2002
I, Gary E. Bischoping Jr., certify that:
1.
I have reviewed this Quarterly Report on Form 10-Q of Varian Medical Systems, Inc. (the “registrant”);
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth quarter in the case of an annual report) that has materially affected, or is reasonable likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Dated:
February 7, 2018
/s/
Gary E. Bischoping Jr.
 
 
 
Gary E. Bischoping Jr.
 
 
 
Senior Vice President and
 
 
 
Chief Financial Officer





Exhibit 32.1
CERTIFICATION
PURSUANT TO 18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the accompanying Quarterly Report of Varian Medical Systems, Inc. (the “Company”), on Form 10-Q for the quarter ended December 29, 2017 (the “Report”), I, Dow R. Wilson, President and Chief Executive Officer of the Company, hereby certify pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002 that:
(1)
the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Dated:
February 7, 2018
/s/
Dow R. Wilson
 
 
 
Dow R. Wilson
 
 
 
President
 
 
 
and Chief Executive Officer





Exhibit 32.2
CERTIFICATION
PURSUANT TO 18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the accompanying Quarterly Report of Varian Medical Systems, Inc. (the “Company”), on Form 10-Q for the quarter ended December 29, 2017 (the “Report”), I, Gary E. Bischoping Jr., Senior Vice President and Chief Financial Officer of the Company, hereby certify pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002 that:
(1)
the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated:
February 7, 2018
/s/
Gary E. Bischoping Jr.
 
 
 
Gary E. Bischoping Jr.
 
 
 
Senior Vice President and
 
 
 
Chief Financial Officer